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ABSTRACT 
Insights into MYC biology through investigation of synthetic lethal interactions 
with MYC deregulation 
Mai Sato 
 
 MYC (or c-myc) is a bona fide “cancer driver” oncogene that is deregulated in up 
to 70% of human tumors. In addition to its well-characterized role as a transcription 
factor that can directly promote tumorigenic growth and proliferation, MYC has 
transcription-independent functions in vital cellular processes including DNA replication 
and protein synthesis, contributing to its complex biology. MYC expression, activity, and 
stability are highly regulated through multiple mechanisms. MYC deregulation triggers 
genome instability and oncogene-induced DNA replication stress, which are thought to 
be critical in promoting cancer via mechanisms that are still unclear.  
Because regulated MYC activity is essential for normal cell viability and MYC is a 
difficult protein to target pharmacologically, targeting genes or pathways that are 
essential to survive MYC deregulation offer an attractive alternative as a means to 
combat tumor cells with MYC deregulation. To this end, we conducted a genome-wide 
synthetic lethal shRNA screen in MCF10A breast epithelial cells stably expressing an 
inducible MYCER transgene. We identified and validated FBXW7 as a high-confidence 
synthetic lethal (MYC-SL) candidate gene. FBXW7 is a component of an E3 ubiquitin 
ligase complex that degrades MYC. FBXW7 knockdown in MCF10A cells selectively 
induced cell death in MYC-deregulated cells compared to control. As expected, cellular 
MYC levels are stabilized when FBXW7 expression is attenuated. Notably, stabilization 
of MYC is more pronounced compared to other FBXW7 targets. FBXW7 knockdown with 
MYC deregulation results in cell cycle defects, as well as CDC45 accumulation on 
chromatin, suggesting DNA replication stress. Intriguingly, FBXW7 and MYC expression 
correlate most strongly in the luminal A-subtype of breast cancer associated with low to 
normal MYC expression. Together, our results suggest that knockdown of FBXW7 
increases cellular MYC levels and promotes cell death possibly through accumulation of 
MYC-dependent genomic stress, and that FBXW7 inhibition may be selectively synthetic 
lethal with breast cancers that retain MYC-dependence.  
We also identified UVSSA and ERCC8, two genes involved in transcription-
coupled repair (TCR), as MYC-SL candidates from our genome-wide screen. TCR is a 
DNA damage repair pathway associated with active RNA polymerase II-transcription 
complexes. We show that both UVSSA and ERCC8 knockdown confer increased 
lethality selectively in MYC-deregulated cells. This MYC-SL interaction is not 
exacerbated by exogenous UV irradiation, suggesting that TCR may be required for 
survival upon MYC deregulation independently of its role in UV damage repair. UVSSA 
knockdown with MYC deregulation results in cell cycle defects and CHK2 activation, 
suggesting genomic stress. Intriguingly, we observe that lethality associated with 
UVSSA down-regulation in cells expressing MYCER is alleviated by inhibiting 
transcription. This suggests that transcription-dependent aberrant genomic structures 
generated during MYC deregulation may require TCR for maintaining survival. Taken 
together, our results suggest that increased levels of transcription-dependent genomic 
stress may accumulate with MYC deregulation, and that TCR may have functions 
outside of repairing UV-induced damage in resolving these lesions or structures. 
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With more than 25,000 associated publications, MYC is undoubtedly one of the 
most extensively studied oncogenes today. Since its discovery as a bona fide human 
oncogene just over 30 years ago, studies on MYC have contributed comprehensively to 
expanding our knowledge about both human cell biology and cancer biology. 
Surprisingly, despite extensive research, many aspects of MYC biology are still not fully 
understood – from the properties of the MYC gene and protein to the functions of MYC 
in normal cells and in oncogenesis, the field of MYC biology continues to evolve at an 
unabated pace. Here we discuss the identification of MYC, the MYC family, the functions 
and regulation of MYC, and MYC in human cancers. 
 
a. History of MYC 
The first MYC gene identified in the late 1970s was from the avian acute 
oncogenic retrovirus MC29, which caused tumors in chicken (Duesberg et al., 1977). 
The viral gene responsible for the chicken myelocytomatosis was identified as v-myc, 
which was then later matched to the proto-oncogenic c-myc gene in the chicken 
genome, and then finally identified through homology in the human genome (Sheiness et 
al., 1980; Vennstrom et al., 1982). Shortly thereafter, groundbreaking studies revealed 
the human MYC gene was deregulated via chromosomal translocations into the 
immunoglobulin locus in Burkitt lymphoma (Dalla-Favera et al., 1982; Neel et al., 1982; 
Taub et al., 1982). These findings revealed for the first time that endogenous human 
proto-oncogenes could cause neoplastic transformation in the absence of mutations 
within the gene, revolutionizing fundamental ideas of tumorigenesis. Today, there is no 
question that MYC remains one of the most critical proteins in human cancer biology, as 
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its copy number, expression, stability, and/or activity is altered in up to 70% of all human 
cancers (Dang, 2012; Santarius et al., 2010). 
One of the earliest and most striking phenotypes identified following MYC 
expression was cellular transformation. MYC expression in embryonic fibroblasts could 
transform cells, albeit with the activation of additional oncogenes (Land et al., 1983). 
These results have been corroborated in transgenic mouse studies, collectively showing 
that deregulated expression of MYC is sufficient to drive tumorigenesis in various 
tissues, though additional genetic alterations accelerate tumor formation (Adams et al., 
1985; Chesi et al., 2008; Morton and Sansom, 2013). Multiple studies have also shown 
that tumor cells can develop an “addiction” to MYC, suggesting that MYC has tumor 
maintenance properties in addition to initiation (Felsher and Bishop, 1999; Jain et al., 
2002; Marinkovic et al., 2004; Pelengaris et al., 1999). Collectively, these studies have 
established that MYC is one of relatively few true “cancer driver” genes, and has both 
causal and maintenance roles in mammalian tumorigenesis. 
Importantly, MYC is also an essential gene for growth and normal development. 
MYC knockout mice are embryonic lethal at E9.5, implying its critical role during 
embryogenesis (Davis et al., 1993). This is because MYC controls a variety of cellular 
processes including proliferation, cell cycle progression, apoptosis, differentiation, 
angiogenesis, metabolism, DNA replication, and genomic stability (Dang, 2012; Meyer 
and Penn, 2008). While fascinating, this multifunctional nature of MYC has complicated 
studies investigating the mechanisms by which MYC causes oncogenesis.  
 
b. MYC family 
MYC, or c-myc, is a 439 amino acid protein belonging to a family of proteins also 
including MYCN (N-Myc), MYCL1 (L-Myc), and a few other less well-characterized 
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members (Figure 1) (Nau et al., 1985; Slamon et al., 1986). All three members share a 
basic helix-loop-helix leucine zipper (bHLH-LZ) domain in their C-terminus, which allows 
for sequence-specific DNA binding upon dimerization with a binding partner, usually 
MAX (Blackwood and Eisenman, 1991; Nilsson and Cleveland, 2003). Though it is 
generally agreed upon that MYC-MAX heterodimerization is required for most MYC 
functions and oncogenesis (Amati et al., 1993), there is substantial evidence of MAX-
independent functions of MYC, initially reported in Drosophila melanogaster, Xenopus 
laevis early development, and in human cells (Cascon and Robledo, 2012; Gallant and 
Steiger, 2009; Lemaitre et al., 1995; Ribon et al., 1994; Steiger et al., 2008). MYC, 
MYCN, and MYCL1 also share the highly conserved Myc box I and II domains, which 
include conserved residues that are posttranslationally modified and/or mediate protein-
protein interactions (Figure 1B) (Nilsson and Cleveland, 2003). The N-terminal region 
spanning Myc boxes I and II in MYC has been extensively characterized as the 
transactivation domain (TAD), which is required for most of its biological roles including 
transcription (Figure 1B) (Meyer and Penn, 2008). MYC family members also contain 
two more conserved Myc boxes, III and IV, which are less well characterized but crucial 
for induction of transcription and apoptosis (Conacci-Sorrell et al., 2014). Unfortunately, 
structural information is still not available for MYC outside its HLH-LZ domain. 
While MYC expression is ubiquitous and is observed throughout most cell types, 
MYCN expression is largely restricted to the brain (Zimmerman and Alt, 1990). Some 
functions of MYC and MYCN may be redundant since MYCN can substitute for MYC in 
murine development (Malynn et al., 2000). Like MYC, MYCN deregulation is also seen in 
human cancers, ranging from brain cancers to breast and small cell lung cancers (Vita 
and Henriksson, 2006). Particularly well established is the prominence of MYCN 
amplification in neuroblastomas, which is utilized as a reliable prognostic marker for the 
disease (Brodeur et al., 1984; Kohl et al., 1984; Schwab et al., 1984). Mouse models 
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have verified that MYCN is in fact a neuroblastoma driver gene when overexpressed in 
neuroectodermal cells (Weiss et al., 1997). 
Lastly, MYCL1, normally only expressed during development, was identified as 
an amplified gene in small cell lung cancers (Nau et al., 1985). Although MYCL1 biology 
is much less understood, MYCL1 amplification has been detected in several other tumor 
types including ovarian carcinomas, suggesting its non-trivial role in cancer biology (Wu 
et al., 2003). However, due to the focus of our work, the rest of this document will 
specifically focus on the biology of MYC (c-myc). 
 
Figure 1. Domains organization of MYC family proteins. (A) Organization of MYC protein. The 
N-terminal transactivation region (TAD) contains critical domains such as Myc box I and II (MBI 
and MBII) which mediate protein-protein interactions. The C-terminal BHLH-LZ domain is 
critical for heterodimerization with MAX or other binding partners and mediates DNA binding. 
Other functional domains are indicated (Myc Box III and IV, PEST and NLS). (From (Conacci-
Sorrell et al., 2014)) (B) Shared domains between MYC family members. MYC, MYCN, and 
MYCL are encoded by different genes but they all harbor a TAD which contains conserved Myc 






c. Functions of MYC 
i. Transcription 
MYC’s function as a transcription factor has been the most extensively 
characterized – in fact, it was thought to be its only molecular function until evidence of 
transcription-independent functions emerged relatively recently. Nevertheless, MYC’s 
role as a transcriptional activator and repressor is considered its major molecular 
function in cells. 
 
1. Transcriptional activator 
In general, MYC and its partner MAX dimerize through their respective bHLH-LZ 
domains, docking onto sequence-specific DNA binding motifs termed E-boxes (5’-
CACGTG-3’) located in the enhancer/promoter regions of target genes (Blackwell et al., 
1990). MYC-MAX dimers have higher affinity for classical E-boxes, though higher 
cellular concentrations can enhance their occupancy at non-canonical E-boxes as well 
(Blackwell et al., 1993). Upon DNA binding, MYC is able to recruit protein complexes 
with histone acetyltransferase (HAT) activity including TRRAP, TIP60, PCAF, GCN5, 
p300/CBP, and TBP, through its N-terminal TAD (Figure 2A) (Luscher and Vervoorts, 
2012; Meyer and Penn, 2008). These HATs then promote increased acetylation of local 
histones, resulting in a relaxed, open chromatin state that favors the binding of 
transcription initiation complexes for efficient transcription of target genes (Figure 2A). 
TRRAP plays a key role in directly interacting with MYC through Myc boxes I and II, and 
subsequently recruiting HATs to target promoters (McMahon et al., 2000). Notably, the 
MAD or MXD family of proteins can compete for MAX binding with MYC, antagonizing 
the transcriptional activity of MYC (Rottmann and Luscher, 2006). 
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Many genes are key transcriptional targets of MYC. Evidence that MYC activates 
the expression of cell cycle promoting genes, including cyclin-dependent kinase CDK4 
and Cyclin E1, have been confirmed in multiple model systems (Hermeking et al., 2000; 
Perez-Roger et al., 1997). Cyclins D1, D2, and A1, as well as CDC25A and the 
E2F1/E2F2 transcription factors are thought to be bona fide MYC targets as well (Barrett 
et al., 1995; Daksis et al., 1994; Jansen-Durr et al., 1993; Meyer and Penn, 2008). 
Upregulation of these genes could explain MYC’s transforming activity, however, more 
comprehensive genome-wide studies are suggesting that MYC biology may be more 
complicated than once thought. 
According to the MYC target gene database, 1697 MYC transcriptional targets 
have been identified to date, though the list is continuously growing as new targets are 
identified and validated (www.myc-cancer-gene.org). In contrast to earlier gene-by-gene 
studies, genome-wide studies utilizing chromatin immunoprecipitation (ChIP) have 
revealed that MYC binds a surprisingly high number of sites on human DNA when 
overexpressed: up to 10-15% of the entire genome, including intergenic regions (Cawley 
et al., 2004; Dang et al., 2006; Fernandez et al., 2003; Li et al., 2003; Orian et al., 2003; 
Zeller et al., 2006). Combined with MYC’s very weak transcriptional activation of target 
genes, this has obscured attempts at defining the “MYC core signature” (MCS). Most 
studies agree that the MCS generally includes genes involved in cell cycle progression, 
nucleotide metabolism, ribosome biogenesis, RNA processing, and DNA replication, all 
of which contribute to a pro-proliferation phenotype (Ji et al., 2011; Margolin et al., 2009; 
O'Connell et al., 2003; Perna et al., 2012; Shaffer et al., 2006). However, whether a 
universal MCS exists at all is still controversial, as more evidence is starting to suggest 
that MYC functions can be specific to various cell types and contexts. 
Of note, MYC is a rather unusual transcription factor since it can stimulate the 
activity of all three RNA polymerases (I, II, and III). MYC can influence the transcription 
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of rRNA and tRNA genes by Pol I and III, respectively, in addition to altering mRNA 
production through Pol II (Gomez-Roman et al., 2003; Grandori et al., 2005). Though 
less frequently studied, effects of MYC on RNA Pol I and III are likely not trivial, since 
protein biosynthesis is a critical component of cell proliferation, and these pathways are 
frequently upregulated in cancer cells (Luscher and Vervoorts, 2012). 
 
Figure 2. Model for MYC-mediated transcriptional activation and repression. (A) MYC-MAX 
dimers can recruit HATs (P300/CBP, GCN5, TIP60) through interaction with TRRAP or other 
mediators and increase local histone acetylation. This leads to opening of chromatin for a 
transcription-permissive state. (From (Cole and Cowling, 2008)) (B) MYC-MAX dimers can 
repress gene expression by inhibiting Miz1-mediated transcriptional activation at specific genes. 
When acting as a transcriptional repressor, MYC can recruit histone deacetylases (HDACs) 





2. Transcriptional repressor 
Though less well understood, MYC can also repress the expression of a large 
number of genes such as anti-proliferative genes involved in cell cycle checkpoints and 
cyclin-CDK inhibitors, including p21, p27, p15, and GADD45 (Chang et al., 2008; Meyer 
and Penn, 2008). Again, this additional function sets MYC apart from most canonical 
transcription factors and adds complexity to MYC biology. 
A subset of MYC-mediated repression occurs through interacting with the 
transcription activators MIZ1 and SP1 (Figure 2B) (Gartel et al., 2001; Schneider et al., 
1997). MYC can displace co-activators of MIZ1 and SP1, repressing their transcriptional 
activation properties, as illustrated in the case of MYC-dependent transcriptional 
repression of p15 (Feng et al., 2002). As opposed to HATs, MYC-associated repression 
complexes can recruit histone deacetylase (HDAC) complexes, leading to the local 
closing of chromatin structures, favoring transcriptional repression (Figure 2B) (Luscher 
and Vervoorts, 2012). Interestingly, MYC/MIZ1 complexes can also recruit DNA 
methyltransferases as a means to repress transcription as well, as shown in the case of 
p21 (Brenner et al., 2005). 
Additionally, MYC is able to activate and/or repress the production of specific 
microRNAs and long noncoding RNAs, leading to indirect changes in downstream gene 
expression (Chang et al., 2008; O'Donnell et al., 2005). Studies connecting MYC and 
small RNAs and their relationship to tumorigenesis are active areas of research. 
 
3. General amplifier of transcription 
It was recently proposed that MYC might be a general, instead of sequence-
specific, amplifier of transcription. Levens’ group and Young’s group utilized ChIP-
sequencing (ChIP-seq) techniques to investigate MYC activity in a genome-wide fashion 
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and observed that MYC bound already-active promoters (Lin et al., 2012; Nie et al., 
2012). MYC bound preferentially to promoters that were already occupied by RNA Pol II 
(RNAPII) and active chromatin marks, and failed to bind to and induce the 
transactivation of silent genes, regardless of MYC concentration. Even more striking, 
these patterns were cell-type specific, suggesting that MYC may indiscriminately amplify 
the existing transcriptional program in the cell without initiating de novo transcription (Lin 
et al., 2012; Nie et al., 2012).  
These results corroborate previous reports showing that MYC is a regulator of 
transcription pause release. MYC controls transcriptional elongation by inducing release 
of promoter-proximally paused RNAPII complexes that are poised for transcription (Rahl 
et al., 2010). RNAPII pausing is a general mechanism that facilitates rapid and efficient 
transcription upon release by P-TEFb (Adelman and Lis, 2012; Levine, 2011; Seila et al., 
2009). Since pharmacological inhibition of BRD4, which plays a role in P-TEFb 
recruitment, can lead to regression of MYC-driven tumors in mice, this function of MYC 
may be relevant to pathogenesis (Delmore et al., 2011; Mertz et al., 2011). It is possible 
that MYC has dual roles in transcriptional initiation and pause release. 
 
ii. DNA replication 
In the late 1980s, it was proposed that MYC may be directly regulating DNA 
replication, since MYC expression resulted in proliferation and transformation (Gutierrez 
et al., 1988). During early Xenopus development in which transcription is silent but 
replication is rapid, MYC is recruited to the nucleus, suggesting a role in DNA replication 
(Gusse et al., 1989). However, follow-up studies were not conducted since the 
transcriptional functions of MYC became uncovered. 
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In 2007, Dominguez-Sola and colleagues confirmed the original findings that 
MYC has a transcription-independent function in DNA replication (Dominguez-Sola et 
al., 2007). Mass spectrometry identified members of the pre-replicative complex (pre-
RC), which are essential for DNA replication, in complex with MYC. In Xenopus laevis 
cell-free extracts where DNA replication occurs readily without the presence of active 
transcription, immuno-depletion of MYC resulted in inhibition of DNA replication, and 
recovery of replication required full-length recombinant MYC. Overexpression of MYC in 
extracts increased the initial rate of DNA replication, but did not allow for its completion 
due to accumulation of replication-dependent DNA damage and S-phase checkpoint 
activation. These results were corroborated in mouse cells, suggesting that MYC could 
be directly initiating origin activation, causing aberrant firing of dormant origins leading to 
harmful replication intermediates that trigger the checkpoint when overexpressed 
(Dominguez-Sola et al., 2007). Srinivasan and colleagues recently confirmed this 
hypothesis by utilizing DNA combing (Figure 3). MYC overexpression decreased inter-
origin distances on replicating chromatin and increased aberrant replication 
intermediates including unidirectional forks and replication-dependent DNA damage 
(Figure 3) (Srinivasan et al., 2013). Critically, overexpression of CDC45 phenocopied 
MYC overexpression, suggesting an epistatic relationship. MYC phenotypes were 
dependent on the presence of CDC45, as partial depletion of CDC45 suppressed MYC 
phenotypes. Taken together, MYC appears to have a substantial role in directly affecting 
origin firing during DNA replication, possibly by recruiting CDC45 to replicative origins to 
facilitate origin activation (Figure 3) (Srinivasan et al., 2013). Consistent with these 
results, other studies have reported similar S-phase phenotypes upon CDC45 
overexpression in human cells, as well as its rate-limiting nature in origin firing (Wong et 
al., 2011) (Frank Grosse, unpublished). 
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This function of MYC could at least in part explain the widespread association of 
MYC with chromatin. In fact, some studies have found E-boxes to coincide with 
replication origins (Swarnalatha et al., 2012). However, since MYC transcriptionally 
activates many genes involved in DNA replication including MCMs, CDC6, and CDT1, 
the relative contribution of MYC towards DNA replication and transcription is still an open 
question (Eilers and Eisenman, 2008). 
 
Normal Myc, CMG 




!IOD, "asymmetry and DNA damage Normal IOD, no "asym. or damage !IOD, "asymmetry and DNA damage 
Figure 3. Direct role of MYC in DNA replication. Spatio-temporal analysis of DNA replication pattern in 
Xenopus extract by DNA combing/DNA fiber assay. Overexpression of MYC or CDC45 (CMG complex 
contains CDC45, MCM2-7, GINS) results in decreased inter-origin distances, increased fork 
asymmetry, and increased replication-dependent DNA damage. Partial depletion of CDC45 abrogates 
MYC phenotypes, suggesting that MYC may contribute to origin activation through directly modulating 
the CMG complex. (From (Srinivasan et al., 2013) 
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iii. Other proposed functions 
MYC plays an integral role in stem cell biology and differentiation. MYC was one 
of the four original genes required for reprogramming fibroblasts to pluripotency, though 
later studies showed that it is dispensable in some conditions (Nakagawa et al., 2008; 
Takahashi and Yamanaka, 2006). This suggests MYC has a role in self-renewal, 
however, others have shown that MYC is required to commit to terminal differentiation 
(Gandarillas and Watt, 1997). It is possible that MYC plays dual roles at various points of 
cell differentiation. 
Others have suggested that MYC is a global chromatin regulator (Varlakhanova 
and Knoepfler, 2009). Nuclei in MYCN-null neuronal cells are smaller in size, with 
condensed chromatin. Global histone acetylation and methylation patterns appear to be 
markedly altered, suggesting that MYCN could be modifying chromatin in a genome-
wide manner (Knoepfler et al., 2006). Similar results were obtained from murine 
epidermal stem cells, in which MYC activation induced changes in global chromatin 
acetylation, rather than local changes at select promoters as would be expected from a 
sequence-specific transcription factor (Frye et al., 2007). Whether these changes are a 
direct or indirect consequence of MYC expression is unclear. 
MYC can also directly promote phosphorylation of the C-terminal tail of RNA 
polymerase II, regulating mRNA cap methylation and promoting translation (Cowling and 
Cole, 2007). Intriguingly, the DNA binding domain of MYC is dispensable for this 
function, suggesting that not all functions of MYC may require DNA binding or 
transcription (Cole and Cowling, 2008). Consistent with this, the PC12 murine cell line 
has no functional MAX protein but is viable, and Drosophila cells without MAX appear to 
retain substantial MYC activity, such as regulation of Pol III (Hopewell and Ziff, 1995; 
Steiger et al., 2008). These studies support the idea that MYC may not require binding 




d. Regulation of MYC 
Since MYC is essential for cycling cells but can drive mitogen-independent 
growth, MYC levels must be tightly regulated. Thus, cells have evolved an intricate 
system of MYC regulation in order to closely monitor MYC homeostasis (Figure 4). Here 
we discuss the regulation of MYC gene expression, protein stability, and degradation. 
 
i. MYC gene expression 
In normal cells, MYC expression can be triggered by a variety of signal 
transduction pathways such as NF-κB, STAT, WNT, Hedgehog, NOTCH, and TGFβ; all 
of which are under strict control of specific mitogens and proliferative signals (Figure 4) 
(Dang, 2012). Transcription of the MYC gene is directly regulated by transcription factors 
including CNBP, FBP, and TCF, as well as by specific DNA structures and sequences 
(Levens, 2013). Several single-nucleotide polymorphisms (SNPs) have been identified in 
the enhancer region of the MYC gene and are associated with multiple cancers (Dang, 
2012).  
The MYC mRNA is also under tight regulation. The short-lived MYC mRNA, with 
an approximate half-life of 20 minutes, can be regulated by several microRNAs including 
let-7, miR-34, and miR-145, which can fine-tune the levels of MYC transcripts (Cannell 
et al., 2010; Kim et al., 2009; Sachdeva et al., 2009). Additionally, translation of MYC 
mRNA is controlled by multiple signaling pathways, adding another layer of regulation 
(Soucek and Evan, 2010). 
Importantly, MYC can also auto-regulate its own expression. Early studies 
showed that exogenous introduction of v-myc or c-myc into cells resulted in down-
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regulation of endogenous MYC, demonstrating yet another mechanism by which MYC 




Figure 4. Multilayered regulation of MYC. MYC gene expression is triggered by various mitogenic 
signaling pathways including TGF-b, Wnt, PDGF, and EGF. Transcription of the MYC gene is 
regulated at the level of DNA structure, transcription initiation, elongation, RNA stability, and 
transport. At the protein level, MYC is again strictly regulated by posttranslational modifications 
and degradation pathways that dictate its stability. Finally, MYC protein functions are diverse, and 
can vary greatly depending on the level of expression and stable MYC proteins available in the 
cell. (From (Conacci-Sorrell et al., 2014)) 
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ii. Post-translational modifications 
The MYC protein is extensively post-translationally modified by phosphorylation, 
ubiquitination, acetylation, and O-linked glycosylation (Vervoorts et al., 2006). These 
modifications regulate distinct aspects of the MYC protein. 
The best characterized phosphorylation events occur on Serine 62 (S62) 
followed by Threonine 58 (T58), and are key modifications that regulate MYC’s 
transcriptional activity and subsequent proteasomal degradation (Thomas and Tansey, 
2011). Mutations in these residues result in stabilized mutant proteins and are prevalent 
in Burkitt lymphoma (Axelson et al., 1995). Several kinases can phosphorylate S62 
including ERK, MAPK, JNK, and CDK1, likely in response to different upstream signaling 
(Luscher and Vervoorts, 2012). T58 phosphorylation, on the other hand, is generally 
attributed to GSK3β, which can only phosphorylate T58 when S62 is phosphorylated 
(Lutterbach and Hann, 1994). Phosphorylated T58 is then finally recognized as a 
substrate by ubiquitin ligases, leading to polyubiquitination and degradation of MYC. 
Other putative phosphorylation sites have been mapped in MYC, however, the kinases 
responsible and their functional significance remains unknown. 
Interestingly, some of the HAT complexes that MYC recruits to target gene 
promoters for transcription initiation can acetylate residues on MYC itself. There are at 
least 8 acetylation sites that have been mapped in the MYC protein, and most appear to 
be acetylated by p300/CBP, TIP60, and GCN5, which have all been implicated in 
transcription initiation by MYC (Luscher and Vervoorts, 2012). It has been proposed that 
acetylation of MYC may compete with ubiquitination to promote stability of the MYC 
protein, as both modifications occur on lysine residues. This phenomenon has been 
shown for other transcription factors, however, definitive results still remain to be shown 
in the case of MYC (Caron et al., 2005). It is also possible that acetylation regulates 
specific protein-protein interactions. 
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Finally, ubiquitination is another key process for regulation of MYC stability 
(Thomas and Tansey, 2011). MYC is primarily degraded through the ubiquitin-
proteasomal system (UPS), in which ubiquitin conjugation serves as a signal for 
degradation by the 26S proteasome. The next section discusses the various UPS-
dependent mechanisms of MYC degradation. 
 
iii. Degradation 
1. Significance of MYC turnover 
An integral component of MYC regulation is turnover, or degradation. The 
average half-life of MYC protein is only 20-30 minutes, and in normal proliferating cells, 
MYC proteins are constantly kept as low as 1000~6000 molecules per cell (Moore et al., 
1987; Rudolph et al., 1999). This is critical, since even a 2-3 fold increase in this number 
can cross a threshold amount of MYC and grant tumorigenic potential (Murphy et al., 
2008). To maintain the tumorigenic state, however, MYC levels must be kept below 
lethal levels, since high levels of MYC expression can activate apoptotic pathways 
(Murphy et al., 2008). Thus, sustaining precise levels of MYC is crucial for normal cells 
for the maintenance of proliferation, and in tumor cells for continued survival.  
 
2. Ubiquitin-mediated degradation 
The bulk of MYC destruction in cells occurs through ubiquitin-mediated 
proteolysis, a highly specific and regulated pathway of protein turnover (Figure 5) 
(Thomas and Tansey, 2011). The process is well characterized and occurs through a 
stepwise program in which proteins are flagged for destruction by the covalent addition 
of ubiquitin molecules to lysine residues (Figure 5) (Pagan et al., 2013). The canonical 
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process usually consists of the ubiquitin activating enzyme (E1), the ubiquitin 
conjugating enzyme (E2), and the ubiquitin ligase (E3), and these components 
respectively activate, conjugate, then transfer ubiquitin onto the target proteins. The E3 
ligase complexes confer substrate specificity, allowing for a widespread but highly 
regulated process. Importantly, proteins that are targeted to the UPS are 
polyubiquitinated with linear ubiquitin chains usually consisting of 4 or more molecules 
linked via Lysine 48 (K48) on the ubiquitin molecule. Monoubiquitination or 
polyubiquitination of other linkage types such as K63-linkages or branched chains are 
not targeted to the 26S proteasome, and instead serve as signaling modifications or 
other functions. The 26S proteasome exclusively recognizes those substrates that are 
appropriately polyubiquitinated via K48 (Muller and Eilers, 2008). 
The interaction between the UPS and target proteins is highly regulated, often by 
post-translational modifications such as phosphorylation of the substrate. This is the 
case for MYC, where specific phosphorylation on S62, followed by T58, are required for 
recognition by different E3 ligase complexes. Notably, ubiquitination can be 
counteracted by acetylation events as described above, or by deubiquitinating enzymes. 
USP28, in particular, has been linked to deubiquitination of MYC (Popov et al., 2007). 
Various domains of MYC have been associated with its degradation. A canonical 
degron region, which is required for its interaction with at least two E3 ligase complexes, 
resides in its TAD domain and spans Myc boxes I and II (Thomas and Tansey, 2011). 
Within these Myc boxes are several key residues, discussed below. Two other domains 
exist in the central region of the MYC protein, the “D” and “PEST” elements, which also 




3. Ubiquitin ligases involved in MYC turnover 
More than five different E3 ubiquitin ligase complexes have been implicated in 
MYC degradation (Luscher and Vervoorts, 2012; Thomas and Tansey, 2011). The best 
characterized is the SCF-like E3 ubiquitin ligase complex containing FBXW7 (Welcker et 
al., 2004). Recent evidence suggests that this FBXW7-containing complex, at least in 
some cell types, controls the bulk of MYC degradation (King et al., 2013; Takeishi et al., 
2013) (see following section). 
The second is SKP2, an oncogene, which is also a component of an SCF-type 
E3 ubiquitin ligase complex (Kim et al., 2003). Unlike FBXW7, however, SKP2 interacts 
with Myc box II of MYC. Interestingly, the in vivo polyubiquitination of MYC by SKP2 
promotes MYC transcriptional activity, acting as a cofactor (Kim et al., 2003). Current 
models suggest that SKP2-mediated degradation of MYC may occur directly on 
chromatin-bound MYC, where efficient and timely degradation of MYC may enhance its 
turnover and transcriptional activity (Thomas and Tansey, 2011). Such coupling of 
Figure 5. The ubiquitin-proteasome system (UPS). First, ubiquitin molecules are activated by 
an ATP-dependent E1 activating enzyme. Ubiquitin is then conjugated onto its target 
substrate via the E2 conjugating enzyme, followed by the E3 ubiquitin ligase which confers 
substrate specificity. Linear ubiquitin chains of 4 or more molecules linked through K48 serve 
as tags for substrate degradation by the 26S proteasome. (From (Pagan et al., 2013))  
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transcriptional activity to degradation has been previously reported for other transcription 
factors (Holt, 2012). Notably, SKP2 is also a MYC target gene and is upregulated by 
MYC, suggesting that MYC may control its own stability (Bretones et al., 2011). 
The HECT-domain ubiquitin ligase Huwe1/HectH9 has been implicated in 
degradation of MYC, as well as p53 (Adhikary et al., 2005). Interestingly, this complex 
has also been linked to the stress response and DNA repair (Hall et al., 2007; Herold et 
al., 2008). Huwe1/HectH9 can ubiquitinate MYC through K48- or K63-ubiquitin chains 
with distinct consequences, as K48-linked polyubiquitination targets MYC for 
degradation, whereas K63-linkages promote the recruitment of p300, enhancing 
transcriptional activities of MYC (Adhikary et al., 2005).  
The β-TrCP-SCF complex can ubiquitinate the same sites on MYC as those 
targeted by the FBXW7-containing complex, but instead of linear chains, adds 
heterotypic polyubiquitin chains that are not recognized by the proteasome (Popov et al., 
2010). This suggests an antagonistic mechanism via competition with FBXW7 (Popov et 
al., 2010). Since β-TrCP-SCF activity is cell cycle-regulated by kinases such as PLK1, it 
is possible that this mechanism regulates the abundance of MYC through cell cycle 
stages (Watanabe et al., 2004). 
TRIM32 (Schwamborn et al., 2009), FBX29 (Koch et al., 2007), and the 
TRPC4AP/TRUSS complex (Choi et al., 2010) have also been implicated in MYC/MYCN 
degradation. Little is known about the relative physiological contribution of each 
degradation pathway, though knockdown of one of these pathways generally only 
causes modest changes in MYC stability, suggesting that the processes likely cooperate 
with each other (Thomas and Tansey, 2011). Recent evidence suggests, however, that 
FBXW7-mediated degradation of MYC may be particularly significant in tumorigenesis, 





FBXW7 (F-box and WD repeat containing protein 7, also known as FBW7, AGO, 
SEL10, or CDC4) is the substrate-specifying subunit in the SKP1-CUL1-F-box protein 
(SCF)-like E3 ubiquitin ligase complex (Figure 6A) (Welcker and Clurman, 2008). 
FBXW7 belongs to the F-box family of proteins and is well conserved in eukaryotes. In 
humans, three isoforms of FBXW7 are expressed which are differentially localized in the 
cell. Whether these isoforms have specific roles is unclear, but all harbor the conserved 
~40 amino acid F-box (interacts with SKP1) and WD repeats (binds phosphorylated 
substrates) in their C-terminus (Wang et al., 2012). 
The FBXW7 ligase complex polyubiquitinates and targets MYC for degradation 
both in vitro and in vivo (Welcker et al., 2004; Yada et al., 2004). The interaction 
between FBXW7 and MYC is tightly regulated, as sequential phosphorylation of MYC, 
first on S62 by one of several kinases, then on T58 by GSK3β, is required to establish 
the phosphodegron recognized by FBXW7 (Thomas and Tansey, 2011). That T58 is a 
hotspot for MYC mutations in cancer is not surprising, since it disturbs the interaction of 
FBXW7 with MYC and leads to MYC stabilization (Tan et al., 2008). Rendering FBXW7 
unable to degrade MYC can increase MYC half-life to up to 120 minutes, throwing off the 
cellular MYC balance (Salghetti et al., 2000). Additionally, the ubiquitin-specific protease 
USP28 appears to be a part of the FBXW7 complex, counteracting the ligase activity of 
FBXW7 for further fine-tuning of the process (Popov et al., 2007). 
Interestingly, MYC is not the only substrate for the FBXW7 complex – in fact, 
FBXW7 can degrade several oncoproteins and master regulators (Figure 6B) (Tan et al., 
2008; Wang et al., 2012). Included in its list of substrates are Cyclin E1, a well-
established oncoprotein that drives cell cycle progression, the c-Jun and NOTCH1 
oncoproteins, as well as Mcl-1, SREBP, mTOR, KLF5, c-Myb, Aurora A, NF1, NRF1, 
HIF-1a, and p100 (Figure 6B) (Wang et al., 2012). The relative cellular contribution of 
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FBXW7 to the stability of each of its targets and resulting oncogenesis remains elusive, 
and is an intense area of study. 
 
For these reasons, FBXW7 is thought to be a tumor suppressor, as mutations in 
FBXW7 are one of the most frequent genetic aberrations (mutated in >30%) in T-cell 
acute lymphoblastic leukemia (T-ALL), as well as cholangiocarcinoma, pancreatic, 
endometrial, and colon cancers (Akhoondi et al., 2007; Thompson et al., 2007; Wang et 
al., 2012). Interestingly, however, mutations or inactivation of FBXW7 are surprisingly 
rare in a significant portion of human cancers, including ovarian and breast (<4%) 
A 
B 
Figure 6. The FBXW7-containing E3 ubiquitin ligase complex and its targets. (A) FBXW7 (FBW7) is 
a component of the SCF-like (SKP1-CUL1-F-box) E3 ligase complex. FBXW7 confers substrate 
specificity to the E3 ligase complex. (B) Known targets of FBXW7. The FBXW7-containing E3 ligase 
complex targets many major oncoproteins and master regulators for degradation, including MYC, 
Cyclin E ,and NOTCH1. The repertoire of FBXW7 targets may differ across various cell types 
depending on specific expression of the oncogenes. 
(From (Wang et al., 2012)) 
 
 23 
(Akhoondi et al., 2010; Kwak et al., 2005). This could be due to the complex 
combinations and interactions of oncoproteins in these cancers, or differential roles of 
FBXW7 in specific cell types and contexts. 
The relative contribution of FBXW7 to overall MYC stability has been 
controversial, though it is the most well characterized MYC-degrading complex. Studies 
in some systems show FBXW7 having minimal effects on MYC protein levels. Deletion 
of Myc box I did not prolong MYC half-life significantly, suggesting that disruption of the 
FBXW7-MYC interaction is not sufficient to promote tumorigenesis (Herbst et al., 2004; 
Thomas and Tansey, 2011). In contrast, recent studies in mouse cells demonstrated that 
MYC accumulation as a direct consequence of FBXW7 disruption caused 
leukemogenesis (King et al., 2013; Takeishi et al., 2013). It is clear that at least in some 
cell types, FBXW7 appears to be a critical regulator of MYC protein levels. 
 
e. MYC in human cancers 
Although MYC is generally essential for survival, only low levels of MYC are 
necessary and sufficient for normal cell viability, and a modest increase in MYC can 
cause malignant transformation. Up to 70% of all human cancers show aberrant MYC in 
one of several ways. These include 1) deregulation of expression due to chromosomal 
translocation of the MYC locus into an active promoter such as immunoglobulin, 2) gene 
amplification of the MYC locus, 3) virus-mediated insertional mutagenesis, 4) gain of 
function mutations in the MYC gene, and 5) mutations or inactivation of other genes that 
regulate MYC stability (Dang, 2012; Vita and Henriksson, 2006). Intriguingly, specific 
types of MYC deregulation are predominant in certain cancer types, suggesting cell 
type-specific regulation of MYC. Here we discuss some of the current information about 




i. Hematopoietic cancers 
The first human malignancies linked to MYC were hematopoietic cancers, with 
the most iconic being Burkitt lymphoma, which is caused by a specific chromosomal 
translocation between chromosome 8, containing MYC, and chromosome 14,2, or 22, 
which include immunoglobulin (Ig) genes (Wasylishen and Penn, 2010). The resulting 
translocation puts the MYC gene under control of the Ig promoter, deregulating its 
expression. The Eµ-MYC transgenic mouse was established to model this specific 
translocation, and showed that it effectively induced clonal B-cell lymphoma (Adams et 
al., 1985). All human cases of Burkitt lymphoma are caused by one of these three 
possible translocations, illustrating the potency of MYC in this cancer subtype. 
MYC rearrangements have also been identified in other hematological 
malignancies such as diffuse large B-cell lymphoma, multiple myeloma, primary plasma 
cell leukemia, and acute lymphocytic leukemia (Vita and Henriksson, 2006). Other than 
chromosomal rearrangements, MYC mutations, as well as deregulation, have also been 
reported. For example, in T-ALL, activating mutations of NOTCH1, the most frequent 
genetic alteration found in the disease, cause overexpression of MYC, which contributes 
significantly to the malignancy (Weng et al., 2006). The prevalence of MYC aberrations 
in hematopoietic cancers emphasizes the importance of tight MYC regulation in rapidly 
dividing cells. 
 
ii. Other non-hematopoietic cancers and breast cancers 
In solid tumors, MYC is deregulated in various ways depending on the tumor type 
(Mazaris and Tsiotras, 2013). Genome-wide studies of amplification and overexpression 
of MYC family genes have shown significant levels in breast, colorectal, lung, and 
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prostate cancers, as well as medulloblastoma, neuroblastoma, and rhabdomyosarcoma 
(Santarius et al., 2010). Other studies have also implicated MYC/MYCN deregulation in 
bladder, cervical, gastric, liver, endocrine, and ovarian cancers, as well as melanoma, 
glioblastoma, and osteosarcoma (Vita and Henriksson, 2006). Whether if MYC is a 
driver gene in these cancers is largely still an active area of research. 
Gene amplification and overexpression of MYC is quite prevalent in breast 
tumors, though no MYC-associated chromosomal translocations have been identified in 
breast (Liao and Dickson, 2000; Xu et al., 2010). Meta-analysis studies have reported 
that MYC amplification (< 2-fold) occurs in about 15% of all breast cancers, while 22-
35% of breast cancers have increased mRNA expression of MYC, and more than 40% 
have increased MYC protein levels (Deming et al., 2000). The mechanisms of MYC 
stabilization are unknown, but it likely entails a complex interplay of signaling pathways 
including TGFβ, WNT/β-catenin, Ras, EGF, Her2/Neu, and ER-α, all of which play 
critical roles in breast tumorigenesis and can affect MYC expression (Xu et al., 2010). 
Breast cancers can be largely classified into five subtypes: normal-like, basal-
like, luminal A, luminal B, and Her2/Neu-positive (Sorlie et al., 2001). Particularly, MYC 
overexpression and amplification have been traditionally associated with the basal-like 
subtype of breast cancer, often referred to as “triple negative” for being estrogen 
receptor (ER-α) negative, progesterone receptor negative, and Her2/Neu negative 
(O'Toole et al., 2013). Though basal-like breast cancers only account for ~15% of all 
breast cancers, they are the most challenging to treat, with the worst prognosis, and 
result in a disproportionate number of deaths (Schneider et al., 2008). Meta-analysis 
studies have confirmed that MYC, along with E2F, has elevated activity specifically in 
basal-like breast cancers (Alles et al., 2009).  
Increasing evidence also suggests that MYC and BRCA1 may be closely related 
in breast tumorigenesis. Breast cancers with either germline mutations or spontaneous 
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inactivation of the breast tumor suppressor gene BRCA1 have been associated with 
amplification or overexpression of MYC (Grushko et al., 2004; Ren et al., 2013). It has 
been proposed that BRCA1 directly interacts with MYC and inhibits its transcriptional 
activity (Wang et al., 1998), suggesting that BRCA1 loss may be an obligate requirement 
for oncogenic MYC overexpression in the breast (Xu et al., 2010). Moreover, BRCA1 
itself has been identified as a MYC transcriptional target, suggesting a complex 
feedback mechanism (Menssen and Hermeking, 2002). 
Interestingly, various breast cancer types may harbor differential sensitivity to 
MYC suppression. A fraction of breast cancer cell lines tested with MYC siRNA or 
shRNA exhibited MYC-independence (Kang et al., 2014; Kessler et al., 2012). 
Consistent with this, some MYC-induced mammary tumors in mice were able to escape 
MYC-dependence after elimination of MYC induction, and acquired more aggressive 
phenotypes with genetic signatures similar to that of tumor-initiating cells (Leung et al., 
2012). These findings raise an important question whether traditionally high-MYC breast 
cancers such as basal-like breast cancers are the best candidates for MYC-based 
therapies, as it is possible that these cells have already acquired MYC-independence.  
 
iv. Current therapies for MYC-driven cancers 
Although MYC is an attractive and obvious target for a wide range of cancer 
types, successful pharmacological targeting of MYC has been limited. Even as a 
biomarker, MYC is not very useful other than in specific cases such as neuroblastoma, 
since it is not always easy to detect MYC deregulation. MYC is not readily “druggable,” 
due to its nuclear localization and lack of a classical active site. Additionally, since MYC 
is essential in normal cells, the therapeutic window of direct targeting is slim. Several 
small molecule inhibitors have been tested to interfere with MYC’s biological activities, 
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but unfortunately, none have made substantial way into the clinic as of yet (Vita and 
Henriksson, 2006). 
Notably, a dominant negative MYC mutant, Omomyc, has been tested in mouse 
models of MYC-driven cancer and has shown potentially promising results (Soucek et 
al., 2008). Omomyc reversibly inhibits the transcriptional activation function of MYC by 
blocking the interaction between MYC and MAX. Administration of Omomyc in murine 
models of non-small cell lung cancer has shown tumor regression with minimal effects 
on healthy tissue. Also, recent studies have shown promising results with bromodomain 
inhibitors such as JQ1 in mice (Delmore et al., 2011; Mertz et al., 2011). However, since 
the toxicity of these drugs in humans is a potential issue, further studies for direct or 
indirect targeting of MYC-driven tumors remains a crucial area of research. 
 
2. Genome instability 
a. Genome instability: a hallmark of cancer cells 
 Historically, genomic instability in human cancer cells has been detected 
cytologically (Hanahan and Weinberg, 2011). More recently, technology has allowed for 
high-resolution studies of genomic aberrancies, providing further evidence that genomic 
instability is a critical hallmark of tumorigenesis and is evident in virtually all cancer types 
(Cassidy and Venkitaraman, 2012). Deregulated genomic transactions, such as DNA 
replication, transcription, and repair, could all contribute to this phenomenon. 
Importantly, while genome instability can be a consequence of tumorigenic growth, it 
may also be a critical prerequisite for tumorigenesis, since a minimum of 6-10 mutations 
or genetic alterations are typically required for neoplastic transformation (Wade and 
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Wahl, 2006). An unstable genome is more likely to accumulate these genetic changes 
more efficiently and quickly. 
 
b. MYC and genome instability 
MYC deregulation can directly cause genome instability, as chromosomal 
abnormalities including translocations, chromosomal missegregation, and aneuploidy 
can arise from MYC hyperactivation (Karlsson et al., 2003; Prochownik and Li, 2007). In 
addition, cells with deregulated MYC can display signs of persistent DNA damage and 
checkpoint activation, as well as increased sensitivity to select DNA damaging agents 
(Felsher and Bishop, 1999; Wade and Wahl, 2006). A variety of MYC-dependent 
processes can directly contribute to genome instability, as discussed below. 
 
i. Transcriptional deregulation of cell cycle and genomic processes 
By upregulating genes that promote cell cycle progression and repressing those 
that inhibit it, deregulated MYC promotes uncontrolled and unscheduled cell division. For 
example, upregulation of CyclinE/CDK2 and repression of p27 by MYC causes 
premature entry into S-phase and desensitizes cells to DNA damage-induced cell cycle 
arrest during replication (Wade and Wahl, 2006). Such a rapid and dysregulated cell 
cycle is a source of genome instability, since cell cycle checkpoints and DNA repair 
pathways cannot perform optimally when these processes are uncoupled. 
In addition, MYC also induces aberrant gene expression of genes involved in 
various genomic processes. DNA replication proteins including MCM4, MCM6, MCM7, 
CDC6, CDT1, and TOP1 have been identified as upregulated MYC target genes (Eilers 
and Eisenman, 2008). This could contribute to accelerated DNA replication, DNA 
replication stress, and subsequent DNA damage. MYC also upregulates genes involved 
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in nucleotide metabolism, ribosome biogenesis, and RNA processing, which contribute 
to increased transcription and protein synthesis which in turn yield genomic stress 
(Dang, 2012). Additionally, MYC can alter the transcription of mitotic proteins (Li and 
Dang, 1999; Menssen et al., 2007). MYC can also induce a DNA damage response 
(DDR) in the absence of exogenous DNA damage, inducing the expression of genes 
such as ATM, Wip1, and TIP60 (Campaner and Amati, 2012). Mechanisms of Myc-
induced DDR is not clear, however, evidence for other oncogene-induced DDR have 
been reported as well (Halazonetis et al., 2008). 
 
ii. Oncogene-dependent DNA replication stress 
Aside from transcription, MYC can also induce damage directly through its role in 
DNA replication. In both Xenopus cell-free extracts and in human B cells, MYC 
overexpression gives rise to DNA damage, as well as activation of the S-phase 
checkpoint (Figure 7) (Dominguez-Sola et al., 2007). This likely is the result of replication 
stress, as it is dependent on active DNA replication. One of the mechanistic hypotheses 
was that MYC overexpression during DNA replication gave rise to aberrant replication 
intermediates, which recruited DDR proteins to stalled or collapsed forks and elicited a 
checkpoint response. Consistent with this, MYC overexpression led to increased origin 
firing and asymmetric replication forks (Srinivasan et al., 2013). It is possible that 
replication-dependent DNA damage is sufficient to drive MYC-dependent genome 
instability, however, this has not been directly investigated in human cells. 
Notably, some transcriptional targets of MYC can also contribute to replication 
stress, including cyclins D1, D2, and E1 (Bartek and Lukas, 2001). For example, MYC 
can induce increased Cyclin E1 expression (Perez-Roger et al., 1997). Cyclin E1 
overexpression results in increased replication-dependent genomic stress and excessive 
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origin firing, closely phenocopying MYC overexpression in human cells and Xenopus 
extracts (Jones et al., 2013). This suggests that oncogene-dependent DNA replication 
stress induced by MYC can be a combination of direct and indirect pathways (Figure 7). 
 
iii. Alternative mechanisms 
MYC deregulation can also give rise to gene amplifications, through either re-
replication of DNA during a single S-phase, or chromosome breakage. Some studies 
have attributed MYC-dependent upregulation of CDC6 and CDT1 to the possibility of re-
replication (Fernandez et al., 2003). Since re-replication was not observed in Xenopus 
extracts, this may be a consequence of MYC transcription rather than its direct role in 

















Campaner and Amati, Figure 2 
Figure 7. Mechanisms of MYC-dependent DNA replication stress. MYC deregulation results in 
accumulation of replication stress due to elevated transcription, aberrant DNA replication, and 
deregulated cell cycle progression. To combat these, MYC engages DDR pathways, checkpoints, 
and other pathways in order to modulate replication stress and DNA damage to maintain an 




Metaphase chromosomal aberrations that can ultimately lead to missegregation 
or breakage have also been detected in MYC-overexpressing cells (Felsher and Bishop, 
1999). Additionally, MYC-dependent alteration of global chromatin structure, as well as 
p53-dependent checkpoint repression, have been proposed to contribute to genomic 
instability (Wade and Wahl, 2006). Future studies are crucial to gain insight into the 
relative significance of these processes. 
 
c. Crosstalk between transcription, replication, and repair 
The crosstalk between the various DNA transactions taking place on chromatin is 
attracting more interest. Transcription, replication, and repair have traditionally been 
studied as three distinct processes, but increasing evidence suggests that they 
communicate with each other substantially (Fong et al., 2013). Since tens of thousands 
of cellular DNA damage occurs per cell per day on average, it only makes sense for 
these pathways to collaborate in order to eradicate these lesions quickly and efficiently 
while allowing for faithful and unperturbed replication and transcription (Bernstein et al., 
2013; Lindahl, 1993). 
These interactions are especially relevant when studying MYC, since MYC 
deregulation or overexpression is associated with elevated levels of transcription, 
replication, and DNA repair. To maintain viability under genomic stress, coordination of 
these processes may be critical. Consistent with this, MYC overexpression can induce 
DDR, suggesting that increased DDR activity may become necessary for survival in 
conditions of hyperactive replication and transcription (Campaner and Amati, 2012). 
Though little has been investigated for the case of MYC specifically, connections 
between transcription, replication, and repair abound. Transcription and replication have 
been suggested to communicate through several modes, including chromatin marks and 
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spatial and temporal regulation (Helmrich et al., 2013). Replication and repair are linked 
through cell cycle checkpoints that can, at least in part, promote temporal separation of 
the processes (Bartek and Lukas, 2001). The fork protection complex (FPC) can aid 
stalled replication forks to prevent collapse during S-phse (Errico and Costanzo, 2012). 
Lastly, transcription and repair have also been shown to be coupled in some cases, the 
most well characterized being the transcription-coupled repair pathway (TCR, or TC-
NER for transcription-coupled nucleotide excision repair) (Vermeulen and Fousteri, 
2013). Though existing evidence of TCR is centered specifically on repair of UV-induced 
DNA lesions, this pathway is an elegant example of coupling two distinct genomic 
processes for the preservation of genome integrity. 
 
i. Transcription-coupled repair 
Transcription is one of the core processes necessary for survival. Thus, any 
obstructions in promoters, enhancers, and gene encoding regions of DNA must be 
thwarted to execute efficient and seamless transcription. To this end, one of the 
mechanisms that cells have evolved is TCR, which augments the already existing 
repertoire of DNA repair systems with one specifically coupled to the transcription 
process (Vermeulen and Fousteri, 2013).  
TCR is considered a sub-pathway of the larger nucleotide excision repair (NER) 
system which repairs bulky adducts on DNA, including cyclobutane pyrimidine dimers 
(CPDs) and other UV-induced lesions. At least in experimental conditions, over 90% of 
UV lesions appear to be repaired by the global NER pathway, accounting only the 
remaining <10% for TCR (Limsirichaikul et al., 2009; Nakazawa et al., 2010). However, 
TCR is extremely significant since mutations in genes specific to TCR give rise to a 
distinct set of human diseases including Cockayne syndrome (CS), cerebro-oculo-facio-
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skeletal syndrome (COFS), and UV-sensitive syndrome (UVSS) (Table 1). CS and 
COFS are characterized by photosensitivity as well as multisystem abnormalities and 
reduced lifespan, and UVSS, though much more mild, also causes increased 
photosensitivity (Table 1) (Lehmann, 1982; Meira et al., 2000; Spivak, 2005). These 
TCR-defective diseases are distinct from xeroderma pigmentosum (XP), which arises 
from mutations in genes of the global NER pathway.  
 
Interestingly, unlike XP patients who are extremely susceptible to skin cancer, 
defects in TCR are not associated with skin cancer susceptibility (Table 1) (Sarasin, 
2012). TCR is a distinct and critical pathway, perhaps with additional functions outside of 
Using cell lines derived from two UVSS-A patients, 
Nakazawa et al. [7] identifi ed homozygous mutations 
(c.367A>T) leading to a premature stop codon in the 
KIAA1530 (renamed UVSSA) gene. Interestingly, a 
homo zygous missense mutation (p.Cys32Arg) in this gene 
was found in an i dividual previously mis-diagnosed 
with mild XP. Zhang et al. [8] carried out microcell-
mediated chromosome transfer of mouse DNA in order 
to complement the repair defi ciency of UVSS-A human 
cells, and isolated the mouse homologue of KIAA1530 as 
the gene responsible for UVSS-A. Sequencing of this gene 
from several UVSS-A cells also revealed mutations 
leading to premature termination of the UVSSA protein 
[8]. Schwertman et al. [9] identifi ed several diff erentially 
ubiquitinated proteins following UV irradiation of HeLa 
cells. Th e most prominent factors were repair proteins 
involved in NER (XPC, DDB2, RNA RNA polymerase 
(RNA Pol) II and CSB) as well as UVSSA. Using mass 
spectrometry, it was demonstrated that UVSSA interacts 
with the deubiquitinating enzyme ubiquitin carboxyl-
terminal hydrolase 7 (also known as ubiquitin-specifi c 
protease 7, USP7) [8,9]. Transfection of wild-type tagged 
UVSSA cDNA restored normal RRS in UVSS-A cells, 
while small interfering RNA (siRNA)-based depletion of 
UVSSA transcripts caused a marked reduction of RRS in 
normal cells, illustrating that the UVSSA-USP7 complex 
is crucial for restoration of gene expression following UV 
irradiation. Taken together these data indicate that 
UVSSA is the causal gene in UVSS-A, and that the 
UVSSA-USP7 complex is involved in TC-NER.
UVSSA interactions and the role of the ubiquitin 
proteasome pathway
Using three-dimensional structure prediction of UVSSA, 
Nakazawa et al. [7] identifi ed two domains of unknown 
function: a VHS domain (homology with the Vps-27, Hrs 
and STAM domain) near the amino terminus and a 
DUF2043 domain (EMBL-EBI IPR018610) near the 
carboxyl terminus. Th e VHS domain has been implicated 
in ubiquitin binding and in interaction with the carboxy-
terminal part of RNA Pol II; it has also been suggested 
that the UVSS-A mutation Cys32Arg might obstruct 
interactions between the VHS domain and ubiquitinated 
proteins. UVSSA truncated mutants lacking either VHS 
or DUF2043 domains failed to complement the UVSS-A 
defi ciency, indicating that these two domains are 
necessary for TC-NER activity.
One of the major players in TC-NER is the ten-protein 
complex TFIIH, involved in both NER and transcription 
initiation [1]. Nakazawa et al. [7] demonstrated that 
UVSSA interacts with ERCC2, ERCC3, p62 and the CAK 
subcomplex (all part of TFIIH). Furthermore, Zhang et 
al. [8] showed that UVSSA interacts with CSA in the 
absence of UV, and with CSB and RNA Pol II after UV 
irradiation, and that both UVSSA and CSB are necessary 
for full completion of TC-NER. Th us, interaction between 
UVSSA and the major proteins involved in TC-NER 
suggests that UVSSA may play a pivotal role in this 
process.
USP7 has several NER and DNA damage response 
(DDR) proteins as substrates. Schwertman et al. [9] 
showed that USP7 resided in chromatin-immuno-
precipitated TC-NER complexes in a UV- and UVSSA-
dependent manner. In UVSS-A cells, the absence of 
UVSSA correlated with the instability of CSB, probably 
due to the lack of USP7 recruitment in the TC-NER 
complex. Indeed, depletion of USP7 by siRNA caused a 
similar RRS defi ciency and decreased levels of CSB. 
Th ese data indicate that UVSSA and USP7 cooperate to 
protect CSB from UV-induced degradation in TC-NER 
via the ubiquitin-proteasome pathway. Because USP7 has 
multiple roles in the DDR, an important role of UVSSA 
might also be to deliver the deubiquitinating enzyme to 
the vicinity of TC-NER factors, allowing smooth regu la-
tion of ubiquitination and deubiquitination. Zhang et al. 
[8] also showed that this recruitment is CSA-dependent.
Using local UV damage, it has also been shown that 
tagged-UVSSA accumulated in vivo at UV-induced DNA 
lesions (with kinetics similar to CSB), and interacted with 
the elongating form of RNA Pol II (Pol IIo) [9]. Following 
UV irradiation, transcription is rapidly inhibited and fast 
repair of lesions is necessary to ensure survival of 
damaged cells. Pol IIo is stalled at UV-induced DNA 
lesions and needs fi rst to be displaced by backtracking or 
degradation to allow access to repair factors. During this 
step, Pol IIo is ubiquitinated, and CSA and CSB proteins 
are necessary for this process. In UVSS-A cells, the 
ubiquitinated Pol IIo was almost undetectable and the 
normal Pol IIo form disappeared over a 6-h period 
Table 1. Clinical, genetic and biochemical comparisons of 
XP, CS and UVSS 
 XP CS UVSS
Sun-sensitivity Yes Yes Yes
Skin cancers Yes No No
Progressive neurological degeneration Yes/noa Yes No
Developmental abnormalities No Yes No
Ageing Yes/noa Yes No
UV-DNA repair defi ciency Yes Yes Yes
ROS-DNA repair defi ciency Yes/noa Yes No
Complementation groups 7 2 3
Involved genes XPA to  CSA and CSA, CSB
 XPGb CSB and 
   UVSSA
aSome XP patients exhibit XP and CS (mutated on XPA, XPB, XPD and XPG). bSeven 
genes are involved in XP. CS, Cockayne syndrome; ROS, reactive oxygen species; 
UV, ultraviolet; UVSS, UV-sensitivity syndrome; XP, xeroderma pigmentosum.
Sarasin Genome Medicine 2012, 4:44 
http://genomemedicine.com/content/4/5/44
Page 2 of 4
Table 1. Clinical, genetic, and biochemical phenotypes associated with XP, CS, and UVSS. XP 
is caused by defects in GG-NER genes, while CS and UVSSA are caused by defects in TCR 
(TC-NER). XP, CS, and UVSS patients all exhibit UV sensitivity, though in UVSS it is relatively 
mild compared to XP and CS. Though CS patients show congenital abnormalities, UVSS 




UV-damage repair as not all symptoms of TCR-defective diseases can be explained 
solely by increased UV sensitivity. Supporting this notion, at least some TCR genes 
have roles in general transcription and other RNA synthesis pathways, which may 
explain at least in part why systemic symptoms occur in TCR-defective diseases (Velez-
Cruz and Egly, 2013). 
Activation of TCR in normal cells by exogenous UV damage results in 
preferential repair on the transcribed strand, since repair is directly coupled to actively 
transcribing RNAPII (Hanawalt and Spivak, 2008). Studies have pointed to at least two 
important functions of TCR: 1) to remove or displace stalled transcription complexes 
from the DNA to provide access for TCR proteins and subsequent repair factors, and 2) 
to remove and repair the lesion for resumption of transcription. TCR is initiated when an 
engaged RNAPII stalls at a lesion and recruits key factors that are unique to TCR. The 
best-characterized factors recruited at this stage include Cockayne syndrome A (CSA or 
ERCC8) and Cockayne syndrome B (CSB or ERCC6). Mutations in ERCC6 or ERCC8 
cause Cockayne syndrome (Vermeulen and Fousteri, 2013). Following recognition and 
displacement of stalled RNAPII by these proteins, the actual excision of the lesion and 
gap filling are performed by proteins which perform these functions in global NER, 
including XPF/ERCC1, XPA, XPG, and TFIIH. After lesion repair, however, TCR 
requires specific factors including XAB2, HMGN1, UVSSA, and ELL, which all appear to 
be required for efficient recovery of transcription. Thus, TCR comprehensively 
orchestrates RNAPII backtracking, recruitment of repair factors, and recovery of proper 
transcription (Mourgues et al., 2013; Vermeulen and Fousteri, 2013). 
Mechanistic details of TCR are not entirely clear. In response to a stalled 
RNAPII, CSB is recruited early and is required for recruitment of subsequent TCR 
factors (Figure 8) (Fousteri et al., 2006; Groisman et al., 2003). Both the DNA-binding 
domain and ubiquitin-binding domains of CSB are required for its role in TCR, however, 
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it is unclear if its enzymatic activities (controversial helicase activity and chromatin 
remodeling activity) are required for TCR in vivo (Vermeulen and Fousteri, 2013). 
Notably, CSB has been implicated in a variety of other processes including 
transcriptional elongation, chromatin maintenance, and mitochondrial DNA stability, 
which adds complexity (Vermeulen and Fousteri, 2013). Nevertheless, CSB is one of the 
central players essential for successful TCR. 
CSA is an E3 ubiquitin ligase that is also recruited early and is essential for TCR 
(Figure 8) (Saijo, 2013). Much interest surrounds the substrates of CSA ligase activity. In 
vitro, CSA can autoubiquitinate, though this has not been shown in vivo. One of the 
current models suggests that autoubiquitinated CSA directly interacts with CSB through 
CSB’s ubiquitin-binding domain, and this interaction regulates the stability of both 
proteins at the sites of TCR allowing for their efficient clearance upon completion of 
repair (Groisman et al., 2006). However, this remains to be demonstrated directly. 
UVSSA was recently identified as a novel TCR factor, of which mutations cause 
UVSS, a rare photosensitive disorder (Nakazawa et al., 2012; Schwertman et al., 2012; 
Zhang et al., 2012). Notably, the mild phenotype of UVSS patients suggests that 
UVSSA’s cellular role may only be in TCR, unlike CSA or CSB which mutations cause 
more profound systemic diseases. UVSSA forms a complex with the deubiquitinating 
enzyme USP7, which appears to accumulate at stalled RNAPII complexes (Figure 8). 
The absence of functional UVSSA impairs TCR and transcription recovery. Collectively, 
these studies suggest that UVSSA-USP7 stabilizes stalled RNAPII-CSB complexes by 
counteracting the polyubiquitination of RNAPII and/or CSB, preventing premature 
degradation to facilitate successful TCR (Sarasin, 2012; Schwertman et al., 2013). 
Theses studies revealed that TCR regulation may involve yet unknown mechanisms of 





Few other factors have been specifically implicated in TCR. The XPA-binding 
protein XAB2 appears to be recruited to TCR sites following CSB and CSA, and bridges 
TCR with RNA splicing (Kuraoka et al., 2008). XAB2 is required for recovery of 
transcription. HMGN1 is another factor required for efficient TCR. HMGN1 is a chromatin 
remodeler, recruited to TCR sites in a CSB- and CSA-dependent manner (Fousteri et al., 
2006). It has been speculated that chromatin remodeling by HMGN1 is required to allow 
Figure 8. Current model of transcription-coupled repair (TCR). (A) When an actively engaged 
RNAPII encounters a UV-induced lesion, UVSSA-USP7 and CSB are initially recruited to aid in 
backtracking or displacement of the transcriptional complex. (B) UVSSA-USP7 complex may de-
ubiquitinate and stabilize CSB on RNAPII complexes to allow recruitment of other repair factors. (C) 
CSA is recruited to further stabilize the RNAPII complex and to recruit other TCR factors. The DNA 
lesion is then able to be repaired by NER factors, and RNAPII can resume transcription, or be 
recycled for a new round of initiation, following DNA repair. (From (Vermeulen and Fousteri, 2013)) 
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RNAPII backtracking before repair. Lastly, it was recently reported that ELL, a 
component of transcriptional elongation complexes, is required for recovery of 
transcription after TCR (Mourgues et al., 2013). Additional TCR factors may be identified 
in future studies, as missing links remain in the pathway. 
Although TCR has almost exclusively been studied in the context of UV-induced 
damage repair, TCR may be important under conditions of general transcription stress. 
The trigger for the TCR response appears to be stalled RNAPII, which could 
physiologically arise from situations such as hyperactive transcription or collisions 
between the transcription and replication machinery. It is possible that such a response 
becomes critical in cells with persistent genome instability from oncogene activation 
such as MYC, though no direct evidence exists regarding the relationship between TCR 
and cancer. 
3. Synthetic lethality 
The concept of synthetic lethality is based on the idea that different genetic 
networks in the cell have distinct interactions. The most simplified definition of a pair of 
synthetic lethal (SL) genes is two genes that confer lethality when lost simultaneously, 
though neither is individually essential for viability. In other words, while inactivation of 
one gene can be tolerated, loss of the second gene confers death (Kaelin, 2009).  
Synthetic lethality has been well studied in model organisms such as 
Saccharomyces cerevisiae and Caenorhabditis elegans (Reinhardt et al., 2009). 
Comprehensive screening in these systems have identified thousands of potential 
classical SL interactions, as well as “synthetic sick” interactions, in which fitness is 
compromised though not to lethal levels (Dixon et al., 2009). In budding yeast, “synthetic 
dosage lethality” has been studied as well, exploring genetic vulnerabilities of cells 
overexpressing certain genes (Tong and Boone, 2006). In most of the literature, 
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however, “synthetic lethality” is generally loosely used to refer to various genetic 
interactions that exploit genetic vulnerabilities that arise, not just through the loss but 
also through point mutations, gain of function, overexpression, or deregulation of specific 
genes (Kaelin, 2005). 
 
a. Synthetic lethality in human cancer therapy 
Efforts to exploit synthetic lethality to combat cancer were pioneered by chemical 
library screens in yeast cells with defects in cell cycle or DNA repair (Matuo et al., 2012). 
This approach was quickly adopted in human cells, as utilizing synthetic lethality for 
cancer therapy is attractive for several reasons (Hartwell et al., 1997). First, SL 
interactions that exploit cancer-specific genetic lesions would be selectively lethal to 
cancer cells, sparing normal cells. This is a critical advantage, since one of the largest 
ongoing problems of cancer therapy are the detrimental side effects of nonspecific drugs 
on surrounding normal cells and tissues (Iglehart and Silver, 2009). Secondly, SL 
interactions could provide alternative druggable targets for commonly deregulated tumor 
suppressors and oncoproteins that are difficult to directly target pharmacologically. Since 
many of the known cancer drivers fall into this category, including p53, KRAS, and MYC, 
utilizing synthetic lethality offers a whole new realm of hope for developing targeted 
therapy for a larger portion of human cancers (Reinhardt et al., 2009). 
Over the last two decades, many potential SL interactions relevant to cancer 
have been reported. Candidate approaches based on existing hypotheses, as well as 
genome-wide interrogations for a more unbiased and comprehensive approach, have 
been widely investigated (Weidle et al., 2011). While many studies have provided 
promising results, one of the standout discoveries was the SL interaction between 
BRCA1/2 and PARP inhibitors (Bryant et al., 2005; Farmer et al., 2005). This pivotal 
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report has been widely recognized as proof of principle for the real-life relevance of 
synthetic lethality to cancer therapy, and has triggered increased interest for SL mining 
in the cancer field. 
 
i. BRCA1/2 and PARPi 
BRCA1 and BRCA2 are classic tumor suppressor genes, initially discovered in 
breast cancers but also with critical tumor suppressor activity in other cancer types 
(Foulkes and Shuen, 2013). Sporadic or germline mutations, inactivation, or loss of 
BRCA1 and/or BRCA2 account for the majority of hereditary, as well as a proportion of 
sporadic, breast tumors. The most relevant function of BRCA1 and BRCA2 to tumor 
suppression is their role in DNA double strand break repair (Liu and West, 2002; Powell 
and Kachnic, 2003). However, breast cancer cells can still survive with dysfunctional 
BRCA1/2, as other DNA repair pathways are able to compensate. This contributes to 
increased genomic instability, since compensatory pathways can be low fidelity and 
mutagenic, further contributing to tumorigenesis. 
Two groups reported in 2005 that blocking the Poly (ADP-ribose) polymerase 
(PARP) enzymes using a chemical inhibitor selectively caused cell death in BRCA1- or 
BRCA2-deficient cells (Bryant et al., 2005; Farmer et al., 2005). PARP enzymes are 
critical in base excision repair (BER), primarily responsible for repairing single-stranded 
DNA breaks (Helleday, 2011). Administration of PARP inhibitors in BRCA1/2-deficient 
cells led to persistent DSBs that caused chromosome instability, cell cycle arrest, and 
apoptosis, showing that the loss of both BRCA1/2 (HR) and PARP (BER) pathways led 
to lethal levels of DNA damage. BRCA1/2-deficient cells selectively develop an 
increased dependence on the PARP pathway, while normal cells are able to survive 
without it (Bryant et al., 2005; Farmer et al., 2005). Preclinical studies using PARP 
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inhibitors on cell lines and mice with BRCA-deficiencies have been largely successful 
(Bryant et al., 2005; Farmer et al., 2005). Particularly, olaparib has shown promising 
results in phase I, phase II, and ongoing phase III clinical trials on cancer patients with 
BRCA1/2 defects (Fong et al., 2009; Tutt et al., 2010).  
 
b. Synthetic lethality and MYC 
A synthetic lethal approach to target oncogenic MYC is attractive, since MYC is a 
major oncoprotein, and notoriously difficult to inhibit pharmacologically. Several groups 
have tested panels of small molecule drugs on MYC-overexpressing cancer cells, and 
have proposed several candidates including chloroquine and topoisomerase inhibitors 
(Frenzel et al., 2011; Maclean et al., 2008). However, finding mechanistic explanations 
for these interactions have proven difficult, as well as replicating results in other cell 
types. Other groups have taken candidate approaches to test specific genes as SL 
candidates in MYC-overexpressing cells by predicting vulnerabilities based on known 
aspects of MYC functions. Some of these studies have brought promising results, 
including DR5, WRN, and various CDKs, as discussed below. Finally, more recently, 
large-scale screening for SL interactions have become possible in mammalian cells, and 
discussed below are three screens that probed for SL interactions with deregulated 
MYC.  
 
i. Candidate approaches 
1. DR5 
A number of studies have reported that cell death pathways may be synthetic 
lethal with MYC, since MYC can influence apoptosis through transcription, and MYC 
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overexpression sensitizes cells to apoptosis (Evan et al., 1992; Juin et al., 1999). 
Particularly, agonists of the TRAIL-death receptor DR5 are synthetic lethal with MYC 
(Wang et al., 2004). Since DR5 is one of MYC’s transcriptional targets, cell surface 
levels of DR5 are increased in MYC-overexpressing cells, leading to this sensitization. 
Although it is unclear whether DR5 is required for MYC-induced apoptosis, this 
demonstrates the vulnerability of MYC-overexpressing cells to a particular cell death 
pathway. 
The group subsequently performed an siRNA screen targeting the human 
kinome, and found that GSK3β is synthetic lethal with MYC overexpression in a TRAIL 
receptor-dependent manner (Rottmann et al., 2005). Knockdown of GSK3β led to 
stabilization of MYC levels, which recapitulated their previous findings of increased DR5 
and induction of apoptosis. This effect was due to reduction of T58 phosphorylation of 
MYC, which prevented its interaction with FBXW7, consequently stabilizing the protein 
(Rottmann et al., 2005).  These early studies pointed to the potential significance of 
increasing levels of cellular MYC as a means to confer lethality.  
 
2. WRN 
Grandori’s group has pioneered studies on the synthetic lethal interaction 
between MYC overexpression and loss of WRN (Grandori et al., 2004; Grandori et al., 
2003; Moser et al., 2012; Robinson et al., 2009). The WRN gene encodes for one of the 
RecQ helicases in humans, and is named for the disease caused by inactivating 
mutations in this gene. Werner syndrome, at the cellular level, is characterized by 
accelerated cellular senescence and increased chromosome instability including 
frequent chromatid breaks (Rossi et al., 2010). Since WRN helicase is involved in DNA 
repair, these phenotypes are thought to be due to persistence of DNA damage.  
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The WRN helicase resolves topologically aberrant structures during HR or other 
DNA repair pathways to promote successful repair. WRN is also active during DNA 
replication, resolving structures such as stalled forks to consequently alleviate replication 
stress (Rossi et al., 2010). In cells derived from patients with Werner syndrome, MYC 
overexpression leads to excessive accumulation of replication-dependent DNA damage, 
which results in accelerated senescence (Grandori et al., 2003; Robinson et al., 2009). 
This led to activation of the ATR-CHK1 pathway, consistent with accumulation of single-
stranded DNA, which colocalized with stalled replication forks. These findings were 
further confirmed in xenografts and transgenic mouse models, suggesting that the 
genetic interaction may be relevant to physiological human tumors (Moser et al., 2012). 
Interestingly, WRN is a direct transcriptional target of MYC, suggesting a positive 
feedback loop in which increased activity of WRN creates a more permissive 
environment for MYC overexpression (Grandori et al., 2003). It is also of note that 
Werner syndrome patients do not present MYC-driven cancers, although they are 
cancer-prone, consistent with the idea that MYC overexpression may confer lethality for 
cells with WRN loss (Grandori et al., 2003). These studies have introduced the potential 
of genome instability being a major vulnerability of MYC-overexpressing cells. 
 
3. CDKs, ATR, CHK1, and Aurora kinases 
Based on evidence of MYC-dependent cell cycle deregulation and genomic 
instability, cyclin-dependent kinases have also emerged as attractive SL candidates 
(Goga et al., 2007). It has been suggested that CDK2 inhibition causes p53-dependent 
apoptosis in MYCN-overexpressing neuroblastoma cells, and that MYC overexpression 
in CDK2-null mouse cells induces senescence (Campaner et al., 2010; Molenaar et al., 
2009). Chemical inhibition of ATR or CHK1 has been shown to trigger a strong DDR 
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response in MYC-deregulated cells, resulting in apoptosis (Murga et al., 2011). 
Furthermore, transgenic mice generated by crossing ATR homozygous hypomorphic 
mutants with Eµ-MYC have shown that the ATR mutation is able to suppress Eµ-MYC-
mediated lymphomagenesis, emphasizing the critical role of ATR (Murga et al., 2011). 
CHK1 inhibition has also been shown to effectively target MYCN-overexpressing cells 
(Murga et al., 2011). These results are promising, however, whether inhibition of these 
kinases that are central to cell viability is practical for cancer therapy is a question. 
It has also been suggested that Aurora kinases, involved in mitotic regulation, are 
SL candidates with MYC overexpression (den Hollander et al., 2010; Yang et al., 2010). 
VX-680, an Aurora B inhibitor, showed selective killing of MYC-overexpressing cells 
(Yang et al., 2010). However, since VX-680 can additionally inhibit Aurora A and C, as 
well as ABL, a well-known oncogene, further studies are necessary (Fei et al., 2010).  
 
ii. High-throughput approaches 
With the advancement of RNAi technology and bioinformatics, high-throughput 
screening has become accessible in mammalian cells (Figure 9) (Simpson et al., 2012). 
Several large-scale screens for synthetic lethal interactions with high-profile oncogenes 
have been published in the last several years (Luo et al., 2009; Mills et al., 2013). Three 
such screens for MYC (MYC-SL screens) have been reported (Kessler et al., 2012; Liu 
et al., 2012; Toyoshima et al., 2012). Though the complexity of data across the screens 
emphasize the need for further studies, the individual studies have proposed interesting 




1. Carla Grandori group: CSNK1E 
Toyoshima and colleagues conducted an siRNA screen using isogenic human 
foreskin fibroblasts (HFFs) with constitutive MYC overexpression from a retroviral vector 
35521 Pooled shRNA Screenings: Experimental Approach
 
 The library pool consists of 58,493 shRNAs integrated into the 
backbone of miR-30  ( 6 ) and cloned into the pGIPZ lentiviral 
vector (Open Biosystems GIPZ Lentiviral Human shRNA Library). 
It is known that 39,458 of these shRNAs target 18,661 human 
genes, which accounts for about 75% of the human genome. 
Combining RNA polymerase II promoters with shRNAs in miR-
30 backbones permits ef fi cient suppression even with the integra-
tion of a single copy. Each shRNA cassette contains two unique 
identi fi ers: the shRNA itself and a random 60-nucleotide barcode 
that was determined for the identi fi cation of a single shRNA 
among the human shRNA library. Overall, the shRNA library 
offers a convenient,  fl exible, and effective tool for studying gene 
function in human cells  ( 9 ) . 
 2.  Materials
 2.1.  shRNA Library
 Fig. 1.  Schematic representation of the steps involved in a negative and positive selection screen. The  fi rst step in both 
selection strategies is transducing the target cell line with the lentiviral pool. The infected population that survives after 
antibiotic selection represents the starting point. In a positive screen, because the shRNAs enable the target cell line to 
acquire a differentiating phenotype or allow it to survive a selective pressure, only a few shRNAs from the original pool will 
be left to analyze. In a negative screening, the shRNAs that are underrepresented after treatment are the analyzed ones. 
To identify these shRNAs, it is necessary to analyze the variation in the representation of each shRNA after the selective 
pressure in comparison to an untreated control. 
 
Figure 9. Large-scale screening in mammalian cells. (A) A “one gene per well” approach 
utilizes  single chemical or RNAi c nstruct in each well. C ll death or other readouts can be 
monitored and compared betwe  different cell lin s ( g. wild ype vs cancer) to identify 
specific vulnerabilities. Red arrow denotes a chemical or specific siRNA/shRNA that confers 
cancer cell-specific death, while tolerated by wildtype cells. (From (Kaelin, 2005)) (B) A 
pooled approach utilizes an siRNA/shRNA library containing individually barcoded clones. In 
a positive selection screen, cells expressing siRNA/shRNA that confer a growth advantage 
under selective pressure are enriched in the surviving population. In a negative selection 
screen, cells expressing siRNA/shRNA that compromise viability under a selective pressure 
(such as oncogene expression) are depleted from the population and can be analyzed. 
(From (Rodriguez-B rrueco et al., 2013)) 
B  Pooled approach 




(Toyoshima et al., 2012). Utilizing a “one gene per well” method, they examined a panel 
of ~3,000 “druggable” human genes for SL candidates (Figure 9A). They were able to 
recover 140 high-confidence hits, of which 98% were confirmed by subsequent 
validation (Grandori, 2013).  
They report that CSNK1E expression correlates with MYCN in neuroblastoma 
samples, and that pharmacological inhibitors of CSNK1E selective kill MYC-
overexpressing cells, inducing tumor regression in mouse xenografts (Toyoshima et al., 
2012). These studies demonstrate that such discoveries of novel candidates previously 
never implicated in MYC biology are one of the greatest advantages of these large-scale 
screens. Furthermore, since chemical inhibitors of CSNK1E already have been 
developed and can selectively target MYC-overexpressing cells, at least in experimental 
conditions, these findings may be translatable to cancer therapy down the line. 
 
2. Thomas Westbrook group: SAE2 
Kessler and colleagues used the HMEC mammary epithelial cell line expressing 
an inducible MYC-ER fusion protein (Kessler et al., 2012). They utilized a pooled human 
retroviral shRNA library, allowing for simultaneous introduction of 74,905 shRNA 
constructs into a large population of cells (Figure 9B). Also known as a “dropout screen,” 
they focused on the shRNAs that were selectively lost from MYC-overexpressing cells 
compared to control. In contrast to other methods, this process allows for the screening 
of a large number of genes at once. 
They reported 403 high-confidence hits, and focused their studies on SAE2, a 
component of the human SUMOylation pathway. Intriguingly, SAE2 knockdown in the 
presence of MYC activation caused mitotic catastrophe, leading to cell death. SAE2 
knockdown altered the landscape of MYC-induced gene expression, including genes 
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involved in mitotic spindle function, which likely led to the phenotype (Kessler et al., 
2012).  
 
3. Daniel Murphy group: ARK5 
Liu and colleagues examined ~800 genes as potential MYC-SL candidates (Liu 
et al., 2012). They employed the “one gene per well” method using siRNA against the 
human kinome in U2OS cells expressing the inducible MYC-ER transgene (Figure 9A). 
For readout, this group utilized PARP cleavage, which signifies apoptosis. Notably, this 
apoptosis readout could yield different results compared to a dropout-type screen like 
the two aforementioned. 
Identified were two hits, ARK5 and AMPK, which are known regulators of cellular 
metabolism (Liu et al., 2012). ARK5 (or NUAK1) depletion in MYC-overexpressing 
conditions resulted in loss of viability and ATP depletion from cells. Since ARK5 and 
AMPK are critical in metabolic processes including protein synthesis and mitochondrial 
respiratory capacity, metabolic stress may be one of MYC’s critical Achilles’ heels (Liu et 
al., 2012). Especially in the light of increasing evidence linking MYC to metabolic stress 
and the Warburg effect, it is possible that modulation of metabolic pathways may 
selectively inhibit the growth of MYC-overexpressing cells (Dang, 2010).  
 
4. Running Themes 
 Due to the varying methods and tools employed, there are very few MYC-SL 
candidate overlaps across the three datasets. Of course, there is a possibility that 
differing modes and levels of MYC deregulation, as well as the cell type in which MYC 
deregulation occurs, dictates the specific genetic vulnerabilities that manifest, especially 
if MYC can function as a general amplifer of transcription (Lin et al., 2012; Nie et al., 
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2012). However, equally likely is that common underlying MYC-SL networks and 
pathways, instead of genes, may be uncovered by analyzing the datasets against each 
other. 
 
 To this end, Grandori’s group have analyzed the three datasets from the above 
screens utilizing functional proteomics, and have revealed three functional “hubs” that 
arise as MYC-SL candidate pathways (Figure 10) (Cermelli et al., 2014). These include: 
1) transcriptional initiation and elongation pathways, 2) regulators of the MYC-MAX 
network, and 3) ubiquitin and sumoylation pathways (Figure 10). Analyses of more 
diverse datasets should provide further insight into how universal these MYC-SL hubs 
may be.
Figure 10. Three functional hubs of MYC synthetic lethal genes.  Proteomics analysis of three 
published MYC-SL screens reveal three functional MYC-SL hubs including the MYC-MAX network 
(I), transcription initiation and elongation (II), and ubiquitination, SUMOylation, checkpoints, and 
DNA repair (III). Light blue circles represent Toyoshima hits, darker blue represent Kessler hits, and 
pink represents a set of genes known to functionally interact with MYC (MYC core). Yellow, green, 
and orange represent gene hits that appear in more than two gene sets. Lines represent genetic 
























1. MCF10A-MYCER as a model system 
 The consequences of MYC deregulation or overexpression can be studied in 
multiple experimental settings. Many engineered cell lines or cell lines derived from 
tumors are available with a wide spectrum of MYC expression and activity. Because 
cumulative research suggests that MYC functions can be specific and tailored to cell 
types, it is important to examine MYC effects and regulatory networks in various cellular 
contexts, especially since MYC can be a more prominent cancer driver in certain cells 
and tissues compared to others.  
Deregulated MYC expression is one of the characteristics of basal-like breast 
cancers (BBCs) (Alles et al., 2009; Horiuchi et al., 2012; Xu et al., 2010). Furthermore, 
overexpression of components of the pre-replicative complex (pre-RC) is often 
associated with the basal phenotype (Alles et al., 2009). Thus, we sought to screen for 
synthetic lethal candidates with MYC overexpression in a breast epithelial cell line with a 
basal-like phenotype (Debnath et al., 2003). To this end, we engineered the MCF10A-
MYCER cell line utilizing MCF10A cells and the MYCER (or MYC-ER) transgene.  
 
a. MCF10A 
 MCF10A (or MCF-10A) is a spontaneously immortalized, non-transformed, 
human mammary epithelial cell line originally derived from a 36-year-old patient with 
fibrocystic breast tissue (Soule et al., 1990). MCF10A cells display characteristics of 
normal breast epithelium including the lack of tumorigenicity when grafted into nude 
mice, lack of anchorage-independent growth, and dependence on growth factors and 
hormones for proliferation (Debnath et al., 2003; Soule et al., 1990). MCF10A cells have 
a relatively stable and near-diploid karyotype. Some have reported MYC gain or 
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amplification in this cell line, which is speculated to be a consequence of immortalization, 
however, cells grow in a relatively normal manner (Kadota et al., 2010; Worsham et al., 
2006). MCF10A cells harbor a deletion in the genomic locus including p16, p14ARF, and 
CDKN2A, but p53 is wildtype, leaving p53-dependent apoptosis pathways intact (Kadota 
et al., 2010; Merlo et al., 1995; Worsham et al., 2006).   
Importantly, MCF10A cells are negative for estrogen receptor (ER), which 
contributes to their basal-like phenotype along with the presence of high molecular 
weight cytokeratins (CK1, 5, 10, 14) and expression of ΔNp63α (DiRenzo et al., 2002). 
Because MCF10A cells can form acini in vitro when grown in three-dimentional (3D) 
cultures, it is often utilized for 3D tumorigenesis assays (Debnath et al., 2003). Such 
aspects of MCF10A cells make them an appropriate tool to model the genetic networks 
surrounding basal-like mammary cells.  
 
b. MYCER 
The MYCER (or MYC-ER) allele is one of the most widely used methods for 
allowing inducible MYC expression in cells. The initial MYCER construct was established 
by fusing the hormone-binding domain of the human estrogen receptor gene to the 3’ 
end of the human MYC gene (Eilers et al., 1989). The chimeric gene encoded for a 
protein that bound estrogen with high affinity, in a reversible manner, and was able to be 
activated by estrogen addition to the cell culture media. Following these initial 
observations, the MYCER transgene was subsequently modified to its current form, 
MYC-ERTAM, in which the human ER domain was replaced with the murine ER domain, 
and mutations were introduced to render the ER domain to respond exclusively to the 
synthetic ligand 4-hydroxytamoxifen (4OHT or 4-OHT) (Littlewood et al., 1995). These 
modifications have allowed bypass of initial problems including the off-target effects of 
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estrogen towards cell growth, and have allowed the MYCER system to become a 
powerful tool to study MYC function in vivo (Littlewood et al., 1995). 
Other methods of MYC overexpression are also commonly utilized, including 1) 
transduction of the native MYC transgene, 2) expression of the MYC transgene with 
protein-stabilizing mutations, and 3) use of cancer cell lines that already overexpress 
MYC. Nevertheless, we selected the MYCER system for our genome-wide screen for 
several reasons. First, the MYCER system allows for readily inducible MYC 
overexpression using 4OHT. While long-term and constitutive MYC overexpression may 
alter the genetic programs of cells in complex ways over time, the MYCER system 
allows for a controlled period of MYC overexpression, minimizing gene expression 
differences between control and MYC-overexpressing cells. Secondly, a substantial 
amount of literature suggests that the MYCER protein behaves as normal MYC, at least 
when assayed for basic MYC functions, suggesting that MYCER can be a physiological 
model for MYC deregulation or overexpression (Dang, 1999).  
2. Genome-wide shRNA screen using MCF10A-MYCER 
 Using the MCF10A-MYCER system, we conducted a genome-wide shRNA 
screen utilizing the GIPZ Lentiviral Human shRNA-mir Library (Thermo Scientific Open 
Biosystems, Waltham, MA, USA) as described in Rodriguez-Barrueco et al (Rodriguez-
Barrueco et al., 2013). The screen was designed as a negative (or dropout) screen, 
whereby shRNAs in the library that confer lethality or decreased fitness to cells are 
depleted from the total surviving population of cells over the course of four weeks 
following infection. We applied this protocol to compare the shRNAs which expression 
confers cell lethality between a population of cells treated with vehicle (MYC OFF) or 
4OHT (MYC ON). The shRNAs that were selectively depleted from the MYC ON 
population but not the MYC OFF population were scored as synthetic lethal candidates. 
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In order to achieve statistically relevant representation of each of the 58,493 
shRNA constructs included in the library, 210 million MCF10A-MYCER cells were first 
infected with the library at an infection efficiency of 30%, optimized for a target of 70 
million infected cells at an multiplicity of infection (MOI) of approximately 1. This 
corresponds to an average of 1000 cells infected with each of the 58,493 shRNA clones, 
which is sufficient representation based on previous works (Silva et al., 2008). After 
infection and antibiotic selection using 2 µg/ml puromycin, the infected MCF10A-MYCER 
cells were passaged twice to allow for 1) population expansion to prepare ten 
populations of 70 million cells, and 2) shRNA targeting essential genes to be depleted 
from the initial population in order to reduce background. Following these two passages, 
cells were divided into ten independent populations of 70 million cells, of which five were 
treated with vehicle (MYC OFF), and the other five were treated with 200 nM 4OHT 
(MYC ON) for the next four weeks. These independent populations served as five 
technical replicates, since they were later statistically analyzed to generate p-values for 
reproducibility between populations. However, since each population was independently 
passaged with vehicle or 4OHT for the next four weeks while constantly maintaining at 
least 70 million cells per population, they also partially served as biological replicates for 
our system. 
3. Screen analysis 
After four weeks, surviving cells from each population were harvested, and 
genomic DNA was isolated as described previously (Rodriguez-Barrueco et al., 2013). 
We used two independent techniques to compare the shRNA representation between 
MYC ON and MYC OFF cells. First, microarray hybridization was employed, by taking 
advantage of the unique shRNA sequences and 60-nucleotide barcodes associated with 
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each hairpin. Second, high-throughput (HTP) sequencing was employed by PCR-ligating 
adaptor sequences with marker nucleotides.  
 
a. Microarray hybridization 
Genomic DNA was subjected to large scale PCR using primers flanking all 
shRNA constructs and associated barcodes recovered from the surviving cells. This 
generated a heterogeneous pooled product of 350 bps on average, which was gel-
extracted and purified, labeled with Cy3, then hybridized to customized microarrays 
harboring complementary probes to the shRNA sequences and barcodes (Agilent 
Technologies, Santa Clara, CA, USA). Importantly, on each array, these experimental 
PCR products were hybridized against Cy5-labeled reference PCR products generated 
from the original shRNA library in order to assess the depletion or enrichment of the 
shRNA compared to the starting material. Data analysis was then performed as 
previously described (Yu et al., 2013). 
2317 shRNA clones were recovered that were depleted at least two-fold in the 
MYC ON population compared to MYC OFF. Within these 2317 shRNAs, the fold 
depletion in MYC ON compared to MYC OFF ranged from 2-fold to 6.63-fold (-
2.73<Log2 FC<-1, FC= fold change) and p-values between the five technical replicates 
ranged from p=0.01 to 0.69 within these 2317 shRNAs (0.01<p<0.69 between five 
replicates). From this set of 2317 shRNAs, 558 shRNAs passed the p-value cutoff of 
p<0.1, and 236 shRNA passed the cutoff of p<0.05, suggesting that they were high-
confidence synthetic lethal (SL) candidates. Upon closer examination, 169/558 of the 
p<0.1 hits and 78/236 of the p<0.05 hits corresponded to annotated genes according to 
PubMed. We decided to primarily focus on these annotated genes. Upon functional 
clustering of these SL candidate genes using the KEGG pathways in the DAVID 
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Bioinformatics Database, we found enrichment of genes involved in ubiquitin-mediated 
proteolysis, PPAR (peroxisome proliferator-activated receptor) signaling pathway, fatty 
acid biosynthesis, fructose and mannose metabolism, and homologous recombination 
(Chapter 3, Figure 2). The full list of synthetic lethal candidates (p<0.1) recovered from 
microarray hybridization is presented in Table 1 in this chapter (Table 1), while the 
shorter list of 78 high-confidence synthetic lethal targets (p<0.05) is included in the next 
chapter (Chapter 3, Supplementary Table 1). 
We combined this statistical analysis with a candidate approach to select hits for 
further validation. Since we were initially interested in finding SL candidates that may be 
involved in maintenance of genome stability during MYC deregulation, we first focused 
on genes with known roles in genome maintenance. Homologous recombination was 
one of the identified candidate SL pathways, and TOP3A and TOP3B both ranked within 
the top 78 SL candidates (Log2 FC<-1, p<0.05). Thus, we first sought to validate TOP3A 
(Log2 FC=-1.17, p<0.05), TOP3B (Log2 FC=-1.43, p<0.05), and TOP2B (Log2 FC=-
1.23, p<0.1) as SL candidates with MYC deregulation (Rank 71, 105, 117 in Table 1). 
However, we were not able to validate a SL interaction through: 1) competition survival 
assays; 2) the use of chemical inhibitors of topoisomerases; or 3) acute siRNA 
knockdown (data not shown). We have also attempted to validate H2AFV (Log2 FC<-1, 
p<0.05, Rank 22 in Table 1), as well as FASN and PARP3 (Log2 FC<-1, p<0.1, Rank 6, 
120 in Table 1), as SL candidates using competitive survival assays, but have failed to 
see results suggesting significant synthetic sickness or lethality (data not shown). 
Notably, two independent shRNAs targeting PRMT8 scored as SL candidates within an 
acceptable p-value (p<0.1, Rank 15 and 136 in Table 1). However, we could not detect a 
significant synthetic lethality in validation assays (data not shown).   
We were able to successfully validate FBXW7 and UBE2I, which are discussed 
in Chapter 3 (Log2 FC<-1, p<0.05, Rank 126 and 139 in Table 1). This brings our raw 
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validation success rate to 2/6, at least within the high-confidence SL candidate list 
(p<0.05). Though this number seems low, it is also important to note that this screen has 
an approximately 30% false discovery rate (FDR) with this method of analysis 
(0.25<FDR<0.31). Taking this into account, within our limited validation studies, our 33% 
success rate in validation appears to be a reasonable outcome, though further validation 
of more high-confidence SL candidates is necessary in order to make statistical 
conclusions. Nevertheless, these results emphasize the fallback of this analysis method 
as well as the screen itself, and suggest the benefits of introducing additional analysis 
methods such as secondary screens or more sophisticated bioinformatics tools in order 
to achieve higher validation success rates. 
 
b. High-throughput sequencing 
 The genomic DNA isolated from the surviving cells was also subjected to PCR 
using primers with adaptor sequences to the Illumina sequencing platform (Illumina, Inc., 
San Diego, CA). By engineering 6-nucleotide codes within these primers to differentiate 
each of the ten populations of cells (five replicates each of MYC OFF and MYC ON), all 
of the PCR products could be sequenced in one lane as a pool. This method allows for 
sequencing of all PCR products generated from shRNAs present in the surviving cell 
populations, instead of assessing relative enrichment/depletion as in the microarray 
hybridization. PCR products were purified from each of the 10 surviving populations (5 
replicates each of MYC ON and MYC OFF) and 500ng of each were pooled into a final 
mixture of 5mg DNA in 25µl of water. This sample was sent to the Columbia Next 
Generation Sequencing Facility (Columbia University, New York, NY, USA) and was 
processed (HiSeq 2000, 200m raw 100bp Single Ends reads per lane, multiplex=1). 
Resulting data was analyzed by Dr. Jiyang Yu as previously described (Yu et al., 2013), 
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to generate a comprehensive list of shRNAs with their respective Log2 FC, p-values, 
and FDRs based on the high throughput sequencing results. 
 30,685 total shRNA IDs were identified that were depleted at least two-fold in the 
MYC ON cells compared to MYC OFF (-45.81<Log2 FC<-1, 0.00007<p<1 between five 
replicates). Within these, 4129 shRNAs passed the cutoff of p<0.1, 2184 shRNAs 
passed p<0.05, and 469 shRNAs passed the cutoff of p<0.01. Again, we elected to 
examine only the genes annotated on PubMed, which pared down these numbers to 
2425, 1319, and 316 shRNAs, respectively. The list of 316 high confidence synthetic 
lethal candidates (p<0.01) from this analysis method is included in this chapter (Table 2). 
Upon functional clustering, we found that the 316 high-confidence SL candidates 
(p<0.01) were enriched in genes involved in ubiquitin-mediated proteolysis and DNA 
replication. Table 3 shows additional biological pathways that are represented in gene 
sets with higher p-value cutoffs (Table 3). Interestingly, we recovered two hits within the 
316 high-confidence SL candidates (p<0.01), GPATCH1 and NOL6, which appear twice, 
which means two independent shRNA clones targeting these genes scored as high-
confidence SL candidates (Table 2, Rank 34, 102, 94, and 230). These candidates are 
expected to be higher confidence SL candidates, and should be validated in future 
studies.  
 We attempted to validate several genes of interest from the high-confidence SL 
candidates through a candidate approach. CP, APLF, and MSH6 were chosen for 
validation from the high-confidence list (p<0.01) due to their low p-values and high rank 
in terms of FC (Table 2, Rank 3, 221, and 52, respectively). WDR89, ERCC8, and 
UVSSA (or KIAA1530) were also chosen for validation due to more than one shRNA 
clone passing the FC and p-value cutoff for each of these genes (Table 4). Additionally, 
HERC2 was also selected since it has a projected role in ubiquitin-mediated proteolysis 
(Log2FC=-4.78, p<0.05, not shown in a list). Unfortunately, we failed to demonstrate a 
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significant synthetic sick or lethal phenotype through competitive survival assays for CP, 
APLF, MSH6, WDR89, or HERC2 in our validation studies (data not shown). However, 
we were successful in validating two of the SL candidates, UVSSA and ERCC8 (see 
Chapter 4). Importantly, as with the microarray methods, the false discovery rate (FDR) 
of the sequencing events in this analysis can be approximately 50-60% (0.5<FDR<0.62), 
which could explain, at least in part, our modest validation success rate of 2/7 (29%). 
Again, though the numbers appear low, this could be improved with the introduction of 
secondary and tertiary layers of analysis. 
  
c. Comparison of analysis methods 
Microarrays have been a method of choice for analysis of large-scale screens 
since it is simple and rapid, as well as being cost-effective. However, it has several 
limitations and data output can be obscured through several steps. One potential 
problem is the individual variability in affinity between probes on the arrays. Probes with 
poor binding affinity can lead to misreading, even if the relative amounts of Cy3- and 
Cy5-labeled sample stay constant. In order words, if a poor probe for gene X in a given 
microarray spot (or feature) only captures a total of 100 cDNAs, while another spot 
containing a better probe to a difference sequence in gene X cDNA can capture 1000 
cDNAs, the first spot may contribute a weaker signal, obfuscating results when in fact 
both spots could be binding the same proportion of Cy3- and Cy5-labeled species. 
Secondly, hybridization conditions can differ between individual array plates, since each 
replicate is analyzed on a different plate. This may increase the technical variability 
between replicate samples, obscuring the final results and corresponding statistics. For 
these reasons, while microarray hybridization is efficient and effective, data analysis 
must be considered carefully.  
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On the other hand, HTP sequencing utilizes newer technology, and is able to 
yield more reads by several orders of magnitude compared to microarrays. Notably, 
since samples from all replicates can be read in the same lane, technical variability is 
minimized compared to the use of microarrays. Therefore, HTP sequencing can be 
considered a more detailed method to analyze these types of screens. However, HTP 
sequencing has limitations, as certain sequences may be less well read than others on 
the sequencing platform, creating a bias that would be difficult to identify from the output 
data. Additionally, the nature of this method yields very large datasets that can 
complicate subsequent analyses if not handled carefully. Thus, while HTP sequencing 
allows for in-depth analysis, a robust method must be employed to take full advantage of 
the data. 
Interestingly, the two analysis methods we employed gave rise to different set of 
data when considered gene-by-gene. When the top 78 SL candidates from the arrays 
(Log2 FC<-1, p<0.05) are compared to the 316 SL candidates from the HTP sequencing 
(Log2 FC<-1, p<0.01), only three genes are common to both lists: APOBEC3A, LRCH3, 
and PAQR3 (Rank 80, 68, and 154 in Table 1, and Rank 254, 184, and 154 in Table 2). 
Though we have not attempted to validate these results as of yet, these genes could be 
considered high-confidence SL candidates since they were identified by both methods. 
Additionally, the number of high-confidence hits recovered is much higher by HTP 
sequencing compared to microarray hybridization (18.1-fold higher for p<0.05). This can 
be explained, at least in part, by the nature of the methods as described above. 
Nevertheless, functional clustering from both datasets points to similar pathways present 
in both datasets, including the ubiquitin-mediated proteolysis pathway (Table 3 and 
Chapter 3, Figure 2). This gives us confidence that both methods of analysis are 
valuable, likely in different ways, and that further analysis of these datasets could 
uncover the existence of additional synthetic lethal candidates.   
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Genome-wide screens like our present work are a relatively new endeavor in the 
field and are constantly being optimized in an ongoing manner. These screens generate 
extremely large datasets that require bioinformatics methods specifically designed for 
effective and efficient analysis. Different criteria can be applied to score hits as high 
confidence, including magnitude of fold change, number of degenerate shRNAs that 
score for each gene, statistical confidence levels such as p-values, and pathway 
representation, just to name a few that have already been mentioned. We chose mainly 
a candidate approach to validate our SL candidates, because of our prior interest in 
genes involved in genome stability and maintenance. In future studies, however, we will 
validate other candidates we have identified in order to expand our understanding of a 





Table 1. List of 169 synthetic lethal candidates from microarray hybridization analysis of 
the MCF10A-MYCER screen (p<0.1). Results were filtered according to fold change 
(Log2 FC<-1) of signal abundance between MYC ON and MYC OFF, and individually 
associated p-values deduced from the reproducibility between five replicates (p<0.1). 
Only shRNA corresponding to annotated target genes are shown. Candidates are 
ranked in order of most depleted in the MYC ON population compared to MYC OFF 
(Log2 FC value). 
 
Rank Name  p-value Log2 FC Acc. Number shRNAi ID 
1 ARL5B 0.0500 -2.7089 NM_178815 v2HS_118631 
2 C2orf44 0.0100 -2.5672 NM_025203 v2HS_137381 
3 TTBK1 0.0300 -2.4316 AB058758 v2HS_238991 
4 PSG6 0.0400 -2.3989 NM_002782 v2HS_170657 
5 NAT9 0.0500 -2.3896 NM_015654 v2HS_263964 
6 PARP3 0.0800 -2.3454 NM_005485 v2HS_68320 
7 CCT6B 0.0800 -2.3438 NM_006584 v2HS_197906 
8 ZNF212 0.0800 -2.2642 NM_012256 v2HS_19557 
9 ANP32C 0.0900 -2.2312 NM_012403 v2HS_44365 
10 TRPM6 0.0300 -2.1357 NM_017662 v2HS_155076 
11 BZW2 0.0600 -2.1075 NM_014038 v2HS_246855 
12 MFN2 0.0100 -2.0827 NM_014874 v2HS_95806 
13 NEURL2 0.0700 -2.0307 NM_080749 v2HS_64846 
14 ANKRD12 0.1000 -2.0028 NM_015208 v2HS_82023 
15 PRMT8 0.1000 -2.0026 NM_019854 v2HS_34352 
16 PXK 0.1000 -2.0001 NM_017771 v2HS_202094 
17 C20orf30 0.0800 -1.9202 NM_014145 v2HS_53618 
18 LARP1 0.1000 -1.8835 NM_033551 v2HS_178542 
19 C18orf54 0.0100 -1.8569 NM_173529 v2HS_160761 
20 DONSON 0.0300 -1.8499 NM_017613 v2HS_154816 
21 ZNF614 0.0400 -1.8499 NM_025040 v2HS_235983 
22 H2AFV 0.0100 -1.8450 NM_138635 v2HS_200741 
23 NUPL1 0.0500 -1.8381 NM_014778 v2HS_233311 
24 LRP12 0.0900 -1.7927 NM_013437 v2HS_58514 
25 IFT81 0.0800 -1.7813 NM_014055 v2HS_59598 
26 LSM10 0.0900 -1.7548 NM_032881 v2HS_178025 
27 OR51B2 0.0800 -1.7478 NM_033180 v2HS_160038 
28 CLCA2 0.1000 -1.7416 NM_006536 v2HS_197853 
29 GHRHR 0.0600 -1.7341 NM_000823 v2HS_130791 
30 ZNF691 0.0100 -1.7257 NM_015911 v2HS_236174 
31 PSMD2 0.0500 -1.7213 NM_002808 v2HS_219275 
32 CDC14B 0.0400 -1.7209 NM_033331 v2HS_203260 
33 PQLC2 0.0600 -1.7160 NM_017765 v2HS_173690 
34 RXRG 0.0600 -1.6959 NM_006917 v2HS_94832 
35 TRIB3 0.0800 -1.6816 NM_021158 v2HS_66315 
36 UGT1A1 0.0300 -1.6796 NM_000463 v2HS_93183 
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37 ZNF43 0.0900 -1.6701 NM_003423 v2HS_191543 
38 ZNF781 0.1000 -1.6565 NM_152605 v2HS_44704 
39 PHF5A 0.0800 -1.6172 NM_032758 v2HS_177402 
40 CDK2AP2 0.1000 -1.6122 NM_005851 v2HS_216445 
41 SOX15 0.0500 -1.6110 NM_006942 v2HS_229072 
42 SERPINB12 0.0900 -1.6101 NM_080474 v2HS_43826 
43 NUPL2 0.0500 -1.6086 NM_007342 v2HS_86275 
44 ANKRD27 0.0500 -1.6068 NM_032139 v2HS_117932 
45 EPHA7 0.0100 -1.5984 NM_004440 v2HS_17738 
46 NPC1 0.0900 -1.5797 NM_000271 v2HS_75887 
47 SULT1C4 0.1000 -1.5718 NM_006588 v2HS_212938 
48 FA2H 0.1000 -1.5582 NM_024306 v2HS_135795 
49 SC5DL 0.1000 -1.5376 NM_006918 v2HS_94838 
50 C14orf101 0.0700 -1.5214 NM_017799 v2HS_173856 
51 PRKCG 0.0800 -1.5196 NM_002739 v2HS_263025 
52 CCDC53 0.0700 -1.5192 NM_016053 v2HS_97322 
53 OSBPL10 0.1000 -1.5174 NM_017784 v2HS_219556 
54 ST8SIA4 0.0500 -1.5098 NM_005668 v2HS_238967 
55 SLC44A2 0.0500 -1.4952 NM_020428 v2HS_72471 
56 SH3BP4 0.0300 -1.4934 NM_014521 v2HS_86832 
57 KIAA0509 0.0300 -1.4922 AB007978 v2HS_259524 
58 DMKN 0.0500 -1.4804 NM_033317 v2HS_160312 
59 C6orf165 0.0600 -1.4761 NM_178823 v2HS_118670 
60 STK17A 0.0100 -1.4726 NM_004760 v2HS_36021 
61 TLR10 0.0600 -1.4720 NM_030956 v2HS_137828 
62 PHF21A 0.0100 -1.4564 NM_016621 v2HS_135309 
63 EYA2 0.0200 -1.4531 NM_005244 v2HS_43093 
64 PGBD2 0.1000 -1.4419 NM_170725 v2HS_100037 
65 PRKRIR 0.1000 -1.4416 NM_004705 v2HS_37080 
66 C6orf184 0.0100 -1.4413 XM_168053 v2HS_121031 
67 ZFYVE9 0.0100 -1.4407 NM_004799 v2HS_35331 
68 LRCH3 0.0400 -1.4395 NM_032773 v2HS_222832 
69 GALNT11 0.0700 -1.4352 NM_022087 v2HS_253801 
70 NR2E1 0.0100 -1.4308 NM_003269 v2HS_261941 
71 TOP3B 0.0100 -1.4280 NM_003935 v2HS_47174 
72 WDSOF1 0.0300 -1.4122 NM_015420 v2HS_229697 
73 PDS5B 0.0700 -1.4061 NM_015032 v2HS_201063 
74 SHFM1 0.0900 -1.4013 NM_006304 v2HS_203233 
75 SCYL1 0.0900 -1.3948 NM_020680 v2HS_247649 
76 CLDN5 0.0500 -1.3596 NM_003277 v2HS_171412 
77 CMTM2 0.0400 -1.3528 NM_144673 v2HS_17530 
78 IRAK1 0.0300 -1.3447 NM_001569 v2HS_132369 
79 PPP1R15B 0.0900 -1.3363 NM_032833 v2HS_223042 
80 APOBEC3A 0.0300 -1.3348 NM_145699 v2HS_286556 
81 FGD1 0.0800 -1.3306 NM_004463 v2HS_17382 
82 MTERFD3 0.1000 -1.3272 NM_025198 v2HS_236692 
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83 ZNF217 0.0800 -1.3268 NM_006526 v2HS_196547 
84 ERGIC1 0.0300 -1.3258 NM_020462 v2HS_71567 
85 PARP15 0.0100 -1.3206 NM_152615 v2HS_44475 
86 DMBT1 0.1000 -1.3137 NM_007329 v2HS_190086 
87 CTTN 0.1000 -1.3105 NM_005231 v2HS_43340 
88 RAE1 0.0500 -1.2995 NM_003610 v2HS_27966 
89 LEPREL1 0.0500 -1.2897 NM_018192 v2HS_156224 
90 ZNF132 0.0300 -1.2802 NM_003433 v2HS_172208 
91 TBC1D19 0.1000 -1.2712 NM_018317 v2HS_174988 
92 SLC7A1 0.0500 -1.2710 NM_003045 v2HS_153014 
93 TCHP 0.1000 -1.2704 NM_032300 v2HS_138395 
94 LAMA2 0.0200 -1.2692 NM_000426 v2HS_92966 
95 CAMKV 0.0800 -1.2689 NM_024046 v2HS_98766 
96 LOC344065 0.0400 -1.2685 XM_292895 v2HS_143532 
97 ATP1B1P1 0.0500 -1.2641 NG_001081 v2HS_169198 
98 C1orf182 0.0500 -1.2536 NM_144627 v2HS_18680 
99 GCLM 0.0800 -1.2479 NM_002061 v2HS_114117 
100 KRIT1 0.0400 -1.2463 NM_004912 v2HS_62790 
101 ASAH3 0.0400 -1.2436 NM_133492 v2HS_99964 
102 NOG 0.0900 -1.2419 NM_005450 v2HS_69206 
103 RGS2 0.0900 -1.2349 NM_002923 v2HS_32625 
104 HTR1D 0.0900 -1.2313 NM_000864 v2HS_131007 
105 TOP2B 0.0600 -1.2300 NM_001068 v2HS_94088 
106 TBX3 0.1000 -1.2293 NM_016569 v2HS_135045 
107 SCD5 0.0800 -1.2230 NM_024906 v2HS_176767 
108 OLFR89 0.0300 -1.2192 AJ132194 v2HS_18007 
109 CYP27A1 0.0900 -1.2165 NM_000784 v2HS_227129 
110 C5orf22 0.0900 -1.2072 NM_018356 v2HS_219318 
111 ENPEP 0.0600 -1.1989 NM_001977 v2HS_151422 
112 DSCR4 0.0800 -1.1931 NM_005867 v2HS_198761 
113 CLTB 0.0800 -1.1828 NM_001834 v2HS_150651 
114 CDCA7L 0.0900 -1.1821 NM_018719 v2HS_26554 
115 C1D 0.0900 -1.1781 NM_006333 v2HS_252502 
116 CCDC25 0.0300 -1.1758 NM_018246 v2HS_156496 
117 TOP3A 0.0100 -1.1740 NM_004618 v2HS_42272 
118 THUMPD3 0.0600 -1.1679 NM_015453 v2HS_96582 
119 P2RY6 0.0800 -1.1663 NM_004154 v2HS_173243 
120 FASN 0.0800 -1.1630 NM_004104 v2HS_173006 
121 C11orf72 0.0700 -1.1623 NM_173578 v2HS_285512 
122 MATK 0.0200 -1.1567 NM_002378 v2HS_203423 
123 ST14 0.0100 -1.1516 NM_021978 v2HS_228778 
124 KIAA0574 0.0300 -1.1513 AB011146 v2HS_130193 
125 PERP 0.0200 -1.1513 NM_022121 v2HS_216968 
126 FBXW7 0.0200 -1.1469 AY033553 v2HS_89326 
127 LENG1 0.0800 -1.1410 NM_024316 v2HS_135854 
128 APOA2 0.0100 -1.1369 NM_001643 v2HS_132594 
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129 C5 0.0400 -1.1342 NM_001735 v2HS_150150 
130 SLC36A4 0.0500 -1.1260 NM_152313 v2HS_25433 
131 PPP3CC 0.0300 -1.1253 NM_005605 v2HS_57300 
132 FCER1A 0.0600 -1.1236 NM_002001 v2HS_265910 
133 TRIM26 0.0500 -1.1229 NM_003449 v2HS_172289 
134 SPCS2 0.0700 -1.1197 NM_014752 v2HS_95186 
135 ELL 0.0500 -1.1181 NM_006532 v2HS_198413 
136 PRMT8 0.0100 -1.1163 NM_019854 v2HS_34353 
137 PRSS21 0.0500 -1.1146 NM_006799 v2HS_83969 
138 XK 0.1000 -1.1030 NM_021083 v2HS_72458 
139 UBE2I 0.0200 -1.0971 NM_003345 v2HS_171781 
140 QRSL1 0.0400 -1.0967 XM_301163 v2HS_49076 
141 PGBD3 0.1000 -1.0956 NM_170753 v2HS_100062 
142 C11orf48 0.0400 -1.0951 NM_024099 v2HS_116419 
143 KIF3B 0.0700 -1.0895 NM_004798 v2HS_35320 
144 C8orf45 0.0800 -1.0855 NM_173518 v2HS_160704 
145 OGG1 0.1000 -1.0801 NM_002542 v2HS_152449 
146 FOSB 0.0800 -1.0746 NM_006732 v2HS_85030 
147 TSKU 0.0700 -1.0743 NM_015516 v2HS_96796 
148 GABRA6 0.0800 -1.0712 NM_000811 v2HS_130723 
149 EPYC 0.0400 -1.0697 NM_004950 v2HS_61963 
150 TNFAIP2 0.0100 -1.0598 NM_006291 v2HS_56492 
151 CPOX 0.0600 -1.0588 NM_000097 v2HS_259707 
152 PHF5A 0.0900 -1.0586 NM_032758 v2HS_219178 
153 KLK2 0.0700 -1.0572 NM_005551 v2HS_63117 
154 PAQR3 0.0300 -1.0499 NM_177453 v2HS_211154 
155 DGKD 0.0600 -1.0495 NM_003648 v2HS_27433 
156 PREB 0.0500 -1.0457 NM_013388 v2HS_64102 
157 DUSP8 0.0900 -1.0445 NM_004420 v2HS_18240 
158 PXMP2 0.0800 -1.0431 NM_018663 v2HS_30524 
159 PPTC7 0.0800 -1.0378 NM_139283 v2HS_56653 
160 TBRG1 0.1000 -1.0307 NM_032811 v2HS_177650 
161 NKIRAS2 0.0600 -1.0270 NM_017595 v2HS_154743 
162 CEND1 0.0300 -1.0194 NM_016564 v2HS_135015 
163 SLC39A7 0.0700 -1.0116 NM_006979 v2HS_95053 
164 BBOX1 0.0300 -1.0107 NM_003986 v2HS_246341 
165 CDKL5 0.0500 -1.0097 NM_003159 v2HS_262311 
166 CMTM7 0.0100 -1.0049 NM_138410 v2HS_70332 
167 CYP2J2 0.0600 -1.0042 NM_000775 v2HS_112459 
168 MYO19 0.0600 -1.0034 NM_025109 v2HS_137025 





Table 2  
Table 2. List of 316 synthetic lethal candidates from HTP sequencing analysis of the 
MCF10A-MYCER screen (p<0.01). Results were filtered according to fold change (Log2 
FC<-1) of sequencing read abundance between MYC ON and MYC OFF, and 
individually associated p-values deduced from the reproducibility between five replicates 
(p<0.01). Only shRNA corresponding to annotated target genes are shown. Candidates 
are ranked in order of most depleted in the MYC ON population compared to MYC OFF 
(Log2 FC value). 
 
 
Rank Gene Symbol p-value Log2 FC shRNA ID 
1 GOLIM4 7.48E-03 -18.52 V2LHS_91423 
2 NCRNA00158 3.80E-04 -17.48 V2LHS_47715 
3 CP 5.60E-04 -13.12 V2LHS_88470 
4 STON1 3.03E-04 -11.73 V2LHS_284988 
5 MPV17L 4.72E-04 -11.28 V2LHS_179353 
6 RIN2 4.96E-03 -10.93 V2LHS_50849 
7 STX7 2.42E-03 -9.82 V2LHS_48525 
8 C7orf13 4.72E-03 -8.82 V2LHS_159570 
9 STAU1 3.96E-04 -8.5 V2LHS_42690 
10 AP3M1 9.63E-05 -8.38 V2LHS_28498 
11 NXNL2 5.31E-03 -7.85 V2LHS_18715 
12 MOGAT3 3.32E-03 -7.71 V2LHS_209424 
13 TPM2 2.77E-04 -7.44 V2LHS_223002 
14 FLJ36157 9.71E-03 -7.04 V2LHS_119804 
15 LIMA1 7.88E-03 -6.99 V2LHS_115557 
16 UBAC2 2.21E-03 -6.96 V2LHS_111302 
17 FKBP1A 8.96E-03 -6.89 V2LHS_191885 
18 DNMT3B 2.48E-04 -6.81 V2LHS_11913 
19 KRTAP4-3 7.21E-03 -6.76 V2LHS_53268 
20 TBX22 3.10E-03 -6.64 V2LHS_154236 
21 PPIL6 4.69E-03 -6.49 V2LHS_179066 
22 FAM182A 3.18E-03 -6.48 V2LHS_269002 
23 UBAP1 4.47E-03 -6.42 V2LHS_134830 
24 LOC286154 4.50E-04 -6.41 V2LHS_184361 
25 POU2F1 1.03E-03 -6.29 V2LHS_170237 
26 DCUN1D3 4.21E-03 -6.22 V2LHS_160480 
27 MPDU1 3.06E-03 -6.02 V2LHS_67726 
28 FGD5 7.89E-03 -5.95 V2LHS_50709 
29 HIST1H1A 6.89E-04 -5.82 V2LHS_37904 
30 PDXDC1 3.60E-03 -5.8 V2LHS_237009 
31 P2RX6 7.03E-03 -5.55 V2LHS_69281 
32 PHLDA2 1.70E-03 -5.51 V2LHS_171588 
33 HERC3 4.42E-03 -5.46 V2LHS_12972 
34 GPATCH1 1.88E-03 -5.44 V2LHS_155291 
35 LAPTM4A 6.68E-03 -5.42 V2LHS_73845 
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36 RAB33A 9.23E-04 -5.34 V2LHS_35338 
37 SLC25A46 1.99E-03 -5.26 V2LHS_202639 
38 HRH1 1.48E-03 -5.25 V2LHS_130994 
39 FAR1 2.49E-03 -5.11 V2LHS_138069 
40 PRAC 2.38E-03 -5.08 V2LHS_138880 
41 MGC15885 7.45E-03 -5.04 V2LHS_185559 
42 NR1I2 6.19E-04 -5.03 V2LHS_3719 
43 COL23A1 1.29E-03 -5.01 V2LHS_160442 
44 CUL4B 5.02E-03 -5 V2LHS_13208 
45 NUDT9 9.37E-03 -4.99 V2LHS_98772 
46 ADIPOQ 7.98E-04 -4.91 V2LHS_35308 
47 LOC151878 3.30E-03 -4.88 V2LHS_119807 
48 CEACAM5 5.63E-03 -4.87 V2LHS_14736 
49 HIST1H3F 2.91E-03 -4.86 V2LHS_189035 
50 KIAA0564 4.16E-03 -4.86 V2LHS_63167 
51 APOBEC4 6.87E-03 -4.85 V2LHS_286923 
52 MSH6 5.25E-03 -4.85 V2LHS_258239 
53 AMIGO2 2.73E-03 -4.84 V2LHS_47942 
54 COL1A1 1.14E-03 -4.72 V2LHS_261190 
55 KLHDC5 6.77E-03 -4.69 V2LHS_13667 
56 VANGL1 1.98E-03 -4.66 V2LHS_206726 
57 CKAP5 2.79E-03 -4.65 V2LHS_95211 
58 TTLL4 3.38E-03 -4.65 V2LHS_79760 
59 BHLHB3 5.83E-03 -4.62 V2LHS_116721 
60 GEN1 4.76E-03 -4.58 V2LHS_121634 
61 PMCH 4.88E-03 -4.57 V2LHS_170150 
62 C1orf127 5.17E-03 -4.56 V2LHS_160635 
63 C5orf23 9.73E-03 -4.56 V2LHS_136341 
64 CDS1 6.98E-03 -4.55 V2LHS_112932 
65 KCNJ2 4.74E-03 -4.53 V2LHS_131152 
66 SLC25A20 3.70E-03 -4.47 V2LHS_92736 
67 PROM2 7.35E-03 -4.45 V2LHS_49441 
68 OVCH1 6.98E-03 -4.44 V2LHS_81556 
69 STYX 6.40E-03 -4.43 V2LHS_149736 
70 RUNDC2C 1.96E-03 -4.37 V2LHS_194853 
71 TMEM178 8.95E-03 -4.37 V2LHS_15796 
72 P2RX3 1.21E-03 -4.34 V2LHS_152524 
73 LOC286467 8.13E-04 -4.32 V2LHS_264894 
74 ELMOD3 7.16E-04 -4.31 V2LHS_138016 
75 GFM2 4.68E-03 -4.3 V2LHS_138846 
76 FLJ45445,  8.62E-03 -4.26 V2LHS_188722 
77 LOC730139 4.23E-03 -4.26 V2LHS_25169 
78 YIF1B 7.04E-03 -4.26 V2LHS_178555 
79 ITK 2.71E-03 -4.23 V2LHS_63241 
80 RREB1 4.21E-03 -4.19 V2LHS_241472 
81 YTHDF2 2.52E-03 -4.16 V2LHS_226992 
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82 SYCP2L 2.96E-03 -4.15 V2LHS_102215 
83 CAMKV 1.06E-04 -4.14 V2LHS_98766 
84 TTC15 2.91E-03 -4.12 V2LHS_77490 
85 GOLT1A 2.91E-03 -4.11 V2LHS_161693 
86 ZNF26 9.78E-04 -4.11 V2LHS_52285 
87 DKFZp434H1419 8.99E-03 -4.09 V2LHS_231924 
88 HELZ 3.88E-03 -4.09 V2LHS_95824 
89 TLR10 3.39E-03 -4.08 V2LHS_137828 
90 LOC144920 5.10E-03 -4.05 V2LHS_275308 
91 TAF15 1.93E-03 -4.04 V2LHS_172494 
92 CAMK2D 3.20E-04 -4.02 V2LHS_112696 
93 CLCN2 9.77E-03 -4.02 V2LHS_24541 
94 NOL6 4.10E-03 -3.94 V2LHS_116373 
95 GPR32 7.70E-04 -3.93 V2LHS_132014 
96 CEP135 2.11E-03 -3.91 V2LHS_136592 
97 TIFA 4.22E-03 -3.91 V2LHS_45605 
98 TP53TG5 3.46E-03 -3.91 V2LHS_208302 
99 FLJ32955 5.38E-03 -3.9 V2LHS_21803 
100 GRHL2 6.03E-03 -3.9 V2LHS_222311 
101 MUC19 1.82E-03 -3.9 V2LHS_178719 
102 GPATCH1 2.02E-03 -3.89 V2LHS_155287 
103 CPVL 5.52E-03 -3.88 V2LHS_176344 
104 NCAPD2 2.44E-03 -3.88 V2LHS_95755 
105 FLJ32810 6.20E-03 -3.87 V2LHS_20743 
106 PLP2 4.65E-03 -3.87 V2LHS_277050 
107 MADCAM1 8.51E-03 -3.84 V2LHS_219254 
108 MARVELD2 1.07E-03 -3.83 V2LHS_245803 
109 CBLN4 3.65E-03 -3.79 V2LHS_72017 
110 HTR2A 5.33E-03 -3.78 V2LHS_111751 
111 ROR2 8.69E-04 -3.77 V2LHS_47949 
112 PLD1 6.47E-03 -3.73 V2LHS_170093 
113 SHISA4 1.54E-03 -3.73 V2LHS_101532 
114 KIAA1602 8.77E-03 -3.72 V2LHS_161149 
115 MFAP5 4.88E-03 -3.7 V2LHS_172458 
116 UBE2H 9.21E-03 -3.68 V2LHS_171775 
117 CA11 4.51E-03 -3.66 V2LHS_228420 
118 CFH, CFHR1 5.50E-03 -3.65 V2LHS_284943 
119 HTA 2.47E-03 -3.63 V2LHS_164195 
120 CLCN3 5.45E-03 -3.62 V2LHS_150623 
121 LOC285771 2.08E-03 -3.62 V2LHS_183765 
122 TM9SF2 7.11E-03 -3.62 V2LHS_68959 
123 PI4KB 8.37E-03 -3.61 V2LHS_170034 
124 TUBA1A 8.44E-03 -3.61 V2LHS_72065 
125 VWC2 5.71E-03 -3.61 V2LHS_62238 
126 WARS 1.42E-03 -3.61 V2LHS_33836 
127 FLJ41423 9.24E-03 -3.58 V2LHS_284656 
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128 HAL 8.61E-03 -3.58 V2LHS_132999 
129 PRICKLE4 3.99E-03 -3.58 V2LHS_63831 
130 C1orf57 2.51E-03 -3.56 V2LHS_138532 
131 NR2F2 3.97E-03 -3.54 V2LHS_239584 
132 TUBGCP5 3.09E-04 -3.53 V2LHS_118096 
133 SNRPA1 3.64E-03 -3.52 V2LHS_153261 
134 ZNF556 5.54E-03 -3.52 V2LHS_278105 
135 NLGN2 5.33E-03 -3.5 V2LHS_120293 
136 GPR137C 6.29E-03 -3.46 V2LHS_91622 
137 UGT2A3 3.97E-03 -3.46 V2LHS_157561 
138 USP8 4.86E-03 -3.45 V2LHS_49251 
139 KIAA1712 1.23E-03 -3.44 V2LHS_100848 
140 CAPN7 1.75E-03 -3.43 V2LHS_198039 
141 LONRF2 4.39E-03 -3.43 V2LHS_247121 
142 C14orf101 9.12E-03 -3.41 V2LHS_173856 
143 FAM108B1 4.04E-03 -3.39 V2LHS_97116 
144 EBP 4.17E-03 -3.38 V2LHS_250591 
145 CLYBL 6.62E-03 -3.37 V2LHS_42101 
146 COMMD1 6.65E-03 -3.37 V2LHS_51356 
147 CYP11A1 6.42E-03 -3.37 V2LHS_224688 
148 NEU1 6.55E-03 -3.37 V2LHS_269212 
149 LOC642574 9.49E-03 -3.36 V2LHS_221160 
150 TOPORS 1.49E-03 -3.36 V2LHS_13406 
151 HIST1H3A 3.21E-03 -3.35 V2LHS_33767 
152 IGF1R 3.69E-03 -3.34 V2LHS_20148 
153 C19orf59 1.78E-03 -3.33 V2LHS_42482 
154 PAQR3 8.57E-04 -3.33 V2LHS_211154 
155 LOC145474 4.10E-03 -3.32 V2LHS_54845 
156 LOC100130348 1.83E-03 -3.31 V2LHS_162592 
157 LTB 4.96E-03 -3.31 V2LHS_134087 
158 TRBV19 5.02E-03 -3.31 V2LHS_65032 
159 ZBTB4 9.16E-03 -3.3 V2LHS_119203 
160 C12orf64 7.64E-03 -3.29 V2LHS_178676 
161 LCP1 8.16E-03 -3.29 V2LHS_133929 
162 PSMA8 3.65E-03 -3.29 V2LHS_17720 
163 TRMT6 1.35E-03 -3.29 V2LHS_134426 
164 ICAM1 8.70E-03 -3.28 V2LHS_77358 
165 MAPKAPK5 4.77E-03 -3.27 V2LHS_27294 
166 FCGR2B, FCGR2C 8.03E-03 -3.26 V2LHS_172622 
167 SQSTM1 7.88E-04 -3.25 V2LHS_47986 
168 DKFZp564N2472 6.86E-03 -3.24 V2LHS_141621 
169 FAM65A 7.93E-03 -3.23 V2LHS_136139 
170 STARD13 1.72E-03 -3.23 V2LHS_99559 
171 ZNF197 4.91E-03 -3.23 V2LHS_230920 
172 HOMEZ 7.66E-03 -3.22 V2LHS_212820 
173 FLJ45949 8.99E-03 -3.21 V2LHS_285519 
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174 C11orf65 5.18E-03 -3.19 V2LHS_49372 
175 THOP1 9.02E-03 -3.19 V2LHS_154041 
176 UBXN10 1.76E-03 -3.19 V2LHS_16091 
177 C6orf165 1.18E-03 -3.17 V2LHS_118670 
178 PDE4DIP 2.25E-03 -3.16 V2LHS_183211 
179 LENG1 8.88E-03 -3.15 V2LHS_135855 
180 DNAJC21 4.32E-03 -3.14 V2LHS_26661 
181 LOC644936 9.07E-03 -3.12 V2LHS_56007 
182 HN1L 9.22E-03 -3.11 V2LHS_14937 
183 GRM5 8.41E-03 -3.1 V2LHS_237235 
184 LRCH3 5.57E-03 -3.1 V2LHS_222832 
185 OVOS2 5.38E-03 -3.1 V2LHS_160596 
186 PI4K2A 2.22E-03 -3.1 V2LHS_175547 
187 CLDN17 5.07E-03 -3.09 V2LHS_16386 
188 MTTP 2.51E-03 -3.08 V2LHS_76312 
189 PLEKHA3 9.09E-03 -3.08 V2LHS_22292 
190 SLC6A8 6.79E-03 -3.08 V2LHS_56679 
191 ADK 7.60E-03 -3.07 V2LHS_233106 
192 LOC100128108 8.43E-03 -3.06 V2LHS_121352 
193 PROC 5.92E-03 -3.04 V2LHS_92305 
194 DHX9 4.71E-03 -3.03 V2LHS_225385 
195 LOC440518 2.16E-03 -3.03 V2LHS_143326 
196 SCAMP4 7.72E-03 -3.03 V2LHS_45909 
197 VWA5B2 7.51E-03 -3.03 V2LHS_213570 
198 C5orf48 3.22E-03 -3.02 V2LHS_140224 
199 OR2A5 1.07E-03 -3.02 V2LHS_59524 
200 BOLA3 8.64E-03 -3 V2LHS_121652 
201 ZNF432 4.53E-03 -3 V2LHS_79484 
202 LOC284661 6.08E-03 -2.99 V2LHS_183283 
203 SAMD12 7.54E-03 -2.99 V2LHS_124893 
204 ANKK1 9.36E-03 -2.98 V2LHS_188466 
205 CXorf22 2.01E-03 -2.98 V2LHS_245763 
206 PNMA2 3.44E-03 -2.97 V2LHS_196882 
207 RUNX1 5.18E-03 -2.97 V2LHS_150257 
208 GGPS1 9.38E-03 -2.96 V2LHS_68132 
209 TOR1AIP2 8.80E-03 -2.96 V2LHS_29443 
210 FANCF 6.41E-03 -2.94 V2LHS_98198 
211 PMPCA 8.89E-03 -2.94 V2LHS_87246 
212 DPY19L3 6.62E-03 -2.93 V2LHS_40744 
213 RIPPLY2 8.21E-03 -2.93 V2LHS_176894 
214 GJB5 8.94E-03 -2.92 V2LHS_42563 
215 HSPC072 9.00E-03 -2.92 V2LHS_53336 
216 CRISP2 4.78E-03 -2.91 V2LHS_171520 
217 STYK1 9.49E-04 -2.91 V2LHS_203597 
218 IPPK 1.00E-02 -2.9 V2LHS_98358 
219 RTF1 8.62E-03 -2.87 V2LHS_257617 
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220 ZBTB26 3.32E-03 -2.87 V2LHS_201438 
221 APLF 8.05E-03 -2.86 V2LHS_160841 
222 NOM1 5.25E-03 -2.86 V2LHS_264810 
223 PPAPDC1B 1.30E-03 -2.84 V2LHS_158944 
224 SLC10A3 3.39E-03 -2.84 V2LHS_34487 
225 CTPS2 9.34E-03 -2.83 V2LHS_34295 
226 DES, KRT81, VIM 6.54E-03 -2.83 V2LHS_193029 
227 DHX38 9.63E-03 -2.82 V2LHS_60541 
228 DHRS7B 4.17E-03 -2.79 V2LHS_96766 
229 EXT2 4.65E-03 -2.79 V2LHS_229747 
230 NOL6 2.89E-03 -2.79 V2LHS_116375 
231 ZFAND3 9.99E-03 -2.79 V2LHS_73350 
232 SLC35E3 7.88E-03 -2.78 V2LHS_30620 
233 SLC7A13 7.14E-03 -2.78 V2LHS_210577 
234 ZC3H13 6.02E-03 -2.78 V2LHS_211696 
235 CCNL2 1.81E-03 -2.75 V2LHS_137749 
236 KRTAP19-1 7.85E-03 -2.73 V2LHS_166581 
237 TMEM138 1.66E-03 -2.73 V2LHS_115942 
238 GDPD5 6.91E-03 -2.67 V2LHS_116874 
239 HDAC9 1.35E-03 -2.66 V2LHS_47877 
240 FLJ25694 4.75E-03 -2.64 V2LHS_190755 
241 ECOP, LOC729086 7.52E-03 -2.63 V2LHS_225838 
242 FANCM 4.74E-03 -2.63 V2LHS_205559 
243 FLJ40330 4.27E-03 -2.62 V2LHS_240144 
244 UBR1 6.67E-03 -2.61 V2LHS_42473 
245 PLD2 6.00E-03 -2.59 V2LHS_222130 
246 HIP1R 3.49E-03 -2.58 V2LHS_212627 
247 CLUL1 8.83E-03 -2.57 V2LHS_197932 
248 KRT27 1.00E-02 -2.55 V2LHS_226224 
249 C1orf168 9.69E-03 -2.52 V2LHS_269806 
250 WIF1 3.59E-03 -2.52 V2LHS_196291 
251 C9orf152 8.51E-03 -2.51 V2LHS_180399 
252 DMTF1 5.76E-03 -2.51 V2LHS_66509 
253 TPST2 9.57E-03 -2.51 V2LHS_32342 
254 APOBEC3A 3.42E-03 -2.48 V2LHS_286556 
255 RPL17 8.22E-03 -2.48 V2LHS_131616 
256 SMC4 9.69E-04 -2.48 V2LHS_68092 
257 HSPA13 6.60E-03 -2.46 V2LHS_94977 
258 GCA 9.00E-03 -2.45 V2LHS_15316 
259 LIPM 1.48E-03 -2.45 V2LHS_104388 
260 EMP3 8.08E-03 -2.44 V2LHS_113721 
261 LOC441476 6.57E-03 -2.43 V2LHS_284840 
262 FOXF1 5.91E-03 -2.41 V2LHS_131755 
263 ORAI3 6.69E-03 -2.41 V2LHS_28967 
264 GAS2L1 6.64E-03 -2.4 V2LHS_196343 
265 GJC1 5.70E-03 -2.4 V2LHS_68097 
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266 UGDH 5.51E-03 -2.39 V2LHS_218865 
267 CBX5 6.47E-03 -2.36 V2LHS_240022 
268 FRRS1 4.96E-03 -2.34 V2LHS_36891 
269 CD84 6.30E-03 -2.33 V2LHS_53205 
270 SI 9.70E-03 -2.33 V2LHS_93929 
271 TAOK2 9.28E-03 -2.33 V2LHS_201841 
272 ACSM5 8.84E-03 -2.31 V2LHS_174334 
273 LRRC38 9.49E-03 -2.31 V2LHS_161613 
274 HPS3 9.39E-03 -2.29 V2LHS_138857 
275 TEX13A 1.00E-02 -2.29 V2LHS_99327 
276 KCTD11 6.93E-03 -2.27 V2LHS_254663 
277 C1orf63 5.30E-03 -2.25 V2LHS_39942 
278 TTC8 1.13E-03 -2.24 V2LHS_24261 
279 APRT 9.82E-03 -2.22 V2LHS_270759 
280 FAM179A 8.08E-03 -2.22 V2LHS_203801 
281 FAM46B 9.34E-03 -2.22 V2LHS_118211 
282 CUL1 7.84E-03 -2.21 V2LHS_32372 
283 ANXA5 9.55E-03 -2.19 V2LHS_94509 
284 UBL4B 8.39E-03 -2.19 V2LHS_180983 
285 THAP9 2.50E-03 -2.16 V2LHS_157174 
286 COPS5 9.97E-03 -2.13 V2LHS_78187 
287 SUMO2 1.55E-03 -2.12 V2LHS_94924 
288 FBXW4 2.96E-03 -2.09 V2LHS_202633 
289 IMPG1 3.08E-03 -2.09 V2LHS_132345 
290 MTMR12 5.69E-03 -2.08 V2LHS_176493 
291 EMR3 4.65E-03 -2.07 V2LHS_159322 
292 C12orf32, IGHA1 6.53E-03 -2.05 V2LHS_213216 
293 DYRK4 4.03E-03 -2.04 V2LHS_139500 
294 DBR1 1.02E-03 -2.03 V2LHS_98028 
295 TBX1 6.47E-03 -2.02 V2LHS_205864 
296 CKM 5.06E-03 -2 V2LHS_279623 
297 BRCA1 1.94E-03 -1.99 V2LHS_280987 
298 LOC646817 5.32E-03 -1.99 V2LHS_200366 
299 PSMB6 6.70E-03 -1.95 V2LHS_277575 
300 SNORA65 4.83E-04 -1.92 V2LHS_168584 
301 C4orf23 3.87E-03 -1.9 V2LHS_176989 
302 ZNF646 8.17E-04 -1.82 V2LHS_78609 
303 FBXO8 3.84E-03 -1.81 V2LHS_254559 
304 PF4V1 4.21E-03 -1.81 V2LHS_285000 
305 TMIGD2 7.07E-03 -1.81 V2LHS_19033 
306 COL27A1 3.42E-03 -1.8 V2LHS_178068 
307 OSBPL2 8.95E-03 -1.77 V2LHS_203142 
308 TNK1 9.81E-03 -1.77 V2LHS_46392 
309 PRKAA1 9.74E-03 -1.76 V2LHS_57699 
310 AOAH 8.45E-03 -1.75 V2LHS_236895 
311 ULBP2 3.85E-03 -1.7 V2LHS_137461 
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312 MYO3B 6.10E-03 -1.69 V2LHS_631 
313 S100A14 5.93E-03 -1.66 V2LHS_58064 
314 KIAA0484 8.27E-03 -1.63 V2LHS_258065 
315 FRMPD1 7.50E-03 -1.62 V2LHS_95991 







Table 3. Functional clustering analysis of HTP sequencing results. Results from HTP 
sequencing were subjected to KEGG pathway analysis using the DAVID Bioinformatics 
Database. The majority, but not all, of input genes were recognized in the database. 
Pathways represented in the HTP sequencing datasets according to DAVID are listed 
below. First list included SL candidates with Log2FC>-1 and p<0.1 (far left), second list 
is a smaller dataset with Log2FC>-1 and p<0.05 (middle), and last list includes high-
confidence SL candidates with Log2FC>-1 and p<0.01 (far left). Pathways listed are in 
order of number of genes in the pathway appearing in the dataset.  
 
p<0.1 p<0.05 p<0.01 
2425 DAVID IDs 1319 DAVID IDs 297 DAVID IDs 
   
Nucleotide excision repair GnRH signaling pathway Ub mediated proteolysis 
Fc epsilon RI signaling pathway Fc epsilon RI signaling pathway DNA replication 
Regulation of autophagy T cell receptor signaling pathway 
 
PPAR signaling pathway Neurotrophin signaling pathway 
 
DNA replication Vibrio cholerae infection 
 
RIG-I-like receptor signaling pathway Epithelial cell signaling  
 
Cytosolic DNA-sensing pathway Ether lipid metabolism 
 
Mismatch repair  Leukocyte transendothelial migration 
 
Pathways in cancer Adherens juntion 
 
Oocyte meiosis Oocyte meiosis 
 
Neurotrophin signaling pathway Glycerophospholipid metabolism 
 
Purine metabolism Long-term potentiation 
 
Jak-STAT signaling pathway Tight junction 
 
Apidocytokine signaling pathway Fc gamma R-mediated phagocytosis 
 
Vibrio cholerae infection Mismatch repair 
 
Toll-like receptor signaling pathway VEGF signaling pathway 
 
Small cell lung cancer ErbB signaling pathway 
 
GnRH signaling pathway Nucleotide excision repair 
 
Natural killer cell mediated cytotoxicity 
  
Phosphatidylinositol signaling system 
  
Tight junction 
   
Epithelial cell signaling in H. pylori 
infection 
  
Maturity onset diabetes of the young 
  
T cell receptor signaling pathway 
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Table 4  
 
Table 4. HTP sequencing results for UVSSA (KIAA1530), ERCC8, and WDR89. Mutiple 
shRNA clones targeting UVSSA (KIAA1530), ERCC8, and WDR89 were detected 
through HTP sequencing results. Below show two shRNA targeting UVSSA, two 
targeting ERCC8, and three targeting WDR89 which scored with a Log2 FC>-1.  
 
 
Gene Symbol p-value Log2 FC shRNA ID 
KIAA1530 2.16E-02 -2.39 V2LHS_274544 
KIAA1530 9.83E-02 -2.35 V2LHS_139628 
    ERCC8 3.00E-02 -3.2 V2LHS_88681 
ERCC8 7.15E-01 -1.22 V2LHS_254783 
    WDR89 3.97E-02 -7.24 V2LHS_70786 
WDR89 4.99E-02 -4.87 V2LHS_70789 
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MYC deregulation is a driver of many human cancers. Altering the balance of MYC 
protein levels at the level of transcription, protein stability, or turnover is sufficient to 
transform cells to a tumorigenic phenotype. While direct targeting of MYC is difficult, 
specific genetic vulnerabilities of MYC-deregulated cells could be exploited to selectively 
inhibit their growth. Using a genome-wide shRNA screen, we identified 78 synthetic 
lethal candidates with elevated levels of MYC in human mammary epithelial cells. 
Among the candidates, we validated and characterized FBXW7, a component of the 
SCF-like ubiquitin ligase complex that targets MYC for proteasomal degradation. Down-
regulation of FBXW7 leads to synergistic accumulation of cellular and active chromatin-
bound MYC, while protein levels of other FBXW7 targets appear unaffected. Over a four-
week time course, continuous FBXW7 down-regulation and MYC activation together 
cause an accumulation of cells in S-phase and G2/M-phase of the cell cycle. Under 
these conditions, we also observe elevated chromatin-bound levels of CDC45, 
suggesting increased DNA replication stress. Moreover, a positive correlation was 
observed between MYC and FBXW7 expression, specifically in the luminal A-type breast 
cancers. These results establish that FBXW7 down-regulation is synthetic lethal with 
high MYC levels, and that MYC is a critical target of FBXW7. 
 
Keywords 




Genetic and epigenetic events altering the expression, the stability, or the activity 
of oncogenes and tumor suppressor genes participate in the initiation and maintenance 
of human cancers (Shen and Laird, 2013). Among the genes which expression is 
modified in cancer, only a relatively small subset is recurrently altered and contributes to 
the tumorigenic phenotype (Vogelstein et al., 2013). Identification of such “cancer driver 
genes” has facilitated the development of targeted treatment options in the recent years, 
yet there are still pharmacological limitations that hinder direct targeting of some major 
cancer drivers including MYC (Dang, 2012). 
The MYC proto-oncogene is deregulated in up to 70% of human tumors including 
hematopoietic cancers, sarcomas, and solid carcinomas (Klapproth and Wirth, 2010). 
MYC is essential for normal cell growth. In particular, MYC is required for cell 
proliferation and is involved in differentiation, metabolism, and apoptosis, most notably 
through its function as a bHLH-LZ transcriptional activator and repressor (Meyer and 
Penn, 2008). In addition, MYC has direct, transcription-independent functions in DNA 
replication (Dominguez-Sola et al., 2007) and protein synthesis (Cowling and Cole, 
2007), further supporting its major role in cellular homeostasis. Therefore, cellular MYC 
protein levels are tightly controlled through regulated expression (Liu and Levens, 2006), 
protein stability (Adhikary and Eilers, 2005), and degradation (Thomas and Tansey, 
2011). Indeed, alterations in MYC abundance are a critical component of MYC-
dependent tumorigenesis (Murphy et al., 2008).  
At least 4 different ubiquitin ligase complexes can target MYC for proteasomal 
degradation (Thomas and Tansey, 2011), including the SCF-like ligase complex 
containing FBXW7 (Welcker et al., 2004; Welcker et al., 2004; Yada et al., 2004). 
FBXW7 (or Fbw7, Sel-10, hCdc4, or hAgo) is an F-box protein that confers substrate 
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specificity for this complex (Welcker and Clurman, 2008). While MYC is a documented 
substrate of FBXW7, FBXW7 also targets several additional oncoproteins and master 
regulator molecules including CyclinE, NOTCH1, mTOR, SREBP, and c-JUN, among 
others (Welcker and Clurman, 2008) and the respective contributions of FBXW7-
dependent regulation of these proteins towards abnormal cell growth is not known. 
Moreover, although the role of FBXW7 as a tumor suppressor is well documented in 
hematopoietic tumors in which FBXW7 mutations are unequivocally linked to 
tumorigenesis (Thompson et al., 2007), this is not as clear for other cancer types 
(Sgambato et al., 2007; Woo Lee et al., 2006). For example, it has been reported that 
the inactivation of FBXW7 can be associated with favorable prognosis in a subset of 
breast cancers (Akhoondi et al., 2010), suggesting that the physiological role of FBXW7 
and consequences of its loss may be dependent on cell types and contexts.  
Exploring synthetic lethality has provided many critical insights into the biology of 
oncogenes (Kaelin, 2005). In addition, identifying genes that are essential to cope with 
activated oncogenes might provide alternatives to direct targeting for cancer therapy 
(Kaelin, 2009). In the case of MYC, several genes which loss is synthetic lethal with 
aberrant MYC expression have been identified. These include DR5 in the death receptor 
pathway (Wang et al., 2004), the WRN helicase (Grandori et al., 2003; Moser et al., 
2012), the Aurora A/B protein kinases (Yang et al., 2010) and CDK (Goga et al., 2007; 
Molenaar et al., 2009) and Chk1/2 kinases (Hoglund et al., 2011; Murga et al., 2011). 
More recently, genome-wide approaches have helped to identify the SAE1/2-dependent 
SUMOylation pathway (Kessler et al., 2012) and CSNK1E kinase (Toyoshima et al., 
2012) as potential synthetic lethal candidates as well. Intriguingly, studies in different 
model systems appear to yield unique results, possibly due to MYC’s cell-context 
specific roles and the differing modes of deregulation. 
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In the present study, we conducted a genome-wide screen to identify genes that 
are required to survive MYC overexpression in MCF10A breast epithelial cells 
conditionally expressing a MYCER allele. We document these synthetic lethal 
interactions and identify 78 potential synthetic lethal targets. Among these, we have 
validated the F-box protein FBXW7 as a synthetic lethal candidate in MCF10A-MYCER 
cells overexpressing MYC. We show that shRNA-mediated knockdown of FBXW7 
confers increased lethality to cells with activated MYCER. Active chromatin-bound 
MYCER is stabilized in cells with down-regulated FBXW7, while protein stability of other 
FBXW7 targets is not affected. We also find that knockdown of FBXW7 upon MYCER 
activation results in accumulation of cells in S/G2 phase with increased chromatin-bound 
CDC45. Furthermore, MYC expression correlates positively with FBXW7 expression in 
the luminal A-subtype of breast cancers. These results suggest that increased cellular 
MYC levels as a result of FBXW7 loss yields sufficient cellular stress to confer selective 
lethality to those cells with deregulated MYC. 
 
Results 
MCF10A-MYCER cells: a model for MYC deregulation  
First, we sought to generate a cellular model for MYC conditional expression that 
recapitulates MYC deregulation in human cancer cells. To this goal, we stably integrated 
an inducible MYCER allele (Littlewood et al., 1995) into MCF10A breast epithelial cells 
via retroviral transduction. The MYCER allele consists of a full-length MYC cDNA fused 
to the hormone-binding domain of the murine estrogen receptor. Upon treatment with the 
synthetic ligand 4-hydroxytamoxifen (4OHT), MYCER protein is rapidly transported to 
the nucleus, rendering it active. MCF10A are non-transformed breast epithelial cells that 
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express markers commonly associated with a basal epithelial phenotype, thus modeling 
breast cancers of basal-origin which are frequently associated with MYC and CDC45 
overexpression (Alles et al., 2009).  
Following retroviral transduction of MCF10A-MYCER cells, we selected a clone 
expressing MYCER (Figure 1a) that fulfilled two criteria: 1) normal levels of endogenous 
MYC expression were retained, and 2) MYCER was expressed at levels 2-3 fold higher 
than endogenous MYC, sufficient for modeling MYC deregulation in human cancers 
without MYC amplification (Nesbit et al., 1999) (Figure 1a). Following 4OHT treatment, 
this clone showed a 1.54 fold increase in active, chromatin-bound MYCER. This 
demonstrates the anticipated 4OHT-dependent nuclear import and activation of MYCER 
(Figure 1b). Next, we tested the ability of the MYCER transgene to activate transcription. 
MCF10A-MYCER cells were transfected with a luciferase reporter construct harboring 6 
E-box sequences, the canonical MYC DNA binding site (Supplementary Figure 1). Upon 
4OHT treatment, we observed a 2.3 fold increase in reporter activity (p<0.0001), 
consistent with the increase in chromatin-bound MYCER (Supplementary Figure 1). 
Finally, we tested the ability of the transgene to accelerate entry into S-phase, another 
hallmark of MYC deregulation. Cells were synchronized at the G1/S transition by double 
thymidine block and labeled with BrdU following induction of MYCER. S-phase entry was 
then monitored by the appearance of BrdU foci assessed by indirect 
immunofluorescence. As anticipated, MYCER induction triggered marked acceleration of 
S-phase entry (Figure 1c and Supplementary Figure 2). These results establish the 





Screen for synthetic lethal candidates with MYCER activation 
 Next, we performed a genome-wide screen to identify genes which loss is 
synthetic lethal with aberrant MYC expression utilizing the GIPZ Lentiviral Human 
shRNA-mir Library (Thermo Scientific Open Biosystems, Waltham, MA, USA). The 
pooled shRNA plasmid library includes 58,493 shRNA constructs and target 18,661 
known human genes (2-3 shRNAs per gene covering 75% of entire genome) as 
described in Rodriguez-Barrueco et al (Rodriguez-Barrueco et al., 2013). We designed 
the screen based on negative selection, i.e. we monitored loss of shRNAs to identify the 
corresponding genes that render cells sensitive to MYCER activation by 4OHT when lost 
(Figure 2a). 
The screen was performed in 5 independent replicates, which were utilized to 
generate p-values for screening of high-confidence MYC-SL candidates. Cells were 
initially transduced with the pooled shRNA library at 30% infection efficiency to achieve, 
on average, single-copy shRNA integration per cell. 200 million cells were infected to 
obtain at least 1000 cells infected with each shRNA from the library. Infected MCF10A-
MYCER cells were first allowed to grow in the absence of MYCER induction for two 
generations to eliminate most shRNAs targeting essential genes. Then, the remaining 
cells were propagated in either the presence or absence of 4OHT for four weeks, 
maintaining a constant total cell number of at least 70 million per sample to preserve the 
representation of at least 1000 cells per shRNA construct. The surviving populations 
were harvested after four weeks, and genomic DNA was isolated (Figure 2a). Stably 
integrated shRNA constructs were then amplified by large scale PCR, labeled with 
fluorescent nucleotides and hybridized to custom microarrays harboring complementary 




The microarray analysis was performed as described previously (Yu et al., 2013). 
We identified 78 candidate genes for which the corresponding shRNAs had a Log2FC 
(fold change) value of -1 or less, thus, depleted 2-fold or more in the MYC ON population 
compared to MYC OFF (with a p<0.05 for the five replicates) (Supplementary Table 1). 
Functional annotation clustering using the KEGG pathways in the DAVID Bioinformatics 
Database revealed the most represented biological pathways within the synthetic lethal 
candidates to be ubiquitin mediated proteolysis, PPAR signaling pathway, fatty acid 
biosynthesis, fructose and mannose metabolism, and homologous recombination 
(Figure 2c). Notably, among the top hits we identified UBE2I, the E2 conjugating enzyme 
cooperating with the SAE1/2 E3 ligase in the SUMOylation pathway. This is consistent 
with recent studies in which SAE1/2 and UBE21 were identified in similar screens  
(Kessler et al., 2012; Liu et al., 2012; Toyoshima et al., 2012). Using a set of 
independent shRNAs, we validated that loss of UBE2I is indeed synthetic lethal with 
MYCER activation in MCF10A-MYCER cells, providing a proof of principle for our 
system (Supplementary Figure 9a and 9b). 
Notably, three major MYC-SL screens have been published to date (Kessler et 
al., 2012; Liu et al., 2012; Toyoshima et al., 2012). Between the datasets from Kessler’s 
screen and our present study, we observed four high-confidence MYC-SL candidate 
genes that overlap: FBXW7, LAMA2, PRMT8, and ZNF614 (Supplementary Table 1) 
(Kessler et al., 2012). When we compare our dataset with Toyoshima’s screen, we only 
observed one overlapping MYC-SL candidate, UBE2I, which has been previously 
validated by Kessler et al. (Supplementary Table 1) (Kessler et al., 2012; Toyoshima et 
al., 2012). When comparing our dataset with Liu’s screen, we did not find a direct 
overlap (Liu et al., 2012). However, one of the eleven top MYC-SL kinases in Liu’s 
dataset was GSK3B, which is required for phosphorylation of MYC to trigger degradation 
by FBXW7 (Liu et al., 2012; Welcker et al., 2004). These results suggest that FBXW7-
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dependent MYC degradation is a significant MYC-SL pathway since at least three 
independent MYC-SL datasets include FBXW7 and/or GSK3B. Consistent with this, the 
MYC ubiquitination (and SUMOylation) network was determined to be one of the three 
major functional MYC-SL hubs, in a comprehensive meta-analysis of the three 
aforementioned MYC-SL datasets (Cermelli et al., 2014). Therefore, we selected 
FBXW7 for further analysis, which ranked 58th in our high-confidence MYC-SL list with 
Log2FC=-1.1469 (p<0.02, Supplementary Table 1). 
 
Loss of FBXW7 together with MYCER activation is lethal 
 We elected to further validate FBXW7, the substrate recognition subunit of the 
SCF-like E3 ubiquitin ligase complex that regulates degradation of MYC and other 
oncoproteins (Welcker and Clurman, 2008). First, we wanted to confirm that loss of 
FBXW7 is lethal when combined with MYCER activation. We generated cell lines stably 
expressing either constitutively expressed or doxycycline-inducible shRNA clones 
targeting FBXW7 to experimentally manipulate its abundance. Following lentiviral 
infection of stable shRNA constructs and antibiotic selection, FBXW7 knockdown levels 
were assessed by quantitative RT-PCR. Both constitutive and doxycycline-inducible 
shRNA clones yielded an average of 45% knockdown of FBXW7 mRNA levels (Figure 
3a). We were unable to achieve further knockdown of FBXW7 in MCF10A-MYCER cells, 
suggesting a threshold level of FBXW7 is required for MCF10A-MYCER viability, even 
when the MYC transgene is off.  
We utilized a fluorescence-based cell competition assay to compare the viability 
of FBXW7 knockdown cells in the absence or presence of 4OHT over a period of 
approximately four weeks, to recapitulate the experimental conditions of the screen. 
Since all shRNA constructs co-express GFP or RFP, cells expressing shRNA are readily 
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detectable by fluorescence. A mixed population of 50% MCF10A-MYCER cells without 
shRNA and 50% MCF10A-MYCER cells infected with shFBXW7 or shCONTROL were 
plated in MYC OFF or MYC ON conditions and continuously treated with vehicle or 
4OHT at every passage. Cells were harvested at the indicated time points during the 
competition assay (Figure 3b and 3c), and subjected to live cell flow cytometry to 
measure the percentage of fluorescent surviving cells (Supplementary Figure 3).  
Clones stably expressing constitutive and inducible FBXW7 shRNAs displayed a 
significant decrease in viability with 4OHT expressing MYCER (p<0.01). Survival of cells 
infected with control shRNA was not affected by MYCER induction over a period of 23 
days, whereas cells with FBXW7 knockdown showed 11% less GFP signal in the 
presence of 4OHT by Day 23 (p<0.003) (Figure 3b). When plotted as the MYC ON/MYC 
OFF ratio of surviving cells, we determined that the constitutive FBXW7 knockdown 
caused a 21% decrease in viability, and the inducible FBXW7 knockdown caused an 
average of 53% decrease in viability compared to control cells (Figure 3c). The inducible 
clones likely yield a more robust reaction due to continuous induction of shRNA by 
1µg/ml doxycycline addition at every passage. 
Of note, due to the lack of reliable FBXW7 antibodies, we were unable to assess 
the effect of knockdown on FBXW7 protein levels. However, all the shRNAs used in our 
secondary screen target different sequences within the FBXW7 mRNA from the shRNAs 
included the library, confirming that the observed phenotype is due to FBXW7 down-
regulation. Taken together, these results validate the initial finding from the screen and 




FBXW7 knockdown specifically leads to stabilization of active MYCER  
To explore the mechanism by which FBXW7 down-regulation leads to lethality in 
MYC expressing cells, we first sought to assess whether down-regulation of FBXW7 
resulted in the stabilization of MYCER. To this end, we examined the cellular and 
chromatin-bound levels of MYCER upon FBXW7 knockdown. Total cellular levels of 
MYCER were significantly increased upon down-regulation of FBXW7 with either 
constitutive or inducible FBXW7 shRNA (3.5 fold and 6.2 fold, respectively, p<0.05) 
(Figure 4a). Moreover, the levels of active, chromatin-bound MYCER detected upon cell 
fractionation (Mendez and Stillman, 2000) were synergistically increased upon FBXW7 
knockdown and MYCER activation (Figure 4b). Chromatin-bound MYCER increased 2-5 
fold upon FBXW7 down-regulation and further increased up to 10-13.5 fold when 
MYCER was induced by 4OHT (p<0.1) (Figure 4b). These results suggest that FBXW7 
knockdown significantly stabilizes deregulated MYCER, resulting in elevated levels of 
active chromatin-bound MYCER.  
As previously noted, FBXW7 controls the proteasome-dependent degradation of 
several cellular oncogenes which could also be stabilized upon FBXW7 knockdown and 
account for the observed phenotype (Welcker and Clurman, 2008). Therefore, we 
examined the stability of other targets of FBXW7 by Western blot: c-Jun, NOTCH1, 
CyclinE, and mTOR upon FBXW7 knockdown (Supplementary Figure 4). We find 
stabilization of MYCER, c-Jun, and CyclinE upon FBXW7 down-regulation in the 
absence of MYCER activation (Figure 4c). Notably, upon MYCER activation by 4OHT, 
only MYCER is stabilized when compared to the other FBXW7 targets examined (Figure 
4c). Similar results were obtained using the inducible FBXW7 knockdown alleles 
(Supplementary Figure 5). These data suggest that FBXW7 knockdown in the context of 
MYCER activation leads predominantly to stabilization of MYCER. Our results point to 
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the major role of FBXW7-mediated MYCER degradation for survival of cells with 
deregulated MYC. 
 
MYCER stabilization results in accumulation of chromatin-bound CDC45 and cells 
in S/G2 phase 
MYC deregulation triggers DNA damage and genomic instability (Dominguez-
Sola et al., 2007; Felsher and Bishop, 1999; Karlsson et al., 2003; Vafa et al., 2002). 
Therefore, we assessed the consequence of down-regulating FBXW7 together with 
MYCER activation on DNA damage and apoptosis. We monitored checkpoint activation 
(phosphorylation of Chk1 by ATR or Chk2 by ATM) and formation of DNA double strand 
breaks (phosphorylated H2AX), but could not detect a significant synergistic increase in 
these markers at any time-point during the four week course of the experiments 
(Supplementary Figure 7a). Next, we probed for the apoptosis markers cleaved 
caspase-3, cleaved PARP, and PUMA, but did not detect significant changes by 
Western blotting (Supplementary Figure 7b). We then examined changes in cell cycle 
distribution. After four weeks of treatment with 4OHT, we found that FBXW7 knockdown 
cells in which MYC was deregulated showed synergistic accumulation of cells in S 
phase and G2/M phase (p<0.05) (Figure 5a, 5b, and Supplementary Figure 6). These 
data suggest that aberrant expression of MYC resulted in slower S-phase progression 
and/or DNA replication stress, and these phenotypes are exacerbated with FBXW7 
knockdown.  
 We have recently demonstrated that MYC-dependent DNA replication stress is 
directly mediated by CDC45, a component of the replicative DNA helicase that marks 
active origins of replication (Srinivasan et al., 2013). To assess if the cell cycle 
phenotype we observed could be attributed to aberrant S-phase progression as a result 
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of accumulation of active MYCER on chromatin, we monitored the levels of chromatin-
bound CDC45 in FBXW7 knockdown cells. We find that FBXW7 knockdown in the 
context of MYCER activation by 4OHT results in a synergistic increase in the levels of 
chromatin-bound CDC45 (6.7 fold increase, p<0.1), suggesting increased origin firing in 
the cells (Figure 5c). Our data suggest that FBXW7 knockdown cells with activated 
MYCER experience aberrant levels of origin firing during DNA replication, a sign of 
replication stress, which may contribute to the synthetic lethal phenotype. 
 
MYC expression correlates with FBXW7 expression in Luminal A-type breast 
cancers 
Since regulation of MYC abundance by FBXW7 is critical for MCF10A cells’ 
viability, we asked if mRNA expression levels of MYC and FBXW7 are correlated in a 
large panel of breast cancer samples from The Cancer Genome Atlas (TCGA) database. 
Comparative analysis of MYC and FBXW7 expression showed a weak correlation when 
all types of breast cancers were pooled and analyzed together (rho=0.23, p<0.0001) 
(Supplementary Figure 8a). Next, we repeated the correlation analysis on specific data 
subsets corresponding to distinct breast cancer subtypes (normal, Her2, basal, luminal 
A, and luminal B). We found a statistically significant positive correlation between MYC 
and FBXW7 expression specifically in luminal A-type breast cancers (rho=0.4052, 
p<0.0001) (Supplementary Figure 8b). Luminal A-type breast cancers are the most 
prevalent breast cancer subtype (40%), and are generally molecularly classified as 
hormone receptor (ER/PR)-positive and Her2-negative (Schnitt, 2010). Of note, this 
breast cancer subtype is typically associated with low to normal MYC expression, 
suggesting that cells retain physiological regulation of MYC abundance (Xu et al., 2010). 
This is in contrast to cells derived from breast cancer types with MYC overexpression, 
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which are unresponsive to MYC suppression (Kang et al., 2014). This observation 
supports our data, since normal-MYC breast cancers such as luminal A are likely more 
sensitive to relatively small fluctuations in MYC protein levels which may arise from 
altered FBXW7 expression.  
Discussion 
 Genome-wide screens utilizing RNAi have become a powerful tool to assess 
genetic interactions in human cells. Several screens specifically designed to identify 
genes required for cell survival upon MYC deregulation have been previously published 
(Kessler et al., 2012; Liu et al., 2012; Toyoshima et al., 2012). Intriguingly, when we 
compare the 78 candidates from our screen (Supplementary Table 1) to published 
datasets, less than 5% of genes overlap in pairwise comparisons of individual screens. 
Several reasons may account for these differences. Different studies use normal or 
cancer cell lines. The mode of MYC deregulation (overexpression vs. inducible) and 
differences between siRNA and shRNA could also account for some differences. 
Furthermore, MYC regulates multiple cellular processes and its function as well as the 
impact of its expression depends heavily on the particular cellular context. Finally, it has 
been proposed that MYC acts as a general amplifier of activated transcription, which 
could explain in part why MYC may be regulating the expression of different genes in 
different cell types (Lin et al., 2012; Nie et al., 2012). Thus, while the differences 
observed between datasets are puzzling, they demonstrate the importance of studying 
MYC biology within highly controlled and specific contexts that best mimic physiological 
systems.   
We have identified 78 genes which down-regulation is synthetic lethal with 
MYCER activation in MCF10A-MYCER cells. Our system utilizes a stably expressed 
fusion MYCER protein to model MYC deregulation instead of endogenous MYC. 
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However, previous studies have established that MYCER does not respond to estrogen, 
which we have further confirmed (data not shown) (Littlewood et al., 1995). Moreover, 
findings from one of the previously published MYC-SL screens with MYCER were 
extended to MYC-dependent breast cancer cell lines, supporting MYCER as a faithful 
model for MYC deregulation (Kessler et al., 2012). However, since we still cannot 
definitively exclude the possibility of the ER portion affecting our results, we are currently 
testing the dependence of several MYC-dependent breast cancer cell lines on FBXW7. 
We expect these breast cancer cell lines to mimic our results in MCF10A-MYCER.  
We have validated FBXW7 as a gene which knockdown causes significantly 
decreased viability for cells with activated MYCER. Though FBXW7 is known to target 
several oncogenes for degradation, our findings indicate that knockdown of the gene in 
the presence of MYCER activation causes preferential stabilization of MYCER. Our data 
suggest that stabilization of MYCER is critical to cause increased accumulation of 
FBXW7 knockdown cells in S/G2 phase and gradual cellular death as demonstrated 
through viability assays. Though we were not able to detect significant levels of DNA 
damage or apoptosis markers, this may be attributed to the slow and gradual nature of 
cell death induction in our experiments. We observe at most 50% decrease in viability of 
FBXW7 knockdown cells compared to control cells over the course of four weeks. We 
believe that any given time-point only a small fraction of cells is expressing markers of 
DNA damage or apoptosis, which is in contrast to what is seen following acute MYC 
overexpression. Nevertheless, the possibility of senescence or alternative cell death 
pathway activation cannot be excluded, and will have to be examined. 
FBXW7 is one of only four MYC-SL candidate genes that were identified from 
both our screen and Kessler’s screen, emphasizing its potential significance as a major 
MYC-SL pathway (Supplementary Table 1) (Kessler et al., 2012). The two other MYC-
SL datasets did not include FBXW7, however, the smaller RNAi libraries utilized in these 
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screens may not have included FBXW7 (Liu et al., 2012; Toyoshima et al., 2012). 
Notably, Liu’s screen that interrogated the human kinome identified GSK3B, the kinase 
responsible for MYC phosphorylation and required for recognition by FBXW7 (Liu et al., 
2012). These findings suggest that the FBXW7-dependent MYC degradation pathway 
may be a common MYC-SL pathway across a variety of cell types (Liu et al., 2012). 
Though this is not entirely surprising given the already documented major role of FBXW7 
in MYC degradation, the identification of common MYC-SL genes and pathways across 
the datasets has not been an easy task (Cermelli et al., 2014). 
 It is well established that FBXW7 is a crucial component of the SCF-like ubiquitin 
ligase complex, which targets ubiquitinated proteins for proteasomal degradation. Since 
many targets of FBXW7 are oncogenes such as MYC, CyclinE, NOTCH1, and c-JUN, 
FBXW7 is generally considered a tumor suppressor gene. In fact, in human T-cell acute 
lymphoblastic leukemia (T-ALL), FBXW7 is one of the most frequently mutated genes 
(approximately 30% of cases (Akhoondi et al., 2007)) and mouse models with tissue 
specific knockout of FBXW7 in various settings develop both hematopoietic and solid 
tumors (Wang et al., 2012), corroborating the tumor suppressing functions of FBXW7 in 
these contexts.  
We propose that FBXW7 can also act as a tumor maintenance gene in the 
context of MYC deregulation. The presence of FBXW7 enables continued proliferation 
and survival of cells expressing MYC at aberrant levels. Consistent with our results, 
increased accumulation of MYC is responsible for the loss of leukemic stemness in 
leukemia-initiating cells lacking FBXW7 (King et al., 2013; Reavie et al., 2013; Takeishi 
et al., 2013). In a T-ALL mouse model, MYC protein levels in leukemia-initiating cells 
were found to rely heavily on FBXW7 activity, demonstrating that MYC is the major 
contributor to the FBXW7 phenotype (King et al., 2013). Indeed, our studies suggest that 
accumulation of active MYC protein is the major contributor to the synthetic lethal 
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phenotype seen upon FBXW7 knockdown and MYCER activation. However, we have 
not tested all documented targets of FBXW7 such as SREBP, p100, NRF1, NF1, Mcl-1, 
KLF5, c-Myb, and Aurora A (Wang et al., 2012). 
While FBXW7 mutations are found in several diverse human cancer types such 
as T-ALL, cholangiocarcinoma, stomach, colon, pancreas, and endometrium, they are 
rare in other cancers (Cheng and Li, 2012). In breast and ovarian cancer, FBXW7 
mutations appear to be infrequent (Akhoondi et al., 2010). This could be explained in 
part by our results showing that MYCER activation combined with loss of FBXW7 in 
breast epithelial cells results in loss of viability. We hypothesize that inactivating 
mutations of FBXW7 may not be able to coexist with MYC overexpression in the breast 
context. Interestingly, our analysis suggests that MYC and FBXW7 expression have a 
positive correlation, specifically in the luminal A-subtype of breast cancers that tend to 
have lower levels of MYC. The synthetic lethal effect between MYC deregulation and 
FBXW7 knockdown might be most relevant for human breast cancers with lower levels 
of MYC, since these cells may retain MYC-dependence and thus affected more robustly 
by alterations in MYC protein levels due to knockdown of FBXW7. To test this 
hypothesis, more detailed analysis of FBXW7 expression in individual breast cancer 
subtypes would be necessary. 
Pharmacological inhibitors of FBXW7 are still under development and not yet 
available to test. We hypothesize that treatment of MCF10A-MYCER cells with FBXW7 
inhibitor would recapitulate the shRNA-mediated knockdown results. Testing FBXW7 
inhibitors in a panel of breast cell lines as well as breast cancer cell lines overexpressing 
MYC would be crucial in order to test the relevance of the synthetic lethal interaction we 
have seen in our system. Nevertheless, our results demonstrating the identification of 
FBXW7 as a synthetic lethal target in the context of MCF10A-MYCER adds insight to the 
still enigmatic role of the interaction between FBXW7 and MYC in human cancer 
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initiation, progression, and maintenance. Ultimately, we hope that these results could 
contribute to the development of more diverse targeted clinical treatment options for 





Materials and Methods 
 
Cell culture 
MCF10A cells were cultured in DMEM/F12 (Invitrogen, Carlsbad, CA, USA) 
supplemented with 5% horse serum (Invitrogen), 20ng/ml EGF (Peprotech, Rocky Hill, 
NJ, USA), 0.5цg/ml hydrocortisone (Sigma-Aldrich Corporation, St. Louis, MO, USA), 
100ng/ml cholera toxin (Sigma), 10цg/ml insulin (Sigma), and antibiotics. 293T cells 
were cultured in DMEM (Invitrogen) supplemented with 10% FBS (Invitrogen) and 
antibiotics. All cells were incubated at 37ºC and 5% CO2.  
 
Isolation of MYCER cells 
MYCER was introduced retrovirally using pBabe-hygro-MYCER into MCF10A cells and 
transduced clones were selected by the addition of 100цg/ml Hygromycin B (Roche 
Holding AG, Basel, Switzerland). Clones were isolated by serial dilution.  
 
Cell lysis and cellular fractionation 
Cells were lysed in RIPA buffer (150mM NaCl, 1% NP40, 0.5% DOC, 0.1% SDS, 50mM 
Tris pH 8.0), supplemented with protease and phosphatase inhibitors (Sigma), for 15 
min on ice. Samples were sonicated (2 x 5 min) and centrifuged for 10 min at 4ºC. 
Cellular fractionation was performed as published by Mendez and Stillman (Mendez and 
Stillman, 2000).  
 
Production of lentivirus and shRNA  
Glycerol stocks of lentiviral shRNA constructs (pGIPZ, pTRIPZ) were obtained from 
Thermo Scientific Open Biosystems (Waltham, Massachusetts, USA) and grown in LB 
medium with 100цg/ml carbenicillin (Sigma) and 25цg/ml Zeocin (InvivoGen, San Diego, 
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CA, USA). Clones used were FBXW7-7 (V2LHS_202932), FBXW7-8 (V2THS_89328), 
FBXW7-10 (V2THS_203045), UBE2I-3 (V2LHS_171776), and UBE2I-6 
(V3LHS_376933). Plasmids were isolated using the E.Z.N.A. Plasmid Miniprep kit 
(Omega Bio-Tek, Inc., Norcross, GA, USA) and packaged into lentivirus by transfecting 
(jetPEI by Polyplus-transfection S.A., Illkirch, France) into 293T cells with pMD.G and 
pCMVR8.91. Viruses were collected in MCF10A media, filtered, and infected into 
MCF10A in the presence of 8цg/ml polybrene (Sigma) and spin infected for 1 hr at 
1000rpm at RT. After 24 hr of incubation, infected cells were selected by the addition of 
2цg/ml puromycin (Sigma).  
 
shRNA screen 
The pooled shRNA screen was carried out using the Thermo Scientific Open Biosystems 
GIPZ Lentiviral Human shRNA-mir Library as described in Rodriguez-Barrueco et al 
(Rodriguez-Barrueco et al., 2013). The library was packaged into lentivirus as described 
above, and MCF10A-MYCER cells were infected at 30% efficiency. Infected cells were 
selected with 2цg/ml puromycin for two passages and divided into 10 independent 
populations. Five populations were treated with 200nM 4OHT (every 48 hr) and five 
were treated with vehicle. After 30 days, genomic DNA of surviving cells was isolated by 
lysing cells with DNA lysis buffer (1% SDS, 100mM EDTA pH8.0, 50mM Tris-HCl pH8, 
100nM NaCl), treating with RNAse A (Qiagen N.V., Venlo, Netherlands), and purifying 
DNA with phenol chloroform extraction and isopropanol precipitation. Resulting DNA 
was subjected to PCR to recover the shRNA and associated barcodes, generating a 
heterogeneous pooled product of approximately 350 bps. The PCR product was gel-
extracted and purified, labeled with Cy3 and Cy5 (Roche), and hybridized to customized 
microarrays (Agilent Technologies, Inc., Santa Clara, CA, USA) harboring 
complementary probes to the shRNA barcodes. Data analysis was then performed as 
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described in Yu et al (Yu et al., 2013). 
 
Competition assays 
250 000 MCF10A-MYCER cells expressing stably integrated shRNA and 250 000 
MCF10A-MYCER cells without shRNA were plated together. At the first passage, 
fluorescent cells were counted by live cell flow cytometry, and replated with either 
vehicle or 4OHT. At each subsequent passage, remaining percentage of fluorescent 
cells was analyzed using flow cytometry. All cell sorting was performed with the BD 
FACSCalibur (BD Biosciences, San Jose, CA, USA). 
 
mRNA isolation and RT-PCR 
RNA was isolated using the Nucleospin RNA II kit (Clontech Laboratories, Inc., Mountain 
View, CA, USA). 1цg of RNA was subjected to reverse transcription using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Life Technologies, 
Carlsbad, CA, USA). cDNA was used as template for quantitative RT-PCR using 
ABsolute Blue QPCR SYBR Green Low ROX Mix (Thermo Scientific) and Applied 
Biosystems 7500 Fast (Life Technologies, Carlsbad, CA, USA). 
 
Luciferase assay 
MCF10A-MYCER cells were plated in 12-well plates. After 24 hr, at 90% confluence, 
they were transfected with MYC reporter and Renilla plasmid and incubated for 48 hr 
with or without 4OHT. Using the Dual-Luciferase Reporter Assay System (Promega 
Corporation, Fitchburg, WI, USA), relative luciferase activity was measured with the 





Double thymidine block and indirect immunofluorescence 
MCF10A-MYCER cells were plated on sterilized coverslips. After 24 hr, cells were 
incubated in 2.5mM thymidine for 17 hr. After a 7 hr recovery, the second block was 
administered at 2.5mM for 14 hr. Vehicle or 4OHT was added 3 hr prior to release. After 
1 hr recovery, cells were treated with an 8 min pulse of 33цM BrdU. Immediately, cells 
were washed and fixed with 4% paraformaldehyde for 15 min at RT, washed, then 
permeabilized with 0.2% Triton-X in PBS for 5 min and washed. DNA was denatured in 
2N HCl for 20 min at RT, following neutralization with 0.1M sodium tetraborate pH8.5. 
Primary antibody incubation with anti-BrdU (#555647, BD Pharmingen, San Jose, CA, 
USA) was performed in PBS-0.5%Tween for 30 min at RT, followed by washing, and 
secondary antibody incubation with goat-anti-mouse-FITC (Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA, USA) was performed in PBS-0.5%Tween for 30 min. 
Cells were washed and stained for 1 min with propidium iodide, airdried, and mounted 
on slides for confocal microscopy. The Zeiss LSM 510 Meta Inverted (Carl Zeiss AG, 
Oberkochen, Germany) was used for all confocal imaging. 
 
Western blotting and quantification 
Cell lysates were prepared as described, added to 5X Laemmli buffer and heated at 
95ºC for 5 min. Samples were run on Tris-Glycine or NuPAGE Tris-Acetate gels 
(Invitrogen) and transferred to PVDF membranes at 35V for 2 hr. Membranes were 
blocked in PBS-0.5%Tween-5%milk for 1 hr and stained with primary antibodies (1:250-
1:2000) for 1 hr or overnight, followed by staining with secondary antibodies (1:10,000) 
conjugated with HRP (Jackson) for 1 hr. After incubation with ECL (Pierce, Thermo 
Fisher Scientific), blots were exposed to film. ImageQuant 5.2 (Molecular Dynamics) was 




Cell cycle analysis 
At the time of harvest, MCF10A-MYCER cells were vortexed in 0.5 ml PBS, and 5 ml of 
70% ethanol was added dropwise for fixing at -20ºC overnight. The next day, cells were 
incubated in 1 ml PBS for 1 hr on ice and centrifuged. To the resulting pellet, RNAse A 
was added at 1/400, and propidium iodide stock (10mg/ml, Sigma) was added at 1/1000 




The following antibodies were used for immunostaining: MYC (9E10, Santa Cruz 
Biotechnology, Inc., Dallas, TX, USA), c-Jun (sc-44, Santa Cruz), cleaved Notch1 (4147, 
Cell Signaling, ), cyclin E (sc-481, Santa Cruz Biotech), mTOR (2972, Cell Signaling 
Technology, Inc., Danvers, MA, USA), βactin (A2228, Sigma), Histone H3 (9715, Cell 
Signaling), Cdc45 (EPR5759, Epitomics, Burlingame, CA, USA), Phospho-Chk2 (2661, 
Cell Signaling), Phospho-H2AX (JBW301, EMD Millipore, Billerica, MA, USA), Cleaved 
Caspase-3 (9664, Cell Signaling), PARP-1 (sc-8007, Santa Cruz), PUMA (sc-28226, 
Santa Cruz). 
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Figure 1. MCF10A-MYCER cells: a model for MYC deregulation. (a) MCF10A-MYCER 
cells express MYCER protein. Whole cell lysates from uninfected or MYCER-infected 
MCF10A cells were analyzed by SDS-PAGE. The positions of endogenous MYC and 
MYCER are indicated. (b) MYCER protein is activated in response to 4OHT treatment. 
Nuclear translocation of MYCER was analyzed by cell fractionation followed by SDS-
PAGE of the chromatin-bound fraction from MCF10A-MYCER cells treated with vehicle 
or 200nM 4OHT for 48 hr. MYCER increase was normalized to histone H3 levels for 
quantification. (c) MYCER activation induces accelerated entry into S phase. MCF10A-
MYCER cells were arrested at G1/S with double thymidine. Cells were treated with 
vehicle (NT=not treated) or 4OHT, then pulse labeled with BrdU 1 hr after release into S 
phase. BrdU incorporation was assessed using indirect immunofluorescence. 
PI=propidium iodide was used to stain genomic DNA.  
 
Figure 2. Genome-wide screen for synthetic lethal candidates with MYCER activation. 
(a) Schematic diagram of screen design. See text for details. (b) Identification of 
synthetic lethal shRNA with MYCER. Heat map shows the relative enrichment or 
depletion of each shRNA in all experimental replicates. The spectrum between red and 
blue denote the relative representation of each shRNA barcode in the sample compared 
to the reference (library at T=0). (c) Five biological pathways most required for the 
survival of MCF10A-MYCER. Pathway analysis of the top synthetic lethal candidates 
(Log2 FC<-1) shows enrichment of genes in five biological pathways. Pathways are 




Figure 3. Loss of FBXW7 combined with MYCER activation is lethal. (a) Knockdown of 
FBXW7 in MCF10A-MYCER cells. FBXW7 expression was inhibited in MCF10A-
MYCER cells using lentiviral transduction of shRNA. Constitutive (FBXW7-7) and 
inducible (FBXW7-8 and -10) knockdown levels were analyzed by quantitative RT-PCR. 
Results show the mean and SEM of 3 independent experiments. (b) FBXW7 knockdown 
compromises the viability of cells with MYC ON. Fluorescence-based competition assay 
over 23 days was performed as described in the text. The GFP-expressing population 
was measured at the indicated timepoints for untreated (NT) and 4OHT-treated cells. 
Cells were treated with vehicle or 4OHT every 72 hr for the duration of the experiments. 
Graphs represent the mean of three replicate experiments. (c) Three independent clones 
of constitutive and inducible FBXW7 shRNA decrease the viability of 4OHT-induced 
MCF10A-MYCER cells. Fluorescence-based competition assay data are plotted as 
ratios of %GFP of MYC ON to MYC OFF at the given timepoints. Graphs represent the 
mean of three independent experiments. 
 
Figure 4. Loss of FBXW7 with MYCER activation results in specific stabilization of active 
MYCER protein. (a) MYCER protein stability is enhanced in FBXW7 knockdown cells. 
Whole cell extracts were prepared from MCF10A-MYCER cells with FBXW7 knockdown. 
Inducible clones were activated with 1µg/ml doxycycline. Quantified values below each 
lane are normalized to β actin and averaged for 3 experiments. Error bars represent the 
SEM. (b) Active MYCER is stabilized on chromatin in FBXW7 knockdown cells following 
4OHT induction. Cells treated with vehicle or 4OHT were fractionated, and fraction P3 
(chromatin-bound) was analyzed on SDS-PAGE. Quantifications are normalized to 
histone H3 and values are averages of 3 experiments. Error bars represent the SEM. (c) 
FBXW7 knockdown with MYCER activation results in specific stabilization of MYCER. 
Whole cell extracts were prepared from control or FBXW7 knockdown cells and 
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analyzed on SDS-PAGE followed by Western blot for FBXW7 targets (MYCER, c-Jun, 
Notch1, Cyclin E, mTOR). Quantifications show the fold enrichment of protein levels in 
control or FBXW7 knockdown cells normalized to β actin. Results are averages of 3 
independent experiments and error bars represent the SEM.  
 
Figure 5. MYCER stabilization results in accumulation of cells in S/G2 phase and 
chromatin-bound CDC45. (a) Constitutive knockdown of FBXW7 with MYCER activation 
results in additive accumulation of cells in S and G2/M phase. MCF10A-MYCER cells 
with control or FBXW7 knockdown were cultured for 7 days in the absence or presence 
of 4OHT (MYC OFF or MYC ON). Cells were fixed and stained with propidium iodide for 
cell cycle analysis. Results are averages of 3 independent experiments and error bars 
represent the SEM. (b) Inducible knockdown of FBXW7 with MYCER activation results in 
accumulation of cells in S and G2/M phase. Control or FBXW7 knockdown cells were 
cultured for seven days with 1µg/ml doxycycline and vehicle or 4OHT every 72 hr. 
Results are averages of 3 independent experiments and error bars represent the SEM. 
(c) Loss of FBXW7 with MYCER activation causes accumulation of CDC45 on 
chromatin. MCF10A-MYCER cells with control or FBXW7 knockdown were cultured for 7 
days with or without 4OHT and fractionated. Fraction P3 was analyzed on SDS-PAGE. 
Shown is a representative image of CDC45 blot, and graph shows the average of 3 
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Supplementary Figures 1-9 
 
  
MYC is a critical target of FBXW7 
 
Supplementary Figures 1-7. 
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Supplementary Figure 1. MYCER protein expressed from the transgene can enhance 
transcriptional activity. (a) A reporter plasmid containing 6 E-box sequences (CACGTG) 
followed by a luciferase reporter was transfected into uninfected parental MCF10A or 
MCF10A-MYCER cells and luminescence was measured 48 hr after transfection. (b) 
Luciferase activity from the reporter was normalized to Renilla luciferase activity. Each 
experiment was done in triplicate and graphs show the average of 3 biological replicates. 









After double thymidine block 
24h post release from DT block 
Supplementary Figure 2. MCF10A-MYCER cells arrest at the G1/S transition following 
double thymidine block. MCF10A-MYCER cells were subjected to two rounds of 2.5mM 
thymidine treatment, then fixed and stained with propidium iodide for flow cytometric 
analysis. Compared to untreated asynchronous cells, thymidine treated cells showed 
accumulation of cells in M1+M2 (<2N DNA content). 24h after release, the cell cycle 















Supplementary Figure 3. Schematic of fluorescence-based competition assay. Uninfected 
MCF10A-MYCER cells which express no fluorescent proteins are plated on the same plate 
with MCF10A-MYCER cells infected with a single shRNA clone of choice co-expressing GFP 
or RFP. At day 1, cells from the plate are subjected to live cell flow cytometry to verify ~50% 
fluorescence. Subsequently, the cells are split into control or 4OHT treated groups, and 
passaged every 48-72 hr. At each passage or desired timepoint, remaining fluorescence on 
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Supplementary Figure 4. FBXW7 knockdown specifically leads to stabilization of MYCER. 
MCF10A-MYCER cells expressing either control or FBXW7 shRNA were cultured in the 
presence or absence of 4OHT for 4 weeks. Whole cell lysates (80µg total protein/lane) were 
run on SDS-PAGE and subjected to Western blot for analysis of major FBXW7 targets. 





Supplementary Figure 5. FBXW7 knockdown leads to preferential stabilization of MYCER. 
MCF10A-MYCER cells stably expressing Dox-inducible shRNA clones of FBXW7 were 
treated with or without 4OHT (MYC OFF or ON) for 4 weeks, then cell lysates were analyzed 
by SDS-PAGE/Western blot. Bands were quantified using ImageQuant v5.2 (Molecular 
Dynamics) and normalized to loading controls. Figure shows averages from 3 independent 










Supplementary Figure 6. FBXW7 knockdown with MYCER activation causes synergistic 
accumulation of  cells in S and G2/M phase. MCF10A-MYCER cells stably expressing 
control or FBXW7 shRNA were cultured for 4 weeks in the presence or absence of 4OHT 
(MYC OFF or ON). Cells were fixed and stained with propidium iodide for flow cytometric 
analysis. Cells accumulate in the M3+M4 region (<1N DNA content) only in the FBXW7 























Supplementary Figure 7. Long term FBXW7 knockdown and MYCER activation do not result 
in significant levels of DNA damage or apoptosis. (a) Control or FBXW7 knockdown cells 
were treated with or without 4OHT for 4 weeks and probed for the presence of 
phosphorylated Chk2 (in whole cell lysate) or H2AX  (in chromatin-bound samples after 
fractionation) as markers of checkpoint activation/DNA damage. shFBXW7 cells did not show 
a significant accumulation of either species after long term treatment with 4OHT. (b) Similarly 
treated cells were probed for the presence of apoptosis markers in whole cell lysates. 
However, we failed to detect any significant levels of cleaved caspase-3, PARP1, or PUMA in 
the surviving cells after 4 weeks of treatment. Shown above are representative images of 3 










Supplementary Figure 8. MYC and FBXW7 expression levels positively correlate in Luminal A-type breast 
cancers. (a) FBXW7 vs. MYC expression in all breast cancers. (b) FBXW7 vs. MYC expression in luminal A-
type breast cancers. RNA-seq (IlluminaHiSeq) data from TCGA breast invasive carcinoma dataset was 
downloaded from the cancer browser (TCGA_BRCA_exp_HiSeqV2). Overall, 1106 samples were assessed, 
including 228 LUMINAL A subtypes. Expression of MYC and FBXW7 were estimated in RSEM normalized 
count and Pearson correlation coefficient (rho) was calculated using STATA (Stata Statistical Software: 










Supplementary Figure 9. UBE2I knockdown is synthetic lethal with MYCER activation. (a) MCF10A-MYCER 
cells stably expressing two independent shRNA clones targeting UBE2I (shUBE2I-3 and shUBE2I-6) were 
subjected to competitive survival assays. By day 27, MYC ON/MYC OFF survival ratios of shUBE2I cells 
decreased to 49% (p<0.001), while ratios of shCONTROL cells decreased to 81%(p<0.001) compared to 
day 0. Graphs represent the average of three replicates. (b) shRNA-mediated knockdown of UBE2I. 
MCF10A-MYCER cells stably expressing shRNA clones targeting UBE2I (UBE2I-3 and UBE2I-6) were 






Supplementary Table 1 
 
Supplementary Table 1. List of top 78 synthetic lethal targets from MCF10A-MYCER screen. 
Results were filtered according to fold change (Log2 FC<-1) of signal abundance between MYC 
ON and MYC OFF, and individually associated p-values (p<0.05). Only annotated target genes 
are shown. Candidates are ranked in order of most depleted in the MYC ON population 
compared to MYC OFF (Log2 FC value). 
 
Rank Name  p-value Log2 FC Acc. Number shRNAi ID 
  1 ARL5B 0.0500 -2.7089 NM_178815 v2HS_118631 
  2 C2orf44 0.0100 -2.5672 NM_025203 v2HS_137381 
  3 TTBK1 0.0300 -2.4316 AB058758 v2HS_238991 
  4 PSG6 0.0400 -2.3989 NM_002782 v2HS_170657 
  5 NAT9 0.0500 -2.3896 NM_015654 v2HS_263964 
  6 TRPM6 0.0300 -2.1357 NM_017662 v2HS_155076 
  7 MFN2 0.0100 -2.0827 NM_014874 v2HS_95806 
  8 C18orf54 0.0100 -1.8569 NM_173529 v2HS_160761 
  9 DONSON 0.0300 -1.8499 NM_017613 v2HS_154816 
  10 ZNF614 0.0400 -1.8499 NM_025040 v2HS_235983 
  11 H2AFV 0.0100 -1.8450 NM_138635 v2HS_200741 
  12 NUPL1 0.0500 -1.8381 NM_014778 v2HS_233311 
  13 ZNF691 0.0100 -1.7257 NM_015911 v2HS_236174 
  14 PSMD2 0.0500 -1.7213 NM_002808 v2HS_219275 
  15 CDC14B 0.0400 -1.7209 NM_033331 v2HS_203260 
  16 UGT1A1 0.0300 -1.6796 NM_000463 v2HS_93183 
  17 SOX15 0.0500 -1.6110 NM_006942 v2HS_229072 
  18 NUPL2 0.0500 -1.6086 NM_007342 v2HS_86275 
  19 ANKRD27 0.0500 -1.6068 NM_032139 v2HS_117932 
  20 EPHA7 0.0100 -1.5984 NM_004440 v2HS_17738 
  21 ST8SIA4 0.0500 -1.5098 NM_005668 v2HS_238967 
  22 SLC44A2 0.0500 -1.4952 NM_020428 v2HS_72471 
  23 SH3BP4 0.0300 -1.4934 NM_014521 v2HS_86832 
  24 KIAA0509 0.0300 -1.4922 AB007978 v2HS_259524 
  25 DMKN 0.0500 -1.4804 NM_033317 v2HS_160312 
  26 STK17A 0.0100 -1.4726 NM_004760 v2HS_36021 
  27 PHF21A 0.0100 -1.4564 NM_016621 v2HS_135309 
  28 EYA2 0.0200 -1.4531 NM_005244 v2HS_43093 
  29 C6orf184 0.0100 -1.4413 XM_168053 v2HS_121031 
  30 ZFYVE9 0.0100 -1.4407 NM_004799 v2HS_35331 
  31 LRCH3 0.0400 -1.4395 NM_032773 v2HS_222832 
  32 NR2E1 0.0100 -1.4308 NM_003269 v2HS_261941 
  33 TOP3B 0.0100 -1.4280 NM_003935 v2HS_47174 
  34 WDSOF1 0.0300 -1.4122 NM_015420 v2HS_229697 
  35 CLDN5 0.0500 -1.3596 NM_003277 v2HS_171412 
  36 CMTM2 0.0400 -1.3528 NM_144673 v2HS_17530 




38 APOBEC3A 0.0300 -1.3348 NM_145699 v2HS_286556 
  39 ERGIC1 0.0300 -1.3258 NM_020462 v2HS_71567 
  40 PARP15 0.0100 -1.3206 NM_152615 v2HS_44475 
  41 RAE1 0.0500 -1.2995 NM_003610 v2HS_27966 
  42 LEPREL1 0.0500 -1.2897 NM_018192 v2HS_156224 
  43 ZNF132 0.0300 -1.2802 NM_003433 v2HS_172208 
  44 SLC7A1 0.0500 -1.2710 NM_003045 v2HS_153014 
  45 LAMA2 0.0200 -1.2692 NM_000426 v2HS_92966 
  46 LOC344065 0.0400 -1.2685 XM_292895 v2HS_143532 
  47 ATP1B1P1 0.0500 -1.2641 NG_001081 v2HS_169198 
  48 C1orf182 0.0500 -1.2536 NM_144627 v2HS_18680 
  49 KRIT1 0.0400 -1.2463 NM_004912 v2HS_62790 
  50 ASAH3 0.0400 -1.2436 NM_133492 v2HS_99964 
  51 OLFR89 0.0300 -1.2192 AJ132194 v2HS_18007 
  52 CCDC25 0.0300 -1.1758 NM_018246 v2HS_156496 
  53 TOP3A 0.0100 -1.1740 NM_004618 v2HS_42272 
  54 MATK 0.0200 -1.1567 NM_002378 v2HS_203423 
  55 ST14 0.0100 -1.1516 NM_021978 v2HS_228778 
  56 KIAA0574 0.0300 -1.1513 AB011146 v2HS_130193 
  57 PERP 0.0200 -1.1513 NM_022121 v2HS_216968 
  58 FBXW7 0.0200 -1.1469 AY033553 v2HS_89326 
  59 APOA2 0.0100 -1.1369 NM_001643 v2HS_132594 
  60 C5 0.0400 -1.1342 NM_001735 v2HS_150150 
  61 SLC36A4 0.0500 -1.1260 NM_152313 v2HS_25433 
  62 PPP3CC 0.0300 -1.1253 NM_005605 v2HS_57300 
  63 TRIM26 0.0500 -1.1229 NM_003449 v2HS_172289 
  64 ELL 0.0500 -1.1181 NM_006532 v2HS_198413 
  65 PRMT8 0.0100 -1.1163 NM_019854 v2HS_34353 
  66 PRSS21 0.0500 -1.1146 NM_006799 v2HS_83969 
  67 UBE2I 0.0200 -1.0971 NM_003345 v2HS_171781 
  68 QRSL1 0.0400 -1.0967 XM_301163 v2HS_49076 
  69 C11orf48 0.0400 -1.0951 NM_024099 v2HS_116419 
  70 EPYC 0.0400 -1.0697 NM_004950 v2HS_61963 
  71 TNFAIP2 0.0100 -1.0598 NM_006291 v2HS_56492 
  72 PAQR3 0.0300 -1.0499 NM_177453 v2HS_211154 
  73 PREB 0.0500 -1.0457 NM_013388 v2HS_64102 
  74 CEND1 0.0300 -1.0194 NM_016564 v2HS_135015 
  75 BBOX1 0.0300 -1.0107 NM_003986 v2HS_246341 
  76 CDKL5 0.0500 -1.0097 NM_003159 v2HS_262311 
  77 CMTM7 0.0100 -1.0049 NM_138410 v2HS_70332 
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Oncogene-induced genomic stress is detected in many types of cancers. Maintenance 
of genome stability is critical for cell survival following oncogene activation (Negrini et al., 
2010). To target pathways required in cancer cells with oncogene activation and to 
identify genes that are synthetic lethal with deregulation of MYC in MCF10A cells, we 
conducted a genome-wide screen using the human lentiviral shRNA library. We 
identified UVSSA and ERCC8, two genes involved in transcription-coupled repair (TCR, 
or TC-NER), as synthetic lethal candidates with MYC deregulation. Both UVSSA and 
ERCC8 knockdowns decreased viability of cells when combined with MYCER activation. 
MYC-deregulated cells are also sensitized to double knockdown of UVSSA and ERCC8 
as well as to chemical inhibitors of USP7. This finding establishes that the 
UVSSA/ERCC8/USP7 module of the TCR pathway is required to cope with MYC 
overexpression. Notably, the role of UVSSA/ERCC8 in maintaining viability of MYC-
deregulated cells is independent of UV-induced damage repair, but dependent on RNA 
polymerase II-dependent transcription. We propose that transcription-coupled repair is 
required for alleviating transcription-dependent genomic stress, which may be one of the 
major sources of MYC-induced genomic instability. 
Introduction 
 Increasing evidence suggests that oncogenes induce various types of genomic 
stress both directly and indirectly. Oncogene-induced genome instability could be an 
Achilles’ heel for cancer cell survival (Moeller et al., 2010; Negrini et al., 2010). Cancer 
cells with oncogene activation such as MYC and RAS show common markers of 
genomic instability including increased DNA damage, microsatellite instability, and 
chromosomal aberrations (Felsher and Bishop, 1999; Saavedra et al., 2000; Wade and 
Wahl, 2006). Targeting genome maintenance pathways that allow cells to survive 
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oncogene-induced genomic stress can be an effective way to halt tumorigenesis induced 
by these oncogenes. Furthermore, the mechanism(s) resulting in genomic stress upon 
oncogene activation in cancer cells are still largely elusive. 
MYC is one of the most frequently deregulated, overexpressed, or amplified 
proto-oncogenes in human cancers ranging from hematopoietic to mesenchymal and 
epithelial tumors (Meyer and Penn, 2008; Morton and Sansom, 2013). MYC activity is 
normally tightly regulated both at the mRNA and protein levels to stimulate growth and 
proliferation only in response to specific mitogenic signals. Thus when deregulated, MYC 
can promote uncontrolled cell division which is one of the driving forces for 
tumorigenesis (Meyer and Penn, 2008). Genomic stress caused by MYC overexpression 
has been documented in tumor cells as well as in mouse models overexpressing MYC 
(Kuttler and Mai, 2006; Prochownik, 2008). MYC directly promotes increased RNA 
transcription as well as DNA replication, two intrinsically mutagenic physiological 
processes (Dang, 2012; Errico and Costanzo, 2012; Kim and Jinks-Robertson, 2012). 
Therefore, it is likely that MYC expression yields genomic instability through aberrant 
DNA replication, transcription, or a combination of both (Helmrich et al., 2013). 
Moreover, MYC can also accelerate the cell cycle and alter the activity of many other 
cellular processes by transcriptionally upregulating or downregulating a massive number 
of downstream genes (Meyer and Penn, 2008). Markers of genomic instability, DNA 
damage, as well as checkpoint activation have been previously identified in MYC-
deregulated cells; however, the relative contribution of different types of genomic stress 
in MYC-deregulated cells is still unclear (Wade and Wahl, 2006).  
Transcription-coupled repair (TCR), also called transcription-coupled nucleotide 
excision repair (TC-NER), is essential for efficient repair of bulky adducts or UV-induced 
lesions specifically on actively transcribed DNA strands  (Hanawalt and Spivak, 2008; 
Vermeulen and Fousteri, 2013). TCR is less well characterized than NER, and specific 
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genes that participate in TCR include ERCC8/CSA, ERCC6/CSB, XAB2, HMGN1, 
UVSSA, USP7, and ELL, all of which are independent from the global genome NER 
(GG-NER) pathway (Mourgues et al., 2013; Vermeulen and Fousteri, 2013). Current 
evidence suggest that TCR plays several roles and that its components coordinate a 
cascade of events including 1) stalling, backtracking, or removal of the active RNA 
Polymerase II (RNAPII) complex when it encounters a lesion, 2) recruiting GG-NER 
factors to repair the DNA lesion, and 3) supporting the resumption of proper transcription 
after repair has been ensured (Vermeulen and Fousteri, 2013). The mechanistic bases 
of these processes are unknown. TCR accounts for less than 10% of genome-wide UV 
lesion repair, while global genomic NER (GG-NER) accounts for the rest (Vermeulen 
and Fousteri, 2013). Nevertheless, mutations in TCR genes give rise to diseases in 
humans that can range from mild photosensitivity (e.g. UV-SS) to severe, congenital 
defects with a significantly reduced lifespan (e.g. Cockayne syndrome), similar to GG-
NER defective conditions (Saijo, 2013). This suggests that TCR may have significant 
cellular roles in addition to repair of exogenous UV lesions.  
In the present study, we conducted a genome-wide screen using a pooled 
lentiviral shRNA library to identify synthetic lethal candidates with MYC deregulation 
using MCF10A breast epithelial cells carrying a MYCER inducible allele. We found 
UVSSA and ERCC8 among our high confidence MYC-synthetic lethal (MYC-SL) 
candidates, both of which have prominent roles in TCR. We validated that loss of either 
gene by individual knockdown of UVSSA and ERCC8 specifically induced loss of 
viability in MYC-expressing cells. Our data therefore suggest that the TCR pathway is 
synthetic lethal with MYC deregulation. UVSSA knockdown in cells with MYC 
deregulation results in accumulation of phosphorylated CHK2, indicating DNA damage 
and genomic stress. Notably, reduced viability of MYC-expressing cells upon TCR down-
regulation is independent of UV-induced DNA damage but is dependent on RNA 
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transcription, suggesting a UV-independent role for UVSSA in maintenance of genome 
stability during increased transcription.  
Results 
Genome-wide synthetic lethal screen for MYC-SL candidates using MCF10A-
MYCER 
To investigate MYC-SL candidates, we conducted a genome-wide synthetic 
lethal screen using MCF10A breast epithelial cells stably expressing the MYC-ER allele, 
which is readily inducible by addition of 4-hydroxytamoxifen (4OHT). These MCF10A-
MYCER cells were infected with the GIPZ Lentiviral Human shRNA-mir library, a pooled 
shRNA plasmid library including 58,493 shRNA constructs targeting 18,661 known 
human genes (2-3 shRNAs per gene covering 75% of entire genome) as described in 
Rodriguez-Barrueco et al (Rodriguez-Barrueco et al., 2013). Our screen was designed 
based on negative selection, whereby loss of shRNAs was monitored to identify genes 
that render cells sensitive to MYCER activation by 4OHT when lost. 
First, MCF10A-MYCER cells were infected with the shRNA library at 30% 
infection efficiency, optimized to achieve single-copy shRNA integration per cell on 
average, and at a density of 1000 cells infected per shRNA clone. After a brief period of 
antibiotic selection, infected cells were divided into independent populations and 
propagated in the presence or absence of 4OHT for the next four weeks. During this 
time, total cell numbers were constantly maintained to preserve representation of at least 
1000 cells per shRNA clone. After four weeks, genomic DNA was isolated from surviving 
cells, and stably integrated shRNA constructs were amplified by PCR using primers 
amenable for high-throughput sequencing. Five independent replicate sets of 
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populations were differentiated in the analysis using independent 6-nucleotide barcodes 
embedded in the primers (for further details, see Chapter 2 and 3).  
Upon high-throughput sequencing of the screen results, we recovered 2,425 
shRNA IDs that were two-fold or more depleted in the MYC ON population compared to 
MYC OFF, within an acceptable p-value (p<0.1). Sub-datasets of this list were also 
generated using more stringent p-value cutoffs revealing 1,319 shRNA IDs at a 
confidence level of p<0.05, and 316 shRNA IDs at p<0.01 (Chapter 2, Table 2). 
Functional clustering analysis of these high-confidence synthetic lethal candidates using 
the DAVID Bioinformatics Database showed that pathways enriched in our list included, 
among others, ubiquitin-mediated proteolysis and DNA replication (Chapter 2, Table 3). 
These pathways are consistent with previous studies linking the importance of MYC 
stability to degradation pathways, and demonstrating the significance of MYC-induced 
replication stress (Dang, 2012; Muller and Eilers, 2008).   
 
UVSSA and ERCC8 are synthetic lethal with MYC 
 High-throughput sequencing of recovered shRNAs identified UVSSA (or 
KIAA1530) as one of our high-confidence hits. Importantly, two independent shRNA 
clones targeting UVSSA were recovered within an acceptable p-value within the five 
replicates (Log2 FC= -2.39, p<0.02, and Log2 FC=-2.35, p<0.09) (Chapter 2, Table 4). 
To validate this finding and confirm whether UVSSA knockdown is synthetic lethal with 
MYC activation, we down-regulated UVSSA expression in MCF10A-MYCER cells using 
three independent shRNA clones that targeted different sequences than the library 
shRNAs. We achieved approximately 40-50% knockdown of mRNA levels (Figure 1A). 
To compare the fitness of cells expressing shRNAs targeting UVSSA to cells expressing 
control shRNAs, we used a fluorescence-based competitive survival assay. Cells with 
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UVSSA knockdown expressing GFP or RFP from the shRNA lentiviral vector were 
plated with cells without shRNA in equal numbers, and the fraction of GFP/RFP-
expressing cells was followed with time. Cells with UVSSA down-regulation were 
markedly less viable in the presence of MYC activation over the course of 30 days 
(Figure 1B). While the survival ratio of MYC ON/MYC OFF cells remained approximately 
at 1.0 for control shRNA cells, the ratio of shUVSSA-1 and shUVSSA-3 cells dropped to 
0.81 and 0.78 respectively, and shUVSSA-4 dropped to 0.46 (p<0.001) (Figure 1B). 
Each of the shRNA clones target different regions of the UVSSA mRNAs and affect all 
known isoforms, strongly suggesting that the synthetic lethal effect is specifically due to 
UVSSA knockdown (Supplemental Figure 1). We therefore conclude that cells with 
UVSSA knockdown have markedly decreased viability when MYC is deregulated, 
validating the synthetic lethal, or sick, phenotype unraveled in the genome-wide screen.  
 UVSSA physically interacts with ERCC8/CSA to participate in TCR (Fei and 
Chen, 2012). Since we also identified ERCC8/CSA as one of our high-confidence 
synthetic lethal candidates (Log2 FC=-3.2, p<0.03), we sought to validate ERCC8 as a 
potential additional MYC-SL candidate. Three independent shRNA clones were used to 
knockdown ERCC8 mRNA levels to approximately 47-68% of control cells (Figure 1C 
and Supplemental Figure 2). Competition survival assays with these cells showed a 67-
78% decrease in the MYC ON/MYC OFF survival ratio over the course of 18 days 
compared to control cells, validating ERCC8 as a synthetic lethal, or sick, candidate with 
MYC deregulation as well (p<0.001) (Figure 1D).  
 Since UVSSA and ERCC8 associate within a protein complex, we next ask 
whether UVSSA knockdown and ERCC8 knockdown had an additive effect on cell 
survival in MYC ON cells. We generated double knockdown cells using shRNA clones 
UVSSA-4 and ERCC8-3, -4, and -6 in combination. The MYC ON/MYC OFF survival 
ratios over the course of 30 days dropped to 0.45, 0.49, and 0.41 respectively (p<0.001). 
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This epistatic relationship is consistent with the effect of the UVSSA-4 clone alone, 
suggesting that knockdown of UVSSA and ERCC8 generate the synthetic lethal effect 
with MYC deregulation through the same pathway (Figure 1B and 1E).  
UVSSA and ERCC8 also interact with USP7, a de-ubiquitinating enzyme 
involved in ubiquitin turnover at RNA polymerase complexes (Schwertman et al., 2012; 
Zhang et al., 2012). Treatment of MCF10A-MYCER cells with a chemical inhibitor of 
USP7 sensitized MYC ON cells approximately 3-fold over MYC OFF cells (Figure 1F). 
These results further suggest that UVSSA and ERCC8, and possibly the TCR pathway 
as a whole, is synthetic lethal with MYC deregulation.  
 
Synthetic lethal interaction is independent of UV damage 
 UVSSA is mutated in UV-sensitive syndrome (UV-SS), and cells from UV-SS 
patients are sensitive to UV radiation, consistent with the role of UVSSA in TCR 
(Nakazawa et al., 2012; Schwertman et al., 2012; Zhang et al., 2012). Therefore, we 
next assessed whether the synthetic lethal effect observed upon UVSSA down-
regulation in MYC ON cells was dependent on the documented role of the TC-NER 
pathway in repair of UV damage. We treated shCONTROL or shUVSSA cells with 
increasing doses of UV radiation in the presence or absence of MYC activation to see if 
UV-induced DNA damage exacerbates the synthetic lethal phenotype. MYC ON cells 
show mildly increased sensitivity to UV both in the shCONTROL and shUVSSA cells, 
consistent with previous studies suggesting that MYC overexpression confers slight UV 
sensitivity (Figure 2A and 2B) (Felsher and Bishop, 1999). UVSSA knockdown alone 
also confers mild UV sensitivity compared to CONTROL, consistent with previous 
reports in UV-SS patient cells and knockdown cells (Figure 2B) (Nakazawa et al., 2012; 
Schwertman et al., 2012; Zhang et al., 2012). Importantly, the induction of MYC did not 
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exacerbate the UV sensitivity of shUVSSA cells (Figure 2B). This suggests that the 
synthetic lethal effect with MYC is independent of the canonical, UV-induced TCR 
pathway. It further suggests that TCR, or at least UVSSA, have additional roles 
independent of UV-lesion repair that are required for survival of MYC-deregulated cells.  
 
UVSSA knockdown with MYC activation results in genomic stress 
 We sought indicators of genomic stress, since UVSSA knockdown may increase 
genomic instability in MYC-deregulated cells. Specifically, we assessed the presence of 
markers associated with DNA damage. We monitored the accumulation of 
phosphorylated CHK2 at T68, an readout of ATM-dependent checkpoint activation. We 
found that phosphorylated CHK2 was enriched in UVSSA knockdown cells with MYC 
activation and peaks at ten days (Figure 3C). Notably, P-CHK2 levels were significantly 
lower than P-CHK2 levels observed following acute treatment with DNA damaging 
agents such as MMS, suggesting that the level of genomic damage generated with MYC 
activation and UVSSA knockdown accumulates slowly (data not shown).  
We reasoned that accumulation of DNA damage, as suggested by the presence 
of P-CHK2, might affect cell cycle progression. After 20 days of culturing UVSSA 
knockdown cells in MYC OFF or MYC ON conditions, we observed a significant 
accumulation of cells in S and G2/M phase, suggesting retardation of the cell cycle 
(Figure 3A and 3B). Knockdown with clones UVSSA-1, -3, and -4 all resulted in an 
increase in S-phase cells compared to shCONTROL when combined with MYC 
induction (Figure 3A). In MYC OFF conditions, there were no significant differences in 
the number of cells in S-phase (Figure 3A). Cells in G2/M-phase were also increased 
when combined with UVSSA knockdown and MYC induction (Figure 3B). These results 




Synthetic lethal effect is dependent on transcription 
 MYC deregulation stimulates both RNA transcription and DNA replication. 
Aberrant activation of each pathway can lead to genomic instability independently or in 
combination (Evertts and Coller, 2012; Helmrich et al., 2013). Previous studies from our 
laboratory have shown that MYC-induced DNA replication triggers DNA damage 
(Dominguez-Sola et al., 2007; Srinivasan et al., 2013).  However, it is not known whether 
hyper-activation of MYC-induced transcription can cause increased DNA damage. 
Because UVSSA and TCR regulate the normal progression of RNA PolII on damaged 
DNA, it is conceivable that they could also counteract MYC-dependent transcription 
stress. However, it is not known whether TCR is activated by DNA damage other than 
UV-induced lesions. To test directly whether the loss of fitness of cells expressing MYC 
with down-regulated UVSSA is dependent on DNA replication or RNA transcription, we 
sought to inhibit either process using low doses of chemical inhibitors of each pathway. 
Specifically, we used aphidicolin to inhibit DNA polymerase delta and epsilon, and α-
amanitin to inhibit RNA Polymerase II. We reasoned that if UVSSA is required for 
repairing a specific type of genomic stress caused by MYC deregulation, modulating that 
process might alleviate the synthetic lethal effect.  
  In a competitive survival assay, cells were either treated with low doses of 
aphidicolin to inhibit replication, or low doses of α-amanitin to inhibit transcription, in 
MYC ON or MYC OFF conditions (Figure 4A and 4B). Remarkably, treatment with 
100ng/ml of α-amanitin increased the MYC ON/MYC OFF survival ratio of UVSSA 
knockdown cells to levels comparable to that of shCONTROL cells over the course of 14 
days (Figure 4A, p<0.005). In contrast, after 26 days, the highest sub-lethal dose of 
aphidicolin (50ng/ml) did not alter the MYC ON/MYC OFF ratio of UVSSA knockdown 
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cells (Figure 4B).  These experiments suggest that MYC-dependent transcription plays a 
role in the synthetic lethal effect between MYC activation and UVSSA knockdown. It 
further suggests that UVSSA or TCR could function outside of UV-induced damage 
repair in maintenance of genome integrity during hyper-activation of RNA transcription.  
Discussion 
 Genome instability is one of the hallmarks of cancer cells, and increasing 
evidence suggests that oncogene activation is a significant contributor to genomic 
damage and stress leading to genomic instability (Negrini et al., 2010; Woo and Poon, 
2004). In the case of MYC activation, multiple pathways cooperate, resulting in genomic 
stress, checkpoint activation and increased chromosomal instability. This makes it 
difficult to assess which specific genome maintenance pathways are required for cell 
survival following MYC activation (Wade and Wahl, 2006). Identifying pathways that are 
specifically required in MYC-deregulated cells but are dispensable for normal cell 
survival has clear potential therapeutic value (Kaelin, 2005; Weidle et al., 2011). 
 To identify such vulnerabilities, we looked for genome maintenance genes and 
pathways that are synthetic lethal with MYC activation, using a genome-wide shRNA 
screen. Other screening approaches have also been utilized in the case of MYC-SL 
screens, such as more targeted gene-by-gene methods using RNAi against a specific 
subset of known human genes such as the kinome or the druggable genome (Liu et al., 
2012; Toyoshima et al., 2012). In the present study, we conducted a large-scale, 
genome-wide screen for several reasons. First, we reasoned that a genome-wide 
approach would provide information about the relative contribution of genome 
maintenance as a synthetic lethal cellular process with MYC compared to other 
biological pathways. Second, a genome-wide method allows for identification of 
candidates beyond the scope of prediction, including previously un-annotated genes and 
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recently identified genes. Lastly, a genome-wide approach gives us insight into the 
multiple pathways that MYC-deregulated cells become dependent on for survival. These 
advantages allowed us to generate a massive dataset of potential synthetic lethal 
candidates, and among them we were able to discover transcription-coupled repair, a 
pathway that had not been functionally associated with MYC.  
 Three other MYC-SL screens have been recently published (Kessler et al., 2012; 
Liu et al., 2012; Toyoshima et al., 2012). Since each screen has utilized different tools 
and cell lines, raw results have varied with relatively low gene-by-gene overlap of top 
MYC-SL candidates between screens (>5%). However, recent meta-analysis performed 
by Cermelli and colleagues of the MYC-SL screen results from these three studies have 
suggested that the data converge in three main functional MYC-SL hubs (Cermelli et al., 
2014). Namely, these three hubs are 1) regulators of the MYC-MAX network, 2) 
transcription initiation and elongation complexes, and 3) DNA repair, cell cycle, and 
checkpoints (Cermelli et al., 2014). Our results showing that transcription-coupled repair 
is a MYC-SL pathway are consistent with two of these hubs, since TCR is critical for 
both transcription and DNA repair. Thus, though previous MYC-SL screens have not 
reported TCR-specific genes in their results, we are confident that the synthetic lethal 
effect we observe between MYC deregulation and TCR is functionally significant. 
 Transcription can be a source of DNA damage. Evidence in E. coli and yeast 
suggests that transcription can induce significant DNA damage in several ways, 
including transcription-associated mutagenesis (TAM) and transcription-associated 
recombination (TAR), rates of which are proportional to transcription rate (Kim et al., 
2007; Nickoloff, 1992; Reimers et al., 2004). Further, collisions between transcription 
and replication machinery have been shown to contribute to genomic stress. This 
represents, at least in part, accumulation of R-loops during RNA transcription, which can 
be a source of DNA damage (Kim and Jinks-Robertson, 2012). In contrast, little is known 
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about the contribution of transcription to DNA damage in mammalian cells. Our findings 
suggest that MYC-deregulated cells experience elevated levels of transcription-induced 
genomic stress, consistent with these previous findings in E. coli and yeast. Moreover, 
this specific type of DNA damage may be a major source of genomic stress for human 
cells with MYC deregulation.  
 Our results suggest that UVSSA, ERCC8, and possibly the TCR pathway have a 
previously unidentified role in alleviating such transcription-induced genomic stress. 
Knockdown of UVSSA conferred a survival defect specifically to cells with MYC 
activation, albeit to different degrees, depending on the shRNA clone. These differences 
in survival ratios, despite a similar mRNA knockdown level may reflect possible off-target 
effects or altered UVSSA protein stability, which we were unable to test due to 
unavailability of antibodies. Strikingly, however, we find that the synthetic lethal effect 
between MYC deregulation and UVSSA down-regulation is alleviated in the presence of 
α-amanitin, which inhibits RNA polymerases. This suggests that UVSSA plays a critical 
role in conferring viability to MYC-deregulated cells in response to hyper-activation of 
transcription. In contrast, retarding genomic DNA replication with aphidicolin did not 
modulate the interactions between MYC deregulation and loss of UVSSA. This suggests 
that UVSSA may be specific to cope with MYC-dependent transcription stress.  
Furthermore, this synthetic lethal effect is independent of UV-induced DNA damage, 
suggesting a separate, UV-independent role of UVSSA or the TCR pathway in genome 
maintenance. Though we were unable to detect significant accumulation of common 
markers of DNA damage including phosphorylated H2AX and phosphorylated ATM (data 
not shown), our observation of consistent accumulation of P-CHK2 suggests genomic 
stress. While the molecular nature of the damage generated following MYC activation is 
not known, it is tempting to speculate that R-loops generated during transcription might 
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accumulate in MYC ON cells and could be the DNA structure from which DNA damage 
arises.  
 MYC is a notoriously difficult protein to target directly with pharmacological 
inhibitors, making synthetic lethality an extremely attractive approach to MYC-dependent 
cancer therapy (Reinhardt et al., 2009). Several SL candidates with MYC have been 
identified in the recent years. However, many tend to be essential or functionally 
important genes in normal cells and might not be suited targets for therapy. Despite its 
function in TCR, loss of function of UVSSA results in UV-sensitive syndrome (UV-SS), 
an extremely rare photosensitive disorder presenting mild photosensitivity and no 
predisposition to cancer (Nakazawa et al., 2012; Schwertman et al., 2012; Zhang et al., 
2012). Indeed, the few UV-SS patients identified to date show virtually no symptoms 
aside from mild UV sensitivity, unlike other TCR-related disorders such as Cockayne’s 
syndrome (CS) associated with severe congenital defects (Vermeulen and Fousteri, 
2013). These differences likely stem from additional roles of some TCR proteins in 
processes such as general transcription (Vermeulen and Fousteri, 2013). Therefore, 
targeting UVSSA to treat MYC-driven tumors is an attractive possibility, since side 




Materials and Methods 
 
Cell culture 
MCF10A cells and 293T cells were cultured as previously described (see Chapter 3).   
 
Production of lentivirus and shRNA  
Glycerol stocks of lentiviral shRNA constructs (pGIPZ, pTRIPZ) were obtained from 
Thermo Scientific Open Biosystems (Waltham, Massachusetts, USA) as previously 
described (see Chapter 3). Clones used were UVSSA-1 (V3THS_398946), UVSSA-3 
(V3THS_398945), UVSSA-4 (V2THS_139628), ERCC8-3 (V3LHS_332967), ERCC8-4 
(V3LHS_332966), and ERCC8-6 (V3LHS_404566). Each plasmid was purified and 
packaged into lentivirus as previously described to obtain stable knockdown cell lines 
(see Chapter 3). 
 
shRNA screen 
The pooled shRNA screen was carried out using the Thermo Scientific Open Biosystems 
GIPZ Lentiviral Human shRNA-mir Library as previously described (see Chapter 3). 
Genomic DNA isolated from surviving populations was subjected to PCR to recover the 
shRNA using primers with adaptor sequences compatible for the Illumina HTP 
sequencing platform (Illumina, Inc., San Diego, CA, USA). Forward primer sequence 
was 5’-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTC 
TTCCGATCT-(6-nt marker)-TAGTGAAGCCACAGATGTA-3’ and reverse primer 
sequence was 5’-
CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTGTAATCCAGAGGTTG 
ATTGTTCCA-3’. The approximately 450bp PCR product was gel-extracted and purified, 
pooled, and subjected to Illumina sequencing. Data analysis was then performed as 
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described previously (Yu et al., 2013). 
 
Competition assays 
Assays were performed as previously described (see Chapter 3). For experiments using 
α-amanitin (A2263, Sigma-Aldrich) or aphidicolin (A0781, Sigma-Aldrich), cells were 
supplemented every 72 hours with the appropriate drug simultaneously with vehicle or 
200nM 4OHT during the duration of the experiments.  
 
mRNA isolation and RT-PCR 
Isolation and analysis were performed as previously described (see Chapter 3).  
 
MTS assay 
MCF10A-MYCER cells were plated in 96-well plates at a density of 3000 cells per well 
with vehicle or 200nM 4OHT. The next day, media in wells were replaced with fresh 
media including the appropriate concentration of DMSO or P5091, along with vehicle or 
200nM 4OHT. Each condition was done in triplicate in each experiment. 48 hours later, 
each well was replaced with fresh media for 1 hour, followed by addition of MTS reagent 
included in the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega 
Corporation, Fitchburg, WI, USA). After 2 hours of incubation, plates were read using the 
uQuant plate reader (BioTek Instruments, Inc., Winooski, VT, USA).  
 
Clonogenic assay for UV sensitivity 
MCF10A-MYCER cells stably expressing shCONTROL or shUVSSA-4 were plated at a 
density of 500 cells per 100mm plate either with vehicle or 200nM 4OHT. The next day, 
media was replaced with 2ml PBS and plates were irradiated with appropriate doses of 
UV-C (254nm) using the Stratalinker UV Crosslinker 2400 (Stratagene California, La 
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Jolla, CA, USA). After irradiation, plates were again replaced with media containing 
either vehicle or 4OHT and incubated for 10 days at 37ºC and 5% CO2. At the time of 
harvest, cells were washed twice with PBS, fixed with 100% methanol, stained with 
crystal violet (C3886, Sigma-Aldrich) solution, and visible colonies were counted.  
 
Western blotting and antibodies 
Cells were lysed and analyzed by SDS-PAGE as previously described (see Chapter 3). 
The following primary antibodies were used for immunostaining: βactin (A2228, Sigma-
Aldrich Corporation, St. Louis, MO, USA), Phospho-Chk2 (2661, Cell Signaling 
Technology, Inc., Danvers, MA, USA). 
 
Cell cycle analysis 
Analyses were performed as previously described (see Chapter 3).  
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Figure 1. MYC deregulation renders cells sensitive to UVSSA and ERCC8 knockdown. 
A) Knockdown of UVSSA. Three independent doxycyline-inducible shRNA clones were 
used to produce stable UVSSA knockdown cell lines. Black bars show UVSSA mRNA 
levels without shRNA induction, and gray bars show mRNA levels after 72 hours of 
1µg/ml doxycycline treatment. Error bars represent the SEM. B) MYC induction 
sensitizes cells to UVSSA knockdown. shCONTROL or shUVSSA cells were subjected 
to a competitive survival assay and viability is represented as survival ratios between 
MYC ON/MYC OFF conditions. Graph shows average of 3 independent replicates. C) 
Knockdown of ERCC8. Three independent shRNA clones were used to produce stable 
ERCC8 knockdown cell lines. Error bars represent the SEM. D) MYC induction 
sensitizes cells to ERCC8 knockdown. shCONTROL or shERCC8 cells were subjected 
to competitive survival assay as described. Graph shows average of 3 independent 
replicates. E) UVSSA and ERCC8 show epistatic relationship in synthetic lethality with 
MYC. Competitive survival assays following knockdown of UVSSA and ERCC8 were 
conducted as described. Graph shows average of 3 independent replicates. F) MYC 
sensitizes cells to USP7 inhibitor P5091. MCF10A-MYCER cells were subjected to MTS 
assays in MYC OFF or MYC ON conditions using increasing doses of P5091. Error bars 
represent the SEM. 
 
Figure 2. Synthetic lethal interaction is independent of UV damage. A) MYC induction 
mildly sensitizes cells to UV treatment. Clonogenic assay using shCONTROL cells were 
treated with vehicle or 1µg/ml doxycycline, in combination with vehicle or 200nM 4OHT, 
and subjected to increasing doses of UVC radiation. Percent survival is based on colony 
numbers after 10 days of incubation. Error bars represent the SEM. B) UVSSA 
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knockdown does not further sensitize MYC-deregulated cells to UV treatment. 
Clonogenic assay as described using shUVSSA cells. Error bars represent the SEM.  
 
Figure 3. UVSSA knockdown with MYC activation results in accumulation of cells in 
S/G2 phase and phosphorylation of CHK2. A) MYC induction combined with UVSSA 
knockdown leads to increased accumulation of cells in S-phase. Cells in S-phase were 
measured using FACS after 30 days of culturing cells with 1µg/ml doxycycline, and 
vehicle or 200nM 4OHT. Error bars represent the SEM. B) MYC induction combined with 
UVSSA knockdown leads to accumulation of cells in G2/M phase. Cells in G2/M were 
measured as described after 30 days of culturing. Error bars represent the SEM. C) 
MYC induction combined with UVSSA knockdown results in accumulation of 
phosphorylated CHK2. shCONTROL or shUVSSA cells were treated with 1µg/ml 
doxycycline, and vehicle or 200nM 4OHT for 9 days and whole cell lysates were run on 
SDS-PAGE for detection of P-CHK2.  
 
Figure 4. Synthetic lethal effect is dependent on transcription. A) Treatment with α-
amanitin inhibits the synthetic lethal effect between MYC induction and UVSSA 
knockdown. shCONTROL and shUVSSA cells were subjected to competitive survival 
assays in the presence of 1µg/ml doxycycline, vehicle or 200nM 4OHT, and vehicle or 
varying doses of α-amanitin, administered every 48 hours over the course of 14 days. 
Graph represents 3 independent replicates. B) Treatment with aphidicolin does not affect 
the synthetic lethal effect between MYC induction and UVSSA knockdown. shCONTROL 
and shUVSSA cells were subjected to competitive survival assays with 1µg/ml 
doxycycline, vehicle or 200nM 4OHT, and vehicle or varying doses of aphidicolin, 














































Supplementary Figure 1. shRNA clones used for UVSSA knockdown. The four isoforms 
of UVSSA mRNA are represented as pX1, pX2, pX3, and pX4 and align as shown, 
compared to the UVSSA gene sequence shown on the top row. shRNA clones UVSSA-
1, -3, and -4 used in our studies target different sequences on the mRNAs as shown 
above, and cover all possible mRNAs. Alignment was conduced using CLC sequence 
viewer (CLC bio, Aarhus, Denmark). 
  










Supplementary Figure 2. shRNA clones used for ERCC8 knockdown. The two isoforms 
of ERCC8 mRNA are represented as pX1 and pX2, and align as shown above 
compared to the ERCC8 gene sequence. shRNA clones ERCC8-3, -4, and -6 used in 
our studies target different sequences on the mRNAs as shown above, and cover both 
































1. Genome-wide screen: strengths and weaknesses 
 For my thesis project, I engineered the MCF10A-MYCER system and conducted 
a genome-wide synthetic lethal screen for genes required for survival of cells with 
deregulated MYC. Smaller scale screens using a well-by-well approach have been 
performed in the past. However, comprehensive genome-wide screens in mammalian 
cells have only become achievable in the last decade with the development of pooled 
RNAi technologies and powerful analysis methods (Silva et al., 2005; Silva et al., 2008). 
The shRNA library utilized in our screen was a second-generation miR-based lentiviral 
shRNA library including 58,493 shRNA constructs targeting 18,661 known human 
genes, with an average of 2-3 shRNAs targeting each gene (Rodriguez-Barrueco et al., 
2013). The library covers approximately 75% of the human genome, which is one of the 
highest coverage libraries available for mammalian RNAi screening today. When 
compared to the three other published MYC-SL screens, our screen examined the 
second largest pool of gene targets next to Kessler’s study (Kessler et al., 2012).  
 Utilizing this powerful screening method led us to discover a large number of 
synthetic lethal candidates, or shRNAs that selectively decrease the viability of MYC-
deregulated cells. These candidate genes fall into a number of biological pathways that 
can potentially provide novel information about MYC biology (see Chapter 2). In the 
present study, we did not seek to validate most of the synthetic lethal candidates we 
discovered, since the aims of our studies concentrated on MYC-induced genome 
instability. We could have performed a more focused screen by using a custom shRNA 
library only targeting genes that have roles in genome maintenance. However, we think 
that a genome-wide screen was more informative for assessing the relative significance 
of genome maintenance as a SL pathway amidst many other cellular pathways, as well 
as providing a wide range of synthetic lethal candidates to pursue in the future. Also, 
since the genome-wide library we used included some shRNAs targeting previously 
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uncharacterized genes, we were able to identify UVSSA, which may have been 
excluded from smaller libraries targeted for specific biological pathways.  
We also learned several valuable lessons through the course of conducting and 
analyzing our genome-wide screen. Firstly, the potency and specificity of some of the 
shRNA constructs included in the library varied greatly. We noted this through validation 
attempts of SL candidates from the screen, when some shRNA clones failed to 
knockdown mRNA expression of the target gene beyond 10-30% of control levels when 
tested individually (data not shown). This could be a quality control issue of the original 
library. These libraries have been and are continuously being modified to achieve better 
and more consistent knockdown to minimize these issues. However, this issue likely 
participated in increasing the level of noise in our screen, which is reflected by the 
modest validation success rate (see Chapter 2). Compared to more stringent, smaller 
scale screens such as the Toyoshima screen, our validation rate was significantly low 
(Toyoshima et al., 2012). Notably, the criteria we used to define our high-confidence hits 
only included: 1) fold-difference of shRNA abundance between MYC ON and MYC OFF 
(Log2 FC<-1), and 2) p-values between the five replicates (p<0.1, p<0.05, or p<0.01). 
Additional filters such as secondary screens, protein-protein interactions, interactome 
analysis, or other bioinformatics methods would likely have increased our validation 
rates, and these methods will be employed for any future screens we pursue.   
We employed two methods to analyze the data: microarray hybridization and 
HTP sequencing (see Chaper 2). Initially, microarray hybridization was the sole method 
available to process data from large-scale screens. Later, HTP sequencing methods 
were developed to allow efficient analysis at a much higher resolution compared to the 
arrays. Surprisingly, we found that the raw data acquired from the two methods differ 
significantly. As anticipated, a substantially larger number of gene targets were identified 
at each p-value cutoff from HTP sequencing. However, only three gene targets 
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overlapped between the high-confidence candidate lists generated by the two methods. 
We did find similar biological pathways represented in each dataset, as predicted. From 
these results, we learned that while both analysis methods are valuable and effective, 
HTP sequencing analysis undoubtedly gives a more sensitive and high-resolution data 
output as compared to microarray hybridization, and that this method would be preferred 
for future screens.  
Nevertheless, we were able to validate different pathways as synthetic lethal 
candidates with MYC deregulation through our genome-wide screen. Identifying FBXW7 
and the MYC degradation pathway as a synthetic lethal candidate was reassuring since 
it strengthened previous findings in other systems. Importantly, our studies suggest a 
prominent role of FBXW7 for MYC degradation in MCF10A cells, which may be relevant 
in breast tumors (Akhoondi et al., 2010; King et al., 2013; Rottmann et al., 2005). In 
contrast, establishing the synthetic lethal relationship between UVSSA and the TCR 
pathway with MYC deregulation is novel since TCR has not previously been linked with 
MYC deregulation. Our discovery of this pathway as a synthetic lethal candidate with 
MYC reflects the value of our genome-wide approach, and additionally gives us 
confidence that further analysis of our existing data could uncover other novel synthetic 
lethal candidates in the future. 
2. FBXW7 knockdown is synthetic lethal with MYC 
 In the present study, we found FBXW7 as a synthetic lethal candidate with MYC 
deregulation in the MCF10A-MYCER system. We validated through a sensitive 
competitive survival assay that multiple shRNA clones targeting FBXW7 indeed 
sensitized MYC-deregulated cells and impaired their viability compared to normal cells. 
Furthermore, we showed that FBXW7 knockdown leads to accumulation of active MYC 
on chromatin, as well as cell cycle abnormalities and increased binding of CDC45 to 
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chromatin, indicative of replication stress. Interestingly, when MYC was deregulated, 
FBXW7 knockdown preferentially stabilized MYC over any of its other documented 
target oncoproteins. This suggests that the FBXW7-dependent MYC degradation 
pathway is vital for the survival of MYC-deregulated MCF10A cells, despite the existence 
of many other alternative degradation pathways (see Chapter 1).  
That FBXW7 knockdown impairs the growth of MYC-deregulated cells is not 
entirely a novel finding, since FBXW7 regulates MYC stability and activity (King et al., 
2013; Rottmann et al., 2005; Takeishi et al., 2013). However, we sought to validate 
FBXW7 as a synthetic lethal candidate with MYC deregulation since there are still some 
conflicting results about this relationship. For example, in some cells and tissue types, 
disrupting the FBXW7-MYC interaction does not seem to alter MYC half-life or stability 
(Chang et al., 2000; Gregory and Hann, 2000; Hemann et al., 2005; O'Neil et al., 2007). 
This suggests that depending on cell types and microenvironments, MYC protein levels 
are controlled by a balance of several pathways. Interestingly, while FBXW7 mutations 
are common in some specific types of cancers including T-ALL, cholangiocarcinoma, 
stomach, colon, and pancreas, it is rare in other cancers including breast and ovarian 
(Akhoondi et al., 2007). Further, promoter methylation of FBXW7 has been correlated 
with favorable prognosis in breast cancer (Akhoondi et al., 2010; Cheng and Li, 2012). 
Since our system utilized the MCF10A breast epithelial cell line, it is possible that the 
synthetic lethal effect we see between FBXW7 knockdown and MYC activation is 
specific to this cell line, or to breast cells in general.  
In order to address some of these questions, studies are currently ongoing to 
expand our results to breast cancer cell lines, including T47D, SKBR3, and MCF7, which 
have been documented to express normal to high levels of MYC and have distinct gene 
expression signatures. Additionally, we have done an initial gene expression analysis 
comparing the expression levels of FBXW7 to MYC in the TCGA breast cancer database 
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(Chapter 3). In total breast cancer samples, we see a significant but modest correlation 
between FBXW7 and MYC expression (Chapter 3, rho=0.23, p<0.0001). Interestingly, 
upon subtype-specific analysis, we found the most robust correlation in the luminal A-
subtype of breast cancers (Chapter 3, rho=0.41, p<0.0001). In contrast, we did not 
detect any significant correlation between FBXW7 and MYC in basal-like breast cancers 
(rho=-0.11, p=0.3242, data not shown) or in any other subtype tested (luminal B, normal-
like, Her2-positive, data not shown). Intriguingly, this suggests that the synthetic lethal 
relationship between FBXW7 and MYC may be more relevant in breast cancer types 
associated with lower levels of MYC. Though it has been traditionally thought that 
targeting MYC should be an effective method to attack MYC-overexpressing cancers 
such as basal-like breast cancers, increasing evidence suggests that these cancers may 
be able to readily achieve MYC-independence (Leung et al., 2012). It is conceivable that 
cancer cells with low to normal MYC expression are more susceptible to subtle 
alterations in MYC stability, given our results with luminal A-type breast cancers. This 
investigation will be extended in the future to other cancer types as well. 
FBXW7 was also identified as a synthetic lethal candidate in Kessler’s screen, 
though it was not selected for further validation (Kessler et al., 2012). Since their screen 
was conducted in the human mammary epithelial cell (HMEC) line, this also gives us 
additional confidence that FBXW7, at least in the breast epithelial context, may be a 
major MYC degradation pathway that is essential for survival of MYC-deregulated cells. 
The other published screens likely did not include FBXW7 as a candidate target since 
they interrogated the kinome or the druggable genome (Liu et al., 2012; Toyoshima et 
al., 2012). In support of this, Liu’s screen using siRNA against the kinome identified the 
GSK3B kinase as a MYC-SL candidate, which is essential for the interaction between 
FBXW7 and MYC (Liu et al., 2012; Welcker et al., 2004). FBXW7 was one of the five 
genes that overlapped between our SL candidate list and the Kessler dataset (FBXW7, 
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FASN, LAMA2, PRMT8, ZNF614) suggesting that this finding may apply to breast 
epithelial cells in general, and may be relevant to MYC-deregulated breast epithelial 
tumors, though additional studies are required to investigate this further (Kessler et al., 
2012). 
 Lastly, it must be noted that pharmacological inhibitors of FBXW7 are not yet 
available, though there are urgent efforts currently underway for development. Because 
one of the ultimate goals of our screening approach is uncovering novel targets for 
therapy of MYC-driven tumors, testing the effect of chemical inhibitors will be a high 
priority in future studies. Our data indicate that in MCF10A-MYCER cells, approximately 
50% of FBXW7 knockdown preferentially confers lethality to cells with MYC activation 
while normal cells are unaffected. Ideally, a chemical inhibitor of FBXW7 with high 
specificity should exhibit similar results, which could be useful for treating at least a 
subset of breast tumors. We would like to test whether FBXW7 inhibitors have 
differential effects on basal-like high-MYC breast cancer cell lines and luminal-like low-
MYC breast cancer cell lines, to further corroborate our current results. 
3. Transcription-coupled repair is synthetic lethal with MYC 
 We showed that knockdown of UVSSA or ERCC8, components of the TCR 
pathway, have a synthetic lethal effect with MYC activation (Figure 1, Chapter 4). Since 
we also see increased sensitivity of MYC-deregulated cells to the USP7 inhibitor P5091, 
and an epistatic relationship between UVSSA and ERCC8 in a double knockdown, this 
strongly suggests that the TCR pathway is required for survival of cells with MYC 
activation (Figure 1, Chapter 4). Although we are still in the process of unraveling the 
mechanisms underlying this synthetic lethal effect, we have detected cell cycle defects 
and a significant increase in phosphorylated CHK2, which signifies genomic stress 
(Figure 3, Chapter 4). Because the viability of MYC-deregulated cells with UVSSA 
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knockdown becomes comparable to control cells when treated simultaneously with low 
doses of α-amanitin, we suspect that cells with MYC deregulation are under significant 
transcription-dependent genomic stress that may require the TCR pathway to maintain 
survival.  
 While UVSSA and ERCC8 were both recovered as synthetic lethal candidates 
from our HTP sequencing, we did not recover TCR genes in our microarray hybridization 
results (Table 1, Chapter 2). UVSSA (KIAA1530) was not included in the total list of 
genes that were at least 2-fold depleted in the MYC ON population compared to MYC 
OFF, as assessed from the microarrays. This can be due to several possibilities, 
including that UVSSA actually did not score as at least 2-fold depleted in MYC ON 
compared to MYC OFF. This could be due to the limit of sensitivity of the arrays, or a 
particularly weak probe for UVSSA. Also, it is possible that a UVSSA “spot” was 
erroneously omitted on the microarrays. On the other hand, ERCC8 actually did score as 
more than 2-fold depleted in the MYC ON population compared to MYC OFF in the 
microarray analysis (Log2 FC=-1.30), but was not included in the candidate list for failing 
to pass the required p-value cutoffs (p>0.1). Thus, this may be a good example of how 
the multiple analysis methods we took allowed for a more detailed and thorough probing 
of our results, since the microarray analysis alone was not able to pick up these 
candidates due to technological limitations. We predict that there are likely additional 
genes and pathways that were not represented in the microarray dataset but were 
included in the HTP sequencing results, and would like to further validate these in the 
future.  
 Our results suggest a key role for transcription-dependent genomic stress in 
MYC-deregulated cells. Transcription-dependent genomic stress is becoming a growing 
field of research in the recent years, however, there has been very limited research 
focusing on this type of genomic stress specifically in conditions of MYC deregulation or 
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overexpression (Fong et al., 2013; Kim and Jinks-Robertson, 2012; Wolters and 
Schumacher, 2013). Transcription, even in normal cells, is a robust and intrinsically 
mutagenic process that can be the source of many different types of genomic stress 
including mutagenesis (TAM), recombination (TAR), collisions with replication forks, and 
accumulation of transcription-associated R-loops and non-B-DNA structures (Kim and 
Jinks-Robertson, 2012). Thus, it is reasonable to speculate that under conditions of MYC 
deregulation, increased transcriptional activity (Lin et al., 2012; Nie et al., 2012) could 
lead to increased transcription-associated genomic stress. While MYC-induced cells can 
adapt to these transcription levels, they may become increasingly dependent on specific 
genome maintenance pathways such as TCR for survival.  
Intriguingly, stalled RNAPII is associated with activation of strong apoptotic 
signals, thus it has been suggested that transcription impediments can be tumor 
suppressive (Kim and Jinks-Robertson, 2012). This is consistent with our results in the 
case of MYC deregulation, in which MYC-deregulated cells are selectively sensitive to 
knockdown of TCR genes, though we were not able to detect significant levels of 
apoptosis in our initial studies (data not shown). We speculate that this interaction may 
be specifically crucial for MYC and other oncogenic transcription factors since 
transcriptional activity in these cells rise significantly (Lin et al., 2012; Nie et al., 2012). 
While we are focusing our studies on MYC, we are also interested in future studies to 
expand our results to other such models.  
The question remains whether other known TCR players, including ERCC6/CSB, 
XAB2, HMGN1, and ELL also have a similar synthetic lethal relationship with MYC 
deregulation. Additionally, it is vital to investigate more detailed molecular mechanisms 
of transcription-induced DNA damage, since the only evidence we have identified so far 
is the induction of phosphorylated CHK2. We plan to generate knockdown cell lines of 
the above TCR players in order to strengthen our findings. 
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Whether MYC-induced elevation of transcription can directly induce genomic 
stress is still a question we are eager to address. At the molecular level, we are 
interested in testing whether MYC induction leads to accumulation of aberrant or 
abortive transcripts due to increased transcription, leading to increased transcription-
associated stress. When TCR is attenuated, these aberrant or abortive transcripts may 
accumulate to toxic levels. To test this, we are in the process of conducting a genome-
wide chromatin immunoprecipitation experiment using antibodies against RNAPII. We 
hypothesize that if TCR is required for survival of MYC-deregulated cells due to 
accumulation of transcription-induced stress, we may detect differences in the landscape 
of chromatin-bound RNAPII on a genome-wide scale. Importantly, since we do not know 
if all RNAPII transcription is affected or only select transcripts are affected, we have 
decided to take a genome-wide approach to interrogate this question.  
Another burning question is the nature of the pathological aberrant structure 
generated by MYC that is normally resolved by TCR. R-loops are attractive candidates 
and we are interested in inquiring whether MYC-deregulated cells accumulate this 
potentially toxic intermediate of transcription (Kim and Jinks-Robertson, 2012). R-loops, 
or RNA-DNA hybrids that can occur in active transcription bubbles when a nascent RNA 
anneals back to the template DNA strand, lead to displacement of the single-stranded 
non-transcribed strand (NTS) of DNA. This leaves the NTS vulnerable to a variety of 
single-strand DNA assaults including base modifications, breaks, mutations, and 
looping, all of which can lead to lethal genomic damage (Kim and Jinks-Robertson, 
2012; Li and Manley, 2006). Accumulation of R-loops is normally limited by the 
protection of naked RNA by co-transcriptional processes, the activity of TOP1, and also 
by enzymes such as RNase H which degrade RNA-DNA hybrids (Kim and Jinks-
Robertson, 2012). It is possible that deregulation of MYC leads to accumulation of these 
intermediates that may require TCR activity, or at least the components of TCR involved 
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in the stalling, restart, or recycling of RNAPII complexes, to maintain survival. To start 
testing whether R-loops are significant in our studies, we are in the process of 
investigating the effect of overexpressing recombinant RNase H in MYC-deregulated 
cells with TCR knockdown. Additionally, we plan to specifically monitor the level of R-
loops in MYC ON and MYC OFF cells using specific antibodies that recognize DNA-RNA 
hybrids independently of their sequence (Boguslawski et al., 1986; Kitagawa and Stollar, 
1982). 
Our findings suggest a novel synthetic lethal relationship between MYC 
deregulation and genes involved in transcription-coupled repair. While the significance of 
transcription-associated genomic stress is becoming clearer, whether it is a significant 
component of oncogene-induced genomic stress has not been extensively studied as of 
yet. From the evidence we have accumulated so far, we propose that in MYC-
deregulated cells, transcription-associated genomic stress may be a significant 
contributor to genome instability. Many questions remain, including the molecular role of 
TCR components, or subcomponents, in non-UV-irradiated conditions, since most 
existing studies on TCR have focused on exogenous UV irradiation. Nevertheless, we 
are eager to further explore details into the mostly genetic evidence we have established 
between MYC and UVSSA/ERCC8 in our studies. 
4. Maintenance of MYC deregulation 
 Previous studies from our laboratory showed that MYC directly regulates DNA 
replication, specifically origin firing, and that increased DNA replication-dependent 
genomic damage and checkpoint activation are direct consequences of MYC 
overexpression (Dominguez-Sola et al., 2007; Srinivasan et al., 2013). As a follow up to 
these studies, we initially performed our MYC-SL screen in pursuit of finding proteins or 
enzymes involved in alleviating MYC-dependent replication stress. Although we opted to 
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screen for MYC-SL candidates in a genome-wide fashion, we were interested in SL 
candidates that could possibly be involved in DNA damage repair, or modulators of 
genomic stress such as topoisomerases or nucleases, which would corroborate our prior 
findings regarding MYC-dependent replication stress. 
 We learned through this project that MYC biology is extremely complex. In 
retrospect, screening a smaller gene set targeted specifically to genome maintenance 
genes might have been a more efficient method to find a synthetic lethal candidate that 
we “expected” to discover. However, because we employed a genome-wide screen, we 
found that MYC is truly a master regulator, regulating diverse cellular pathways. For 
example, one of the strongest synthetic lethal pathways recovered from our microarray 
data was metabolism and fatty acid synthesis. The connection between oncogenesis 
and metabolism has been an emerging and growing field of research, and our results 
are in agreement that metabolic pathways may be a strong genetic vulnerability for 
MYC-deregulated cells. Though we did not follow up much with this data, many other 
interesting SL candidates are represented in our datasets that should be followed up in 
separate projects in the future.  
 We have established that at least two independent pathways are synthetic lethal 
with MYC in the MCF10A-MYCER system (Figure 1). While there are numerous other 
MYC-SL pathways as demonstrated by other groups and by our dataset, we focused our 
studies on two pathways as genetic vulnerabilities of MYC: 1) ubiquitin-mediated MYC 
degradation by FBXW7, and 2) transcription-coupled repair involving UVSSA and 
ERCC8 (Figure 1). We saw that FBXW7 knockdown alone, despite the existence of 
multiple MYC degradation pathways, was sufficient in our system to significantly impair 
the survival of MYC-deregulated cells. This is consistent with the threshold model of 
MYC-induced oncogenesis, in which MYC protein levels dictate differential fate for cells 
(Murphy et al., 2008). We can hypothesize that our MCF10A-MYCER cells have a 
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growth-permissive low level of MYC deregulation when MYCER is activated by 4OHT. 
Upon FBXW7 knockdown, MYC protein levels were stabilized and surpassed a 
threshold level, leading to activation of tumor suppressor and cell death pathways that 
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Figure 1. Model of vulnerabilities during MYC deregulation. At deregulated, tumorigenic levels of cellular 
MYC, both aberrant DNA replication and amplification of transcription contribute to genomic stress. 
These are alleviated by DNA repair pathways such as TCR to maintain survival in the tumorigenic state. 
When cellular MYC exceeds tolerable levels, increased genomic stress leads to cell death. Increase in 
MYC levels can be suppressed by a steady state of FBXW7-mediated MYC degradation. (Adapted from 
Jean Gautier)  
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At the growth-permissive low level of MYC deregulation, however, cells still 
experience stress (Figure 1). These may include metabolic stress, proliferative stress, 
DNA damage, and replication stress among many others (Dang, 2012). We propose that 
transcription-associated genomic stress may be one type of stress that increases during 
low levels of MYC deregulation, likely as a result of increased transcriptional activity 
induced by MYC and other downstream transcription factors. Under these conditions, 
survival may become increasingly dependent on processes that alleviate transcription 
stress such as TCR, or specific components of the TCR pathway that may be critical in 
RNAPII metabolism such as UVSSA (Figure 1).  
Encouragingly, ubiquitination/SUMOylation and transcription initiation/elongation 
constitute two of the three functional MYC-SL “hubs” that were determined through 
comprehensive bioinformatics analysis of data from three previously published MYC-SL 
screens (Cermelli et al., 2014). These two processes, along with a third including 
regulators of the MYC-MAX network, were the most highly represented and statistically 
reliable MYC-SL biological functional groups across the three screens (Cermelli et al., 
2014; Kessler et al., 2012; Liu et al., 2012; Toyoshima et al., 2012). Our findings 
confirming FBXW7 and UVSSA/ERCC8 as MYC-SL genes are consistent with their 
results, since FBXW7 is involved in ubiquitination and UVSSA/ERCC8 are related to 
transcription pathways. We hope to further explore other genes and pathways from our 
data that have been highlighted as MYC-SL hubs in hopes to gain more detailed insight 
into MYC-SL networks. 
Lastly, we are interested in extending our results to mouse models, possibly by 
testing the loss of UVSSA in transgenic mice that develop MYC-dependent tumors such 
as Eµ-MYC, or MYC-induced tumors in mammary tissue (Adams et al., 1985; Leung et 
al., 2012). Further, the end goal of our studies has always been to contribute to the 
development of novel methods to combat MYC-driven cancers. To this end, we are 
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eager to target UVSSA since we know that UVSS patients with loss of UVSSA function 
survive relatively well with no significant cancer susceptibility, despite mild UV sensitivity 
(Schwertman et al., 2013). Since many of the previously identified MYC-SL targets have 
been essential or high-risk proteins such as ATR, CDKs, and checkpoint proteins, we 
are interested to see effects with UVSSA inhibitors. To conclude, we have learned 
through our studies that deciphering mechanisms of MYC oncogenesis and potential 
therapy are truly a collaborative and ongoing feat, and are excited to further corroborate 
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APPENDIX 1 – MCM6 interacts with BUBR1 and AURKA in Xenopus laevis extracts 
 
This work has been published (Lefebvre et al., 2010).  
 
 
 Elucidating comprehensive regulatory networks of protein-protein interactions in 
specific cell types are critical in confirming significant tumorigenic pathways, as well as in 
predicting novel ones. The human B-cell interactome (HBCI) developed by Lefebvre and 
colleagues predicted novel protein-protein interactions between genes involved in the 
pre-replicative complex (pre-RC), DNA replication, and mitosis (Lefebvre et al., 2010). 
Although origin recognition complex proteins (ORCs) had previously been detected on 
mitotic kinetochores, it was unknown whether the pre-RC complex also interacted with 
mitotic machinery (Sasaki and Gilbert, 2007). 
 In collaboration with Dr. Andrea Califano’s laboratory, we investigated the 
predicted protein-protein interactions between MCM6, a member of the pre-RC complex, 
and mitotic proteins BUBR1 and AURKA. BUBR1 and AURKA (or Aurora A) have 
prominent roles in regulation of proper mitosis and induction of the mitotic checkpoint 
(Fu et al., 2007). We used Xenopus laevis cell-free extracts to investigate the 
interactions. Low-speed supernatant was prepared from unfertilized Xenopus oocytes. 
These extracts contain large stores of maternal proteins and mRNAs necessary for initial 
cell cycles during early development, and are devoid of genomic DNA (Danilchick et al., 
1991). I performed co-immunoprecipitation (co-IP) using Xenopus MCM6 (XMCM6) 
antibodies conjugated to Protein A-Sepharose beads. Beads, following incubation in 
extracts, were washed and subjected to SDS-PAGE. I found that Xenopus BUBR1 
(XBUBR1) and AURKA (XAURKA) co-immunoprecipitated with XMCM6 (Figure 1B). 
Similar results were established in human B-cells (Ramos) through MCM3 IP (Figure 
1A). Taken together, these results confirm the predicted protein-protein interactions 
between members of the pre-RC (MCM3/MCM6) and mitotic proteins (BUBR1/AURKA). 
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Importantly, our results in Xenopus extracts suggest that this interaction does not require 




Figure 1. MCM3 and MCM6 interact with BUBR1 and AURKA. (A) MCM3 interacts with 
BUBR1 and AURKA in human B cells. In Ramos cells, BUBR1 and AURKA co-
immunoprecipated with human MCM3 antibody. Ramos cell lysates were used for 
endogenous protein IP. (B) MCM6 interacts with BUBR1 and AURKA in Xenopus 
extracts. Xenopus BUBR1 and AURKA co-immunoprecipitated with Xenopus MCM6 
antibody. Figures are representative images of replicate experiments. (Published in 





XMCM6 antibodies were previously described (Ying and Gautier, 2005). XBUBR1 
antibodies (Mao et al., 2003) and XAURKA (Satinover et al., 2006) antibodies were 
generously gifted by Dr. Mao and Dr. Stukenberg, respectively. 
 
Lentiviral infection of B-cell lymphoma cell lines
Control shRNA (SHC002), FOXM1 shRNA (TRCN0000015546), or
MYB shRNA (TRCN0000040062) cloned into pLKO.1-puro lentiviral
vector was purchased from Sigma. To generate lentiviral particles, the
individual shRNA clones (2.8mg) were co-transfected with VSVG
envelope plasmid (280 ng) and D8.9 packaging vector (2.5 mg) into
subconfluent 100 mm plate of 293FTcells using Fugene 6 (Roche). The
viral particles were collected at 48 and 72 h post-transfection, filtered
and concentrated by ultracentrifugation in Beckman SW28 rotor at
25 000 rpm for 1.5 h 5!106 ST486 cells were transduced with the viral
particles in the presence of 8 mg/ml polybrene and centrifuging at 450 g
for 1.5 h.
Immunoblot analysis
For immunoblotting, whole-cell lysates were prepared from ST486
cells by using RIPA buffer (Teknova) with protease inhibitor cocktail
(Roche). Proteins were fractionated by SDS–PAGE and analyzed by
standard immunoblotting procedures using the following antibodies:
anti-FOXM1 (sc-502; Santa Cruz), anti-MYB (sc-517, Santa Cruz),
anti-MCM3 (559543, BD Pharmingen), anti-BUBR1 (ab4637, Abcam),
anti-AURKA (gift from Dr PT Stukenberg), anti-XBubR1 (gift from
Dr Y Mao), and anti-GAPDH (sc-32233; Santa Cruz).
Co-immunoprecipitation
Whole-cell lysates of 40!106 Ramos cells were prepared by using cell
lysis buffer (50 mM Tris–HCl pH 8.1, 150 mM NaCl and 0.5% NP-40)
with protease inhibitor cocktail. The lysate was incubated overnight at
41C with mouse IgG or anti-MCM3 antibody (M038-3, MBL Intl),
followed by incubation in protein-G agarose beads (17-0618, Amer-
sham) for 2 hours. The beads were washed in buffer (20 mM Tris–HCl
pH 8.1, 150 mM NaCl, 10% glycerol, 0.2% NP-40 and 1 mM EDTA) for
four times and incubated in SDS-loading buffer at 1001C for 10 min.
Similarly, cell-free extract (LSS) was prepared from unfertilized
Xenopus eggs as described earlier(Smythe and Newport, 1991). Co-
IPs were performed by incubating extracts with anti-XMCM6
antibodies as described earlier (Ying and Gautier, 2005)) or control
antibodies (Rabbit IgG, Sigma) for 30 min at 41C, followed by addition
of Protein A Sepharose beads (GE Healthcare) for 1 h at 41C. Beads
were washed with ELB-0.2%NP-40 and ELB-0.5MNaCl, then boiled to
release bound proteins. Proteins were fractionated by SDS–PAGE and
analyzed by standard immunoblotting procedures.
Indirect immunofluorescence
Ramos cells were fixed in 10% formalin for 20 min and post-fixed in
ice-cold 100% methanol for 20 min. Cells were then blocked in 5% BSA
for 1 h and incubated with anti-MCM3 (559543, BD Pharmingen) and
anti-BUBR1 (ab4637, Abcam) or anti-MCM3, and anti-AURKA
(ab13824, Abcam) antibody for 2 h at room temperature. The cells
were washed three times in PBS with 0.01% Tween-20 followed by
incubation with biotinylated goat anti-mouse IgG for 30 min. It was
then incubated with FITC-conjugated goat anti-rabbit antibody and
Cy3-conjugated Streptavidin antibody (Jackson ImmunoResearch) for
30 min. Stained cells were acquired at ! 100 magnification in LSM510
Multiphoton confocal microscope (Zeiss).
Figure 6 MCM3 and MCM6 interact with BUBR1 and AURKA. (A) MCM3 co-immunoprecipitates with BUBR1 and AURKA. Cell lysates of Ramos cell line were
immunoprecipitated with control IgG or anti-MCM3 antibodies and probed with anti-BUBR1 and anti-AURKA antibodies. (B) MCM6 binds to BUBR1 and AURKA in
Xenopus cell-free extracts. Interphase extracts from Xenopus cytosolic fraction were immunoprecipitated with anti-XMCM6 or control IgG antibodies and probed with
anti-XMCM6, anti-XBUBR1, and anti-XAURKA antibodies. (C) Co-localization of MCM3 with BUBR1 and AURKA in Ramos cells shown by confocal dual-color indirect
immunofluorescence with (a) anti-MCM3 and anti-BUBR1 antibodies or (b) anti-MCM3 and anti-AURKA antibodies. DNA was stained with DAPI. Data shown are
representative of one of three independent experiments.
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